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 Abstract 
Cancer stem cells (CSCs), also known as tumor-propagating cells or tumor-
initiating cells, are subpopulations of undifferentiated, highly tumorigenic cells found 
within bulk tumors. The rapid advances of cancer research and development of relative 
technologies have provided more and more evidence for the existence of CSCs, as well as 
the important roles they play in drug resistance and disease relapse of cancer. However, 
because of their quiescent nature and the similarities to normal stem cells, eradicating 
CSCs presents a challenging task. Chapter one provides an overview of cell surface 
markers of CSCs. Those markers are potential diagnostic macromolecules and targets for 
drug delivery. 
Parthenolide (PTL) is a sesquiterpene lactone natural product isolated from 
Mexican Indian medicinal herb Tanacetum parthenum (feverfew plant), a known medical 
herb utilized for centuries. PTL has been extensively studied as an anticancer agent, 
showing significant efficacy towards a wide spectrum of human cancer cells. In 2005, the 
identification of PTL as the first stand-alone and selective cytotoxic agent against the 
acute myeloid leukemia CSCs further heightened its therapeutic potential. However, the 
mechanism of action of PTL’s CSC inhibitory activity is still an area of debate. Our 
efforts to elucidate the molecular targets of PTL is described in chapter two. The design 
and synthesis of two PTL affinity probes with diverse biological activity as well as their 
utilization in comparative and competitive protein pull-down experiments to enrich the 
cellular protein targets of PTL is presented.  
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Although exhibiting promising anticancer and anti-CSC activities, the modest 
biological potency and poor water solubility prevent further development of PTL. 
Chapter three describes our efforts to synthesize PTL analogues, as well as our strategy to 
prepare water-soluble PTL prodrugs. 
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Chapter I. Cell Surface Markers of Cancer Stem Cells: 
Diagnostic Macromolecules and Targets for Drug Delivery 
1.1 Introduction 
Cancer stem cells (CSCs), also known as tumor-propagating cells or tumor-
initiating cells, are subpopulations of undifferentiated, highly tumorigenic cells found 
within bulk tumors. CSCs have the ability to self-renew, differentiate, and generate a 
phenotype-identical copy of the tumor from which they were isolated upon implantation 
in a recipient animal (Fig. 1.1). Accordingly, CSCs reside at the apex of the tumor cell 
hierarchy and can differentiate into all of the cell types that comprise the host tumor.
1-8
 
CSC theory directly challenges the traditional stochastic model of cancer cell growth 
that predicts that all cells from a tumor have tumorigenic potential.
9
  
The development of suitable technologies to isolate CSCs from tumors (e.g., 
monoclonal antibodies of unique CSC surface macromolecules coupled with 
fluorescence-activated cell sorting (FACS) techniques) and appropriate animal models 
 
Figure1.1 Depiction of the properties that are characteristic of cancer stem cells 
(CSCs). A: CSCs (shown in gray) can self-renew and undergo multi-lineage 
differentiation (cells in color). B: Tumorigenicity. CSCs are more tumorigenic than 
differentiated bulk tumor cells. 
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for xenotransplantation assays of isolated cell populations (e.g., non-obese diabetic, 
severe combined immuno-deficient (NOD/SCID) mice) have facilitated the 
identification of CSC populations from a variety of blood and solid tumors.
4
 These 
technological advancements were prerequisite to the discovery of CSCs in acute 
myelogenous leukemia (AML), which is arguably the prototypical human cancer bearing 
an established CSC hierarchy. Seminal work by John Dick and colleagues provided the 
first critical evidence for CSCs by isolating (with FACS) the CD34
+
/CD38
−
 fraction of 
human donor AML cells and engrafting those cells into severe combined 
immunodeficient (SCID) mice.
9,10
 Engrafted cells were able to proliferate and 
differentiate, resulting in identical disease to that of the donor. Isolation of the AML 
CSC population (CD34
+
/CD38
−
) from the recipient mouse, followed by serial 
transplantation into a secondary recipient mouse yielded the same disease, thereby 
demonstrating the selfrenewal properties of the initially engrafted CD34
+
/CD38
−
 AML 
cell fraction. This pioneering study provided insight into the long-standing observation 
that AML cells have only limited proliferative capacity by supporting the hypothesis that 
a rare leukemic clone must maintain the AML population.
11-13
 Additionally, this work 
provided crucial evidence for the hierarchy model of tumor heterogeneity by 
demonstrating that some populations of leukemic cells (CD34
+
/CD38
−
) exhibited CSC 
activity, whereas other leukemic cell populations (e.g., CD34
+
/CD38
+
 and CD34
−
) did 
not.
10
 The feature that only a sub-population of cells from a tumor can facilitate 
tumorigenesis is a tenant of the hierarchy model of tumor cell growth.
4
 AML CSCs 
exclusively give rise to clinical AML.
9,10
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Cancer therapies that are resisted by the CSC population are predicted to fail by 
the CSC model.
6,7
 Although outside the focus of this review, the drug resistance 
properties of CSCs may result due to increased cell quiescence,
14,15
 expression of anti-
apoptotic proteins,
16
 and upregulation of ABC multidrug resistance transporter 
proteins.
16,17
 The CSC hypothesis is also supported by clinical data. In the case of AML, 
approximately 44,000 new cases of AML are diagnosed annually in the United States, 
and 5-year survival rates are only 24%.
18
 Front-line small molecule treatments for AML 
include nucleoside analogues (e.g., cytarabine) and anthracyclines (e.g., idarubicin, 
daunorubicin), which are designed to induce apoptosis in rapidly dividing cancer 
cells.
19,20
 AML CSCs, which are largely quiescent, are typically resistant to standard 
chemotherapeutic agents. Furthermore, recent data have demonstrated that cytarabine 
actually facilitates AML CSC entry into G0/G1 phase, thereby promoting cell cycle 
quiescence and providing a mechanism that allows AML CSCs to survive 
chemotherapy.
21
 Consequently, viable strategies to eradicate CSC populations are 
clearly needed if curative cancer therapies are to be developed. A realized example of 
this concern has been documented with patients receiving the targeted bcr-abl tyrosine 
kinase antagonist imatinib (Gleevec®) for chronic myelogenous leukemia (CML). 
Although imatinib effectively converts CML into a chronically managed disease,
22,23
 
patient withdrawing from imatinib treatment ultimately results in disease relapse 
because imatinib does not eliminate CML CSCs.
24,25
 
Elucidation of the molecular differences between differentiated cancer cells with 
high proliferation rates and nondifferentiated CSCs that are mostly quiescent is an 
intense area of ongoing research.
4,26-28
 Equally important is the need to characterize 
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those chemical features that confer cancerous versus non-cancerous stem cells (e.g., the 
differences in biochemistry between a leukemic stem cell and a normal hematopoietic 
stem cell).
4
 A variety of cytosolic and cell surface macromolecules have been 
characterized as diagnostic markers for the identification of CSCs from differentiated 
cancer cells, normal stem cells, or other cells from tissue. Many of these markers are 
utilized in combination for characterization of the CSC population (e.g., CD34
+
/ CD38
−
 
for AML CSCs described above).
10
 However, for isolation and drug targeting of CSCs, 
surface markers have proven to be more useful.
29-32
 Cell surface macromolecules are 
readily captured by magnetic micro-bead isolation techniques and are easily detected by 
flow cytometry, and the unique ligands presented on the cell surface offer receptors for 
targeted drug delivery.
33
 In this review, we have consolidated the known CSC cell 
surface markers that have been described for various blood and solid tumors into one 
document. Since intracellular markers for CSCs have been described and reviewed 
elsewhere,
30,34
 we have focused this review only on well-characterized cell surface 
markers due to their ability to serve as mediators for drug delivery into CSCs. In 
addition to compiling CSC surface markers, we review the unique chemical and 
structural features of the most well-known CSC surface markers and report recent efforts 
to deliver therapeutic agents into CSCs mediated by CSC specific cell surface 
macromolecules.  
 
1.2 Compendium of cell surface markers for identification of cancer stem cells 
Summarized herein is the current knowledge of CSC markers from the following 
human cancers: leukemias (Table 1.1), breast, colorectal, liver, pancreatic, prostate, 
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melanoma, brain, bladder, lung, and ovarian carcinomas (Table 1.2). Recent efforts to 
deliver therapeutic molecules to CSCs are described in Table 1.3. Table 1.4 provides a 
compendium of the other commonly used names of the CSC markers discussed in the 
following sections. 
 
1.2.1 Leukemia 
Leukemia is a family of diseases, comprised of blood, bone marrow, or lymphoid 
system cancers that are characterized by abnormal increases in white blood cell count.
35
 
In 2011, more than 44,000 children and adults in the United States were expected to 
develop some form of leukemia, and approximately 22,000 deaths were projected.
18,36,37
 
In 1994, Dick and coworkers first characterized the acute myelogenous leukemia stem 
cell population utilizing the CD34
+
/CD38
−
 cell surface marker combination.
10
 This 
landmark discovery catalyzed the search for CSC populations from related blood as well 
as solid tumors. The repertoire of CSC markers in leukemia is complicated and variable 
depending on leukemia subtype and stage of disease.
38
 The current state of knowledge of 
leukemia CSC surface markers is described herein and shown in Table 1.1. 
 
1.2.1.1 Acute myelogenous leukemia (AML) 
As has been introduced above, CD34
+
/CD38
−
 (Table 1.1) is the earliest 
documented stem cell marker combination in cancer and is still widely used to identify 
leukemic CSCs. In a seminal study, Dick and coworkers demonstrated that a small 
subpopulation of AML cells with the CD34
+
/CD38
−
 cell surface phenotype was capable 
of producing a large number of colony-forming progenitors when engrafted to SCID 
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mice. On the other hand, CD34
+
/CD38
+
 and CD34
−
 cell fractions did not exhibit these 
properties.
10
 Later studies from the same group provided evidence that CD34
+
/CD38
−
 
was a common immune phenotype for leukemic CSCs in multiple AML subtypes and 
also demonstrated their self-renewal potential.
9
 
Additional studies have further refined and developed the cell surface 
phenotypes of AML. The Suthland group has shown that, in both in vitro and in vivo 
models, CD34
+
/CD90
−
 (Thy-1), CD34
+
/CD71
−
/HLA-DR
−
, and CD34
+
/CD117
−
 (c-kit) 
are unique cell surface marker phenotypes of AML CSCs.
39-41
 In 2000, the Jordan group 
indicated that CD34
+
/CD38
−
/CD123
+
 (interleukin-3 receptor α chain) is a specific cell 
surface phenotype for human AML stem cells.
42
 Additionally, CD123 expression has 
also been reported on CSCs in CML, myelodysplastic syndrome, and systemic 
mastocytosis,
43
 suggesting that CD123 might be a broadly applicable cell surface marker 
for the development of targeted therapies against CSCs across multiple leukemias. CD33 
is another important surface marker for characterizing AML CSCs. CD33 has long been 
known for its extensive expression on leukemic blasts,
44
 but only recently has it been 
reported as a marker for AML CSCs. Hauswirth et al. have shown that addition of 
CD33
+
 to phenotype CD34
+
/CD38
−
/CD123
+
 yields a robust marker combination for 
AML CSCs that is unique to cancerous stem cells.
45
 Additionally, Florian et al. 
demonstrated that CD34
+
/CD38
−
/CD45
+
/CD123
+
 was a general marker phenotype for 
AML CSCs and that additional markers, such as CD13
+
, CD71
−
, CD33
+
, CD117
+
, 
CD133
+
, and HLADR
−
, were observed in variable combinations with the 
CD34+/CD38−/CD45+/CD123+ phenotype.43 CD34+/ CD38−/CD123+ CSC populations 
have also been noted for their upregulation of drug efflux pumps. Compared with bulk 
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(differentiated) tumor cells, the upregulation of multidrug-resistance related protein 1, 
breast cancer resistance protein, and lung resistance protein have been observed in AML 
CSC populations.
46
 C-type lectin-like molecule-1 (CLL-1), which is a transmembrane 
protein with a heavily N-glycosylated extracellular domain, has been found to be 
exclusively expressed on AML CSCs in 92% of all studied AML cases. Isolation and 
transplantation of CD34
+
/CD38
−
/CLL-1
+
 cells generated AML blasts in NOD/SCID 
mice.
47
 Another important marker of AML CSCs is CD96, which belongs to the 
immunoglobulin superfamily. Recent studies have demonstrated that CD96 protein 
might be selectively overexpressed as a CD34
+
/CD38
−
/CD90
−
/Lin
−
/CD96
+
 phenotype 
on AML CSCs as compared with the basal expression level of CD96 on normal HSCs.
48
 
The elevated expression of several isoforms of adhesion molecule CD44 has been 
identified in the interaction between hematopoietic progenitor cells and the surrounding 
stromal cells (i.e., CSC niche) in primary human AML samples.
49
 CD44 has been 
previously exploited in targeted drug delivery to AML CSCs
20
 (see section 1.3, Table 
1.3). The Ishikawa group has reported the identification of CD25 and CD32 in 
conjunction with CD34
+
/CD38
−
 as potential CSC markers for AML. In their study, they 
found that both CD34
+
/CD38
−
/CD25
+
 and CD34
+
/CD38
−
/CD32
+
 leukemia cells are 
enriched in quiescent, chemotherapeutic drug-resistant CSCs, are capable of initiating 
AMLs in vivo, and are expressed at a very limited level in normal HSCs.
50
 Majeti et al. 
also reported CD47 as a new potential target for CSC therapy of AML. 
CD34
+
/CD38
−
/CD90
−
/ Lin
−
/CD47
+
 expression was observed only in AML CSCs when 
compared with their HSC counterparts.
51
 See Table 1.1 for a listing of AML CSC 
surface markers. 
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1.2.1.2 Acute lymphoblastic leukemia 
Acute lymphoblastic leukemia (ALL) is the most common childhood cancer and 
is characterized by clonal proliferation of lymphoblasts.
18
 ALL CSCs present the same 
CD34
+
/CD38
−
 cell surface marker phenotype as AML CSCs; however, the 
CD34
+
/CD38
−
/CD33
−
/CD19
−
 phenotype has been characterized as a more robust marker 
to define ALL CSCs.
52
 A population of ALL CSCs that are committed to lymphoid 
differentiation has been shown to express the Philadelphia chromosome 
(CD34
+
/CD38
−
/Ph
+
).
53
 The Philadelphia chromosome contains a chromosomal 
translocation between the break point cluster region (bcr) and the gene encoding c-Abl 
(abl), which encodes for the bcr-abl tyrosine kinase.
54
 The presence of the Philadelphia 
chromosome in ALL indicates an overall poor prognosis.
55
 Subsequent studies have 
shown that, in CD34
+
/CD38
−
 bone marrow cells, a predominant and aberrant 
CD34
+
/CD38
−
/CD19
+
 cell population that is not present in healthy individuals carries 
the Philadelphia chromosome, while the CD19
−
 cell population in this compartment 
does not.
56
 These results indicate that the CD34
+
/CD38
−
/CD19
+
 phenotype marrow 
compartment in childhood ALL is another potential marker of ALL CSCs,
56
 which is 
contradictory to previous findings,
52
 However, it has been suggested that CD19
+
 might 
not be a broadly applicable AML CSC marker.
56
 ALL can be classified as T lineage (T-
ALL) or B lineage (B-ALL).
57
 Cox et al. have demonstrated that ALL cells capable of 
long-term proliferation and differentiation into pre-B-ALL in vitro (suspension culture 
assay) and in vivo (NOD/SCID transplant model) were derived from only 
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CD34+/CD10− or CD34+/CD19− sub-fractions, indicating that the target cells for 
transformation in pre-B-ALL have a more immature phenotype than the bulk ALL 
population.
58
 The same group also discovered that CD34
+
/CD4
−
 or CD34
+
/CD7
−
 sub-
fractions of childhood T-ALL cells were highly proliferative and capable of NOD/SCID 
engraftmen.
59
 More recently, Cox et al. reported that in childhood ALLs, the small 
subpopulation of CD133
+
/CD19
−
 cells were capable of initiating and maintaining long-
term in vitro cultures of B-ALLs and engrafting serially into NOD/SCID recipient 
mice.
60
 In a recent study from the Morimoto group, the stem cell characteristics of CD9
+ 
cell populations in B-ALL were demonstrated both in vitro and in transplantation 
experiments, suggesting that CD9 is a useful positive-selection marker for the 
identification of CSCs in B-ALL. Their study also showed that, in some cases, CD9
+
 in 
ALL CSCs was a more reliable CSC marker than CD34
+
.
61
 The same group also 
reported the importance of CD90 (Thy-1) and CD110 (c-Mpl) as positive-selection 
markers for T-ALL CSCs. In both in vitro and in vivo assays, their results suggested that 
small subpopulations of CD90
+
/CD110
+
 cells isolated from either childhood or adult 
ALL specimens retained the ability to self-renew, proliferate, and differentiate.
62
 See 
Table 1.1 for a listing of ALL CSC surface markers. 
 
1.2.1.3 Chronic myelogenous leukemia (CML) 
CML is often characterized by the overproduction of mature myeloid cells. As 
with ALL, CML is most closely associated with the bcr-abl chromosomal translocation, 
which is present in pluripotent stem cells.
38
 CML CSCs are also characterized by the 
CD34
+
/Ph
+
 cell phenotype (Table 1.1) and are phenotypically similar to normal HSCs.
63
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In addition to its role as an AML CSC marker, CD123+ has also been characterized as a 
surface marker for CML CSCs (phenotype CD34
+
/CD38
−
/CD123
+
). Queries for the 
presence of other markers in CML cells bearing the CD34
+
/ CD38
−
/CD123
+
 phenotype 
revealed variable positivity for CD13, CD33, CD44, and CD117 molecules;
43
 however, 
the presence of CD117 on the surface of CML CSCs conflicts with previous reports.
41
 
See Table 1.1 for a listing of CML CSC surface markers. 
 
 
1.2.2 Breast cancer  
Breast cancer accounts for the deaths of more than 40,000 women each year in 
the United States. Although the 5-year survival rate for breast cancer patients has 
Leukemia Type Marker(s) Reference 
Acute Myelogenous Leukemia 
(AML) 
CD34
+
/CD38
-
 [10] 
 CD34
+
/CD90
-
 [39] 
 CD34
+
/CD71
-
/HLA-DR
-
 [40] 
 CD34
+
/CD117
-
 [2, 41] 
 CD34
+
/CD38
-
/CD123
+
 [42, 46] 
 CD34
+
/CD38
-
/CD45
+
/CD123
+
 [43] 
 CD34
+
/CD38
-
/CD123
+
/CD33
+
 [4, 45] 
 CD34
+
/CD38
-
/CLL-1
+
 [47] 
 CD34
+
/CD38
-
/CD90
-
/Lin
-
/CD96
+
 [48] 
 CD44
+
 [49] 
 CD34
+
/CD38
-
/CD25
+
 [50] 
 CD34
+
/CD38
-
/CD32
+
 [50] 
 CD34
+
/CD38
-
/CD90
-
/Lin
-
/CD47
+
 [51] 
Acute Lymphocytic Leukemia 
(ALL) 
CD34
+
/CD38
-
/CD33
-
/CD19
-
 [10, 52] 
 CD34
+
/CD38
-
/Ph
+
 [53] 
 CD34
+
/CD38
-
/CD19
+
 [56] 
 CD34
+
/CD10
-
 [58] 
 CD34
+
/CD19
-
 [12, 58] 
 CD34
+
/CD4
-
 [59] 
 CD34
+
/CD7
-
 [59] 
 CD133
+
/CD19
-
 [60] 
 CD9
+
 [61] 
 CD90
+
/CD110
+
 [62] 
Chronic Myelogenous Leukemia 
(CML) 
CD34
+
/CD38
-
/CD123
+
 [43] 
CD34
+
/Ph
+
  [63] 
Table 1.1. Previously reported CSC markers for human leukemias. 
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dramatically increased over the past few decades, tumor relapse and metastasis is still a 
significant problem in breast cancer therapy.
18,64
 The evasion of breast CSCs during 
therapy is a significant contributor to disease relapse.
65
 
Al-Hajj et al. were the first to identify breast CSCs from whole cell population of 
breast cancer specimens using the cell surface marker profile CD44
+
/CD24
−/low
/Lin
−
 (see 
Table 1.2 at the end of section 1.2), which was the seminal report of CSCs identified 
from a solid tumor.
66
 The marker profiles CD44
+
/CD24
−/low
/Lin
−
 has been correlated 
with high resistance to traditional cancer therapies,
67
 poor prognosis,
68
 and enhanced 
invasive properties.
69
 Notably, lineage (Lin) markers are a standard combination of 
monoclonal antibodies including CD2, CD3, CD4, CD5, CD8, NK1.1, B220, TER-119, 
and Gr-1 in mice and CD3, CD14, CD16, CD19, CD20, and CD56 in humans.
70
 
Addition of epithelial cell adhesion molecule (EpCAM), yielding marker combination 
CD44
+
/CD24
−/low
/ EpCAM
high
, was later found to be a more robust surface marker 
combination for the isolation of human breast CSCs.
66
 The multiplexing of cytoplasmic 
enzyme ALDH1, membrane protein CD44, and cytokeratin has been employed to 
identify putative breast CSCs and indicate poor prognosis, which is independent of 
tumor size, nodal status, ER-, PR-, and HER2-status, and histological grade.
71
 
Another important cell surface marker of human breast CSCs is Thy1 (CD90). In 
an MMTV-Wnt-1 breast cancer mouse model, cancer cells with the phenotype 
THY1
+
/CD24
+
 (1–4% of tumor cell population) were identified to be highly tumorigenic 
in comparison to non-THY1+/CD24+ populations and displayed properties of CSCs.
72
 
The observation of CD24+ phenotype in combination with Thy1 is contradictory to 
previous reports that found breast CSCs to have a CD44
+
/CD24
-/low
/Lin
-
 phenotype.
66
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The expression of cell surface marker CD133 is also reported to be of significance and 
prognostic value for identifying CSCs in breast tumors, especially when combined with 
CD44
+
.
73-75
 CD173 (H2) and CD174 (Lewis Y) are cell surface carbohydrate antigens 
that are expressed to varying extents on different human carcinomas. Co-expression of 
CD173 and CD174 with CD44 is another cell surface marker combination proposed to 
identify breast CSCs.
76
 Similar to CD173 and CD174, CD176 is also a cell surface 
carbohydrate antigen that has been reported to be co-expressed with CD44 and CD133 
in breast carcinoma.
77
 Another study has shown that in BRCA1 (breast cancer-
associated gene 1)-mutant breast cancer cell lines, a small subpopulation of cancer cells 
expressing CD24
+
/CD29
+
 (β integrin) or CD24+/CD49f+ (α6 integrin) surface markers 
exhibited enhanced proliferation and colony forming ability in vitro and increased tumor 
generating ability in vivo. In addition, purified CD24
+
/CD29
+
 cells exhibit self-renewal 
capability, and as low as 500 cells could reconstitute the heterogeneity of the parent 
cancer cells in vivo, which is strongly indicative of a CSC population.
78
 Shipistin et al. 
confirmed that CD201, which is also known as protein C receptor (PROCR), was 
expressed on 100% of CD44
+
 breast cancer cells and was used as a cell surface marker 
to isolate CSCs from primary invasive breast cancer tumors.
79
 In addition, high PROCR 
expression was also reported to associate with poor prognosis in clinical patients.
79
 See 
Table 1.2 for a listing of breast CSC surface markers. 
 
1.2.3 Colorectal cancer 
Dalerba et al. have isolated colorectal CSCs from specimens using cell surface 
markers CD44 and EpCAM.
80
 When purified CD44
+
/EpCAM
high
 epithelial cells (Table 
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1.2) were injected into immunodeficient mice, the engrafted tumors yielded the 
differentiated phenotype profile as well as the morphologic heterogeneity of the parent 
lesions from which the CD44
+
/EpCAM
high
 epithelial cells were isolated. Furthermore, 
the authors also reported CD166
+
 as a co-marker that could be used for validation of 
colorectal CSCs in both xenografts and primary tumors, and the 
CD44
+
/EpCAM
high
/CD166
+
 phenotype was consistent with poor prognosis.
80
 However, 
the CD44/EpCAM marker phenotypes were not the first reported colorectal CSCs. Prior 
studies had first indicated that CD133 was a potential cell surface CSC marker in 
primary human colorectal cancer,
81,82
 but more recent findings by Shmelkov et al. have 
shown that both CD133
+
 and CD133
−
 populations are tumorigenic and contain tumor-
initiating cells.
83
 In order to explain this discrepancy, Du et al. have suggested that, 
unlike CD44, a surface protein that is of functional importance for the survival of CSCs, 
CD133 has not been found to have any essential functions associated with the growth 
and survival of colorectal CSCs.
84
 Although CD44
+
/EpCAM
high
/CD166
+
 is a relatively 
more reliable marker for colorectal CSCs than CD133
+
, some exceptions have also been 
documented. Lugli et al. reported that the loss of this combined marker 
(CD44
+
/EpCAM
high
/CD166
+
) was rather linked to an aggressive tumor phenotype.
85,86
 
Studies have also shown that CD49f, which has been reported as a CSC marker in breast 
cancer,
78
 is expressed on colon cancer cells, and that even higher levels of CD49f 
expression are observed with CD44
+
 cells, a known marker of colorectal CSCs.
80
 
Additionally, CD133
+
/CD24
+
 has been identified as a colorectal CSC marker.
87
 See 
Table 1.2 for a listing of colorectal CSC surface markers. 
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1.2.4 Liver cancer 
The incidence of hepatocellular carcinoma (HCC) cases has risen by 3% every 
year since 1992, and the 5-year survival rate ranges from 14% to 26% depending on the 
stage of diagnosis.
18
 In spite of the intensive research efforts devoted to the discovery of 
new HCC drugs, tumor relapse is still observed in the majority of cases.
88
 The recent 
identification of liver CSCs has yielded new targets for HCC drug discovery efforts, 
which, if successful, may help to address the problem of disease relapse. 
The CD133
+
 phenotype was the first reported putative HCC CSC population.
89
 
In this report by Ma et al. CD133
+
 HCC cells exhibited greater colony-forming 
capacities and higher proliferation rates than CD133
−
 HCC cells, as well as the ability to 
generate new tumors in both in vitro and in vivo models. Additionally, in CD133
+
 tumor 
cells, the expression level of stemness genes such as those involved in Wnt/β-catenin, 
Notch, and Hedgehog/SMO signaling were largely upregulated, indicating those 
CD133
+
 tumor cells were putative HCC CSCs. The CD133
+
 population was further 
characterized for other common CSC markers and CD34 and CD44 were found to be 
upregulated when compared with the CD133
−
 population.
89
 Another well-established 
cell surface marker of HCC stem cell is CD44
+
. Within the HCC CD133
+
 population, 
CD44
+
 cells were found to be more tumorigenic than CD44
−
 cells in NOD/SCID mouse 
model. Recent studies also revealed that the blocking of CD44 function by treatment 
with a CD44 specific monoclonal antibody might be a potential strategy to eradicate 
liver CSCs
90
 (see section 1.3). Moreover, the cell surface carbohydrate antigen CD176 
was found to co-express with CD44 at a high rate on the surface of HCC stem cells in 
both cancer cell lines and surgical specimens of malignant tumors.
77
 Besides CD133 and 
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CD44, EpCAM was identified as an early biomarker of HCC CSCs.
91,92
 The sorted 
EpCAM
+
 subpopulation of HCC cells yielded more colonies in clonogenicity assays 
than the sorted EpCAM
−
 cells from the same cell line. Further in vivo evaluation in 
mouse models indicated that as little as 100 EpCAM
+
 HCC cells were needed to 
generate a new tumor, and EpCAM
+
 cells retained the ability to differentiate into both 
EpCAM
+
 and EpCAM
−
 cells, while EpCAM
−
 cells always sustained their phenotype 
during cell propagation.
91
 Additionally, CD133 expression was observed in both 
EpCAM
+
 and EpCAM
−
 populations, indicating that EpCAM functions as a better 
indicator of the CSC population.
92
 Recently, CD13 (alanine aminopeptidase), which is a 
membranebound enzyme, has been identified as a marker for semiquiescent CSCs and a 
potential therapeutic target for liver cancers. CD13
+
/CD133
+
 and CD13
+
/CD90
−
 
populations were observed to be extremely tumorigenic, requiring only 100 cells for 
tumor formation upon transplantation.
93
 In a xenograft mouse model, CD13 inhibition, 
which was achieved with either a CD13 neutralizing antibody or by the CD13 inhibitor 
Ubenimex, repressed tumor-initiating and self-renewing capability of the majority of 
CSCs
93
 (see section 1.3). CD90 (Thy-1) has also been identified as a CSC marker in 
HCC cell lines.
94
 In comparison to CD90
−
 cells, CD90
+
 cells sorted from HCC cells 
lines were found to exhibit strong tumorigenic capacity, and the subpopulation of cells 
with CD90
+
/CD45
−
 phenotype could generate tumor nodules in an immunodeficient 
mouse model.
94
 OV6, which is a marker of hepatic progenitor (oval) cells, has been 
shown to be another CSC marker in HCC cells. OV6
+
 HCC cells are capable of 
generating new tumors in vivo and show substantial resistance to standard 
chemotherapeutic drugs compared with OV6
−
 HCC cells. Furthermore, the inhibition of 
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the Wnt/β-catenin signaling pathway, which is known to be important for the survival of 
CSCs,
95
 decreases the population of OV6
+
 cells. The OV6
+
 cell population also gained 
higher proliferation potential after β-catenin activation.96 See Table 1.2 for a listing of 
liver CSC surface markers. 
 
1.2.5 Pancreatic cancer 
Pancreatic cancer is one of the deadliest forms of human cancers. Currently, 
there are no known methods of early detection, and the average 5-year survival rate is 
6%.
18
 The mortality rate of this disease approaches 100% because of its 
characteristically high resistance to radiation and chemotherapy, and the tendency of 
early systemic dissemination.
97
 In spite of the significant advances in cancer biology 
over the past decade, the efficacy of drugs to treat pancreatic cancer has not substantially 
improved.
98
 Targeting the pancreatic CSC population could allow development of more 
efficacious therapies to combat this lethal disease. 
A pancreatic CSC population was identified only recently.
98
 A small population 
(0.2–0.8%) of highly tumorigenic pancreatic cancer cells with the CD44+/CD24+/ 
EpCAM
high
 phenotype (Table 1.2) from primary human pancreatic adenocarcinomas 
was xenografted into immunocompromised mice. In comparison with non-tumorigenic 
cells, the CD44
+
/CD24
+
/EpCAM
high
 pancreatic cancer cells exhibited a 100-fold 
increase in tumorigenic potential, and as few as 100 such cells could reconstitute tumors 
that were indistinguishable by histology from the original ones.
98
 In related studies, 
Hermann et al. demonstrated that CD133
+
 expression on the surface of pancreatic cancer 
cells was consistent with increased tumorigenicity and high resistance to standard 
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chemotherapy. In addition, they further revealed that a unique small population of CSCs 
bearing the CD133
+
/ CXCR4
+
 phenotype determined the metastatic potential of the 
tumor. Although CD133
+
/CXCR4
+
 cells and CD133
+
/CXCR4
−
 cells showed similar 
tumorigenicity when xenografted into nude mice, only the CD133
+
/CXCR4
−
 cells 
eliminated tumor metastasis.
99
 See Table 1.2 for a listing of pancreatic CSC surface 
markers. 
 
1.2.6 Melanoma 
Approximately 70,000 new cases of human melanoma and 9,000 melanoma-
related deaths were expected in the United States in 2011
18
. Although melanoma is not a 
leading cause of cancer-related mortality, it is one of few cancer types associated with 
both annual increases in incidence and death rate
100
. Human malignant melanoma cells 
are highly aggressive and drug resistant and contain cell populations with enhanced 
tumorigenicity.
101
 The discovery of putative CSCs in melanoma cell lines was first 
reported in 2005,
101
 preceding their subsequent isolation and characterization from cell 
lines and surgical specimens.
102
 Nestin (Table 1.2), which is an intermediate filament 
protein, was first described as a potential stem cell marker in melanoma cell lines.
103
 
Nestin expression was associated with aggressive behavior of the malignant tumors and 
was found to be upregulated during the development of invasive melanoma from banal 
nevi (a benign chronic lesion of the skin).
103
 Co-expression of nestin with CD133 has 
been described in context with stem cell populations in circulating melanoma cells, 
which are closely related to their metastatic potentials.
104
 Monzani et al. first utilized 
CD133 as a cell surface marker to separate melanoma stem cells. Their data showed that 
  18 
in contrast to CD133
−
 cells, CD133
+
 melanoma cells were highly tumorigenic and able 
to generate a Mart-1 (a typical melocytic marker) positive tumor when implanted into 
NOD/SCID mice. In the same study, they also revealed that melanoma cells expressing 
both CD133 and ABCG2 (ATP-binding cassette sub-family G member 2) were able to 
self-renew and differentiate into astrocytes and mesenchymal lineages under specific 
conditions, demonstrating the utility of ABCG2 as a CSC marker.
102
 Schatton et al. 
identified a small subpopulation of melanoma cells that were enriched for human 
malignant melanoma-initiating cells, which were defined by the expression of P-
glycoprotein ABCB5, a well-known chemoresistance mediator. ABCB5
+
 melanoma 
cells were found to be highly aggressive, possess greater tumorigenic capacity than 
ABCB5
−
 cells, and could re-establish clinical tumor heterogeneity. ABCB5 has also 
been studied as a target of anticancer therapy
105,106
 (see section 1.3). See Table 1.2 for a 
listing of melanoma CSC surface markers. 
 
1.2.7 Brain cancer  
Malignant brain tumors are among the deadliest human cancers. Glioblastoma 
(GBM) multiforme is the most common primary brain tumor in adults with 12,000 
deaths in the United States annually.
107
 In children, glioblastoma multiforme occurs less 
frequently, accounting for 7–9% of all intracranial tumors, yet the median survival after 
diagnosis is 50 weeks.
108
 Currently, there is a scarcity of effective treatments for brain 
cancers, which is attributable to the sensitive environment of the disease and the 
inability of many drugs to permeabilize the blood–brain barrier. Unfortunately, most 
drugs that can access brain malignancies are inefficient at eradicating the tumor cells and 
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frequently leave behind a side population of radio- and chemoresistant cells. The 
existence of this side population provides a mechanism for disease relapse,
33
 and recent 
studies strongly suggest that brain tumors have an established CSC hierarchy.
109,110
 Drug 
targeting of brain CSCs may yield better therapy outcomes. 
In 2003, Singh et al. first identified CD133 as a CSC marker (Table 1.2) in 
glioblastomas and medulloblastomas.
111
 Studies of human medulloblastoma specimens 
from children have also revealed a CD133
+
 subpopulation of cells that is positive for 
nestin.
112
 Sorted CD133
+
 populations of childhood medulloblastoma specimens have 
demonstrated the stem cell characteristics of self-renewal and differentiation, and 
subjection of these cells to differentiation conditions resulted in the loss of the CD133
+
 
marker.
111
 The tumorigenicity of CD133
+
 human donor medulloblastoma and 
glioblastoma cancer cells were evaluated in NOD/SCID mice, and as few as 100 cells 
were required for the development of new tumors of the same phenotype.
112
 
Another glioblastoma CSC marker that has been identified is integrin A2B5, a 
polysialo ganglioside. Tchoghandjian et al. used A2B5 to characterize CSC populations 
in glioblastoma samples using magnetic micro-beads and FACS. In addition, the authors 
sorted the cells for a secondary known CSC marker, CD133. A2B5
+
 populations 
expressed characteristic features of CSCs regardless of CD133 expression, and both 
A2B5
+
/CD133
+
 and A2B5
+
/CD133
−
 populations were highly tumorigenic, requiring 
only 1,000 cells for development of a new tumor of the same phenotype. However, only 
the A2B5
+
/CD133
−
 population of cells was found to be invasive within the brain.
113
 
Studies by Ogden et al. have suggested that only the A2B5
+
 phenotype is characteristic 
of glioblastoma CSCs, and CD133 positivity is not indicative of a CSC population.
114
 In 
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support of the evidence that CD133
+
 cells are putative CSCs, studies by Wang et al. 
found that CD133
+
 glioblastomas were aggressive tumors and were typified by the onset 
of angiogenesis, shorter survival times, and metastatic potential. However, the CD133
−
 
populations were also shown to be capable of differentiating into CD133
+
 cells, which 
suggests that CD133
−
 are stem cell-like.
115
 Although characterization of universal 
diagnostic markers for CSCs is the ultimate goal for the development of targeted 
therapies, these contradictory results with CD133 clearly illustrate that patients can 
express different surface markers for the same disease and/or that multiple CSC 
populations can be present in glioblastoma specimens. 
L1CAM, a transmembrane adhesion protein found in CD133
+
 glioma cell 
populations, was identified as a brain CSC marker in 2008.
116
 D456MG pediatric 
glioblastoma xenografts and primary human samples were utilized to study the role of 
L1CAM.
117
 Neurosphere formation, a cellular morphology consistent with a stem cell-
like state, was quantified as a measure of the self-renewal properties of the CSC 
population. Targeting L1CAM with shRNA decreased the ability of the CD133
+
 cells to 
form neurospheres, indicating that the L1CAM
+
/CD133
+
 population was the in vitro 
CSC population. In vivo studies conducted in nude mice also showed that knockdown of 
L1CAM with shRNA resulted in a reduction in tumor size and increased survival.
116
  
Stage-specific embryonic antigen-1 (SSEA-1), or CD15, has also been identified 
as a potential marker of GBM CSCs.
118
 Utilizing primary human samples, SSEA-1
+
 
cells were isolated and characterized for self-renewal, differentiation, and 
tumorigenicity. The presence of CD133
+
 was also investigated in the SSEA-1
+
 
populations in early studies; however, SSEA-1
+
/CD133
+
 and SSEA-1
+
/CD133
-
 were 
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both shown to have CSC characteristics. Sorting of primary human GBM specimens for 
only SSEA-1 expression and xenograftment of isolated cells into NOD/SCID mice 
revealed that SSEA-1
+
 cells exhibited at least 100-fold greater tumorigenic potential 
than SSEA-1
−
 GBM cells. Therefore, SSEA-1
+
 can be used to identify CSC populations 
in GBM.
118
 SSEA-1 has also been identified as a medulloblastoma CSC marker.
119
 See 
Table 1.2 for a listing of brain CSC surface markers. 
 
1.2.8 Lung cancer 
Lung cancer is the most common, yet preventable, cancerrelated death 
worldwide, resulting in more mortalities than colon, breast, and prostate cancers 
combined. The 5-year survival rate for small cell lung carcinoma is 6% while nonsmall 
cell carcinoma is 17%.
18
 Current lung cancer therapies are usually transient and fail to 
completely eradiate the tumor, causing resistance. One potential hypothesis for drug 
resistance to chemotherapy is the presence of drugrefractory lung CSC populations in 
the tumor masses.
120
 Eramo et al. identified CD133
+
 CSC subpopulations (Table 1.2) in 
small cell and non-small cell lung cancer from primary human donors. CD133 
expression was observed on the surface of 0.32–22% of lung cancer cells by flow 
cytometry analyses, which varied depending on different disease stages of the sample. In 
vivo analysis showed that tumor formation required only 1,000 cells to be implanted into 
SCID mice, while differentiated cell populations injected at 50,000 cells per animal 
failed to produce tumors.
121
 CD176 has also been identified as a potential marker for 
lung CSC populations and has been observed in combination with CD133 and CD44 cell 
surface markers. CD176
+
/CD133
+
 and CD176
+
/CD44
+
 phenotypes were observed after 
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sorting cells for CD176 expression, and CD176
+
 cell populations were found to exhibit 
features of CSCs, such as tumorigenicity. These results imply that CD176
+
 may be used 
as a potential lung CSC marker.
77
 See Table 1.2 for a listing of lung CSC surface 
markers. 
 
1.2.9 Bladder cancer 
Bladder transitional cell carcinoma (BTCC) is the second most prevalent cancer 
of the urinary tract.
122
 Five-year survival rates for BTCC vary by stage of development, 
ranging from 6% to 97%.
18
 Traditional therapy consists of surgery, radiation, and 
chemotherapy,
123
 but if disease becomes invasive, then treatment outcomes are typically 
poor due to metastasis.
124
 The development of diagnostic markers and new therapies for 
BTCC is currently needed. 
Yang and Chang have identified a subpopulation of BTCC samples from primary 
human donors that display a CD44
+
/EMA
−
 (epithelial membrane antigen) phenotype 
(specifically the isoform CD44v6; Table 1.2). CD44
+
/EMA
−
 populations were shown to 
overexpress Bmi-1 and EZH2, which are proteins that play a role in self-renewal of 
normal bladder stem cells. CD44
+
/EMA
−
 cells also were able to form colonies and 
proliferate in vitro, which are characteristic features of CSCs.
125
 
Chan et al. have also postulated that BTCC CSCs can be characterized by the cell 
surface phenotype Lin
−
/CD44
+
/cytokeratin (CK)5
+
/CK20
−
. Tumors from primary human 
donors were sorted for CD44
+
 and CD44
−
 cells and then transplanted into 
immunocompromised mice (RAG2
−/γc−). The CD44+ cells were found to be more 
tumorigenic, requiring only 100–1,000 cells to form tumors, while the CD44− population 
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required 200,000–500,000 cells to elicit tumors in mice. Immunofluorescence analysis 
of CD44
+
 xenografts showed co-expression of CK5 and lack of expression of CK20 
(phenotype Lin
−
/CD44
+
/CK5
+
/ CK20
−
), and this marker phenotype was deemed to be 
the BTCC CSC population. The authors also queried for other common CSC cell surface 
markers and discovered that CD47 is highly expressed on CD44
+
 cells. CD47 inhibits 
phagocytosis by macrophages, allowing for pathogenesis of the bladder cancer.
124
 
Hoechst 33342 dye is a widely used indicator of side populations with potential 
CSC characteristics.
126
 ATP binding cassette (ABC) and multidrug resistance efflux 
pumps are responsible for the elimination of Hoechst 33342 dye, as well as cytotoxic 
drugs, from cells. This process is detectable by FACS and allows for the identification 
and isolation of subpopulations of cells displaying these characteristics that are common 
of CSCs.
126,127
 ABC-G2 transporters were detected in the BTCC cell line T24. ABC-G2
+
 
and ABC-G2
−
 cells were cultured in vitro, and their growth characteristics were 
evaluated. ABC-G2
+
 cells demonstrated consistent proliferation, whereas the ABC-G2
−
 
did not. Side populations of ABC-G2
+
 also were able to differentiate into ABC-G2
−
 
cells, which further supports the hypothesis that ABC-G2
+
 is a marker of BTCC 
CSCs.
126
 See Table 1.2 for a listing of bladder CSC surface markers. 
 
1.2.10 Prostate cancer 
Prostate cancer is the most commonly diagnosed malignancy and second leading 
cause of death in men in the United States.
18
 More than 80% of men will develop 
prostate cancer in their lifetime, and most diseases will not be diagnosed.
128
 Prostate 
cancer is routinely treated by hormone ablation therapy, but this therapy regimen fails 
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when the disease progresses to a hormone-refractory state.
129
 Currently, cytotoxic small 
molecules are the only therapeutic regimen able to improve outcomes for patients with 
hormone-refractory prostate cancers.
130
 Identification of CSC surface markers could 
provide a foundation for the development of next-generation drugs that target prostate 
CSCs.
129
 
The first CSC surface marker identified for prostate cancer was CD44 (Table 
1.2). In 1997, Liu et al. reported their observation that CD44
+
 prostate cancer cells were 
negative for prostate-specific antigen (PSA) and prostate acid phosphatase secretion, 
which are proteins that are produced during cancer cell differentiation. On the other 
hand, when CD44
+
 prostate cancer cells were co-cultured with stromal cells, the 
secretion of PSA was detected, indicating that the interaction between stromal cells and 
CD44
+ 
prostate cancer cells stimulated the differentiation ability of the latter, since PSA 
production was not detected when either stromal cells or CD44
+
 prostate cancer cells 
when cultured alone.
131
 Collins et al. demonstrated that prostate CSCs could be 
identified from human specimens with a CD44
+/α2β1high/CD133+ phenotype, and this 
population comprised 0.1– 0.3% of the total amount of cells in the tumor. In a colony-
forming assay, the CD44
+/α2β1high/CD133+ population yielded 3.7-fold greater number 
of colonies compared with the total cell population and more than 30-fold greater 
number of colonies compared with CD44
+/α2β1high/CD133− or CD44+/α2β1low cells, 
which suggests the CD44
+
/α2β1high/CD133+ phenotype has the ability to self-renew.28 
Patrawala et al. performed in vivo studies in NOD/SCID mice utilizing prostate cancer 
cell lines that were enriched for the CD44
+
/α2β1high combination phenotype.132,133 They 
found that the CD44
+/α2β1high population had greater tumorigenicity than other 
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populations isolated (CD44
+/α2β1low, CD44−/α2β1high, CD44−/α2β1low), further 
supporting the evidence that the CD44
+/α2β1high phenotype is the CSC population.133 
Mulholland et al. later confirmed that the Lin
−
/Sca-1
+
/CD49f
high
 subpopulation of 
prostate cancer cells were CSCs in a murine prostate PTEN
−
 model (PTEN is a tumor 
suppressor gene in the protein kinase B pathway).
129
 The loss of PTEN activity is 
strongly associated with the initiation and metastasis of prostate cancer.
134
 Tissue 
samples were taken from murine PTEN mutant prostate tumor grafts on SCID mice after 
6–8 weeks, digested into single-cell suspensions, and sorted by FACS. Through a 
systematic study of various potential surface markers, Sca-1 and CD49f were identified 
as surface markers of prostate CSCs. Sorted cells (Lin
−
/Sca-1
+
/CD49f
high
 and Lin
−
/Sca-
1
+
/ CD49
flow
) were then injected into SCID mice and only Lin
−
/Sca-1
+
/CD49f
high
 cells 
induced tumor growth.
129
 See Table 1.2 for a listing of prostate CSC surface markers. 
 
1.2.11 Ovarian cancer 
The most lethal disease of the female reproductive tract is ovarian cancer.
135
 
High mortality rates occur due to the difficulty in diagnosing early stage ovarian cancer 
as well as the high prevalence of drug-refractory relapse after initial treatment, which is 
likely a result of CSC subpopulations that survive therapy.
136
 Ovarian cancer 5-year 
survival rates vary depending on the stage of development of the tumor. Early stage 
diagnosis, when the disease has yet to metastasize, has a 5-year survival rate of 73%, 
while late-stage ovarian cancer diagnosis results in a 28% survival rate.
18
 
Zhang et al. first identified CD44 as a potential ovarian CSC surface marker in 
2008. Analysis of human ovarian specimens revealed a small population (0.14–0.2%) of 
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CD44
+
/CD117
+
 cells (Table 1.2) that were highly tumorigenic and demonstrated self-
renewal by spheroid formation. Tumorigenicity was measured by engraftment of 
CD44
+
/CD117
+
 and CD44
−
/CD117
−
 subpopulations into nude mice. The CD44
+
/ 
CD117
+
 subpopulation was able to repopulate the tumor following injection of only 100 
cells, whereas the isolated CD44
−
/CD117
−
 phenotype required 500,000 cells for tumor 
development after 3 months.
135
 
Ferrandina et al. identified CD133
+
 subpopulations as ovarian CSCs in primary 
human samples. The CD133
+
 subpopulation was 4.7-fold more active in a colony-
forming assay, which demonstrated replicative capacity.
137
 Work by Curley et al. 
verified the presence of a CD133
+
 subpopulation with tumor-initiating properties and 
found that 0.2 – 12.5% of the tumors expressed this phenotype.138 
CD24
+
 has also been characterized as a potential surface marker of human 
ovarian CSCs. Two weeks after the plating of isolated CD24
+
 ovarian cancer cells, 
analysis of the cell population revealed both CD24
+
 and CD24
−
 phenotypes, which 
suggests that CD24
+ 
cells are CSCs due to their ability to self-renew and differentiate. 
Conversely, the same experiment performed with CD24
−
 cells failed to yield CD24
+
 
cells after the same amount of time in culture. Additional in vivo studies demonstrated 
that only 5,000 CD24
+
 cells were needed for tumor formation after injection into nude 
mice, whereas CD24
−
 cells injected at the same concentration were unable to generate 
tumors.
139
 Therefore, CD24
+
 cells are more tumorigenic than CD24
-
 cells. 
To add to the growing number of ovarian CSC markers, Wei et al. isolated a 
triple surface marker phenotype, CD44
+
/CD24
+
/EpCAM
+
, which best characterized the 
most proliferative cell subpopulation when compared with all other marker 
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combinations. Cells lines OVCAR-5, SKOV-3, and IGROV-1, as well as primary 
human donor samples were used for experiments. Colony-formation assays were 
performed on CD44
+
/CD24
+
/ EpCAM
+
 sorted cells to measure proliferation rates and to 
characterize self-renewal properties. In vivo studies were performed comparing 
CD44
+
/CD24
+
/EpCAM
+
 and CD44
−
/CD24
−
/EpCAM
−
 phenotypes by injection into 
NOD/SCID mice. These studies demonstrated that as few as 100 
CD44
+
/CD24
+
/EpCAM
+
 cells injected in NOD/SCID mice were capable of tumor 
formation, and CD44
+
/CD24
+
/EpCAM
+
 cells grew tumors faster and more aggressively 
than the CD44
−
/CD24
−
/EpCAM
−
 population.
140
 Consequently, the 
CD44
+
/CD24
+
/EpCAM
+
 phenotype was deemed to be more tumorigenic and likely a 
CSC population. See Table 1.2 for a listing of ovarian CSC surface markers. 
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Solid Tumor Type Marker(s) Reference 
Breast CD44
+
/CD24
-/low
/Lin
-
 [66, 69] 
 CD44
+
/CD24
-/low
/EpCAM
high
 [66] 
 ALDH1
+
/CD44
+
/cytokeratin
+
 [71] 
 CD90
+
/CD24
+
 [72] 
 CD133
+
/CD44
+
 [73-75] 
 CD173
+
/CD174
+
/CD44
+
 [3, 76] 
 CD176
+
/CD44
+ [5, 77] 
 CD176
+
/CD133
+
 [6, 77] 
 CD24
+
/CD29
+ 
[7, 8, 78] 
 CD24
+
/CD49f
+ 
[78] 
 CD44
+
/CD201 (PROCR)
+
 [79] 
Colorectal CD44
+
/EpCAM
high
 [80] 
 CD44
+
/EpCAM
high
/CD166
+
 [80] 
 CD44
+
/CD49f
+
 [80] 
 CD133
+
 [81, 82] 
 CD44
+
 [84] 
 CD133
+
/CD24
+
 [13, 87] 
Liver CD176
+
/CD44
+
 [77] 
 CD133
+
 [89] 
 CD133
+
/CD44
+
 [90] 
 EpCAM
+
 [91, 92] 
 CD13
+
/CD133
+
 [93] 
 CD13
+
/CD90
-
 [7, 93] 
 CD90
+
/CD45
-
 [94] 
 OV6
+
 [96] 
Pancreatic CD44
+
/CD24
+
/EpCAM
+
 [20, 98] 
 CD133
+
 [99] 
 CD133
+
/CXCR4
+
 [99] 
Skin CD133
+
 [102] 
 CD133
+
/ABCG-2
+ 
[25, 102] 
 Nestin
+
/CD133
+ 
[26, 27, 104] 
 ABCB5
+
 [28, 106] 
Brain CD133
+
 [111] 
 CD133
+
/Nestin
+
 [112] 
 CD133
+
/A2B5
+
 and CD133
-
/A2B5
+
 [113] 
 A2B5
+
 [30, 114] 
 CD133
+
/L1CAM
+
 [31, 116] 
 SSEA-1
+
 [118] 
Lung CD176
+
/CD44
+
 [32, 77] 
 CD176
+
/CD133
+
 [77] 
 CD133
+
 [121] 
Bladder Lin
-
/CD44
+
/CK5
+
/CK20
-
 [124] 
 CD47
+
/CD44
+
 [124] 
 CD44v6
+
/EMA
-
 [125] 
 ABC-G2
+
 [36, 126] 
Prostate CD44
+/α2β1
high
/CD133
+
 [28] 
 Lin
-
/Sca-1
+
/CD49f
high
 [37, 129] 
 CD44
+
/ α2β1
high
 [133] 
Ovarian CD44
+
/CD117
+
 [135] 
 CD133
+
 [137, 138] 
 CD24
+
 [139] 
 CD44
+
/CD24
+
/EpCAM
+
 [140] 
Table 1.2. Previously reported CSC markers for human solid tumors. 
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1.3 The chemical biology and drug targeting of cell surface markers on cancer stem 
cells 
The repertoires of cell surface macromolecules found on CSCs are widely used 
as markers for characterizing CSC populations (described previously). In addition to 
these diagnostic applications, the unique molecules that are presented on the surfaces of 
CSCs are valuable targets for drug delivery. However, many of the surface markers that 
are presented on CSCs are known to also be expressed at varying levels on the surfaces 
of normal, non-cancerous cells. Some of the reported CSC surface markers, in addition, 
have not been rigorously queried for expression across panels of non-cancerous tissue. 
Therefore, cell surface markers that are selected for targeted drug delivery applications 
must be evaluated for cancer cell selectivity during development studies to probe for off-
target effects.
8
 In the following section we review, where known, several of the 
established chemical and structural features that are characteristic of the most common 
CSC surface molecules, as well as previous efforts to deliver therapeutic agents to CSCs 
by targeting their unique cell surface markers. We recognize that an equally exciting 
area of intense investigation involves the identification of small molecules that possess 
CSC inhibitory properties, such as the recent reports of the anti-CSC activities of the 
natural products parthenolide and salinomycin.
19,141
 However, we have focused here on 
those therapeutic molecules that target CSC surface markers as part of their mechanism 
of inhibition. 
 Targeting of CD133. CD133 is a five-transmembrane protein consisting 
of 865 amino acid residues. It consists of two extracellular glycosylated loops and two 
cytoplasmic loops, bringing the final molecular weight of CD133 to 120 kDa.
142
 Under 
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bioenergetic stresses, such as hypoxic conditions, CD133 expression is upregulated 
significantly.
143
 No ligands or signaling mechanisms have been defined for CD133. 
Although the biological functions of CD133 have not been fully elucidated, the 
localization of CD133 to protrusions in the plasma membrane suggests a possible role in 
membrane organization.
142
 The rationale for this hypothesis is the observation that 
CD133 is commonly located on cell membrane protrusions, such as microvilli-like 
structures on epithelial cells, which are important for increasing the surface area and the 
reabsorption characteristics of those cells.
144,145
 In addition to its presence on CSCs from 
multiple diseases (vide supra), CD133 is commonly found as a marker of somatic stem 
cells, ranging from hematopoietic, neural, prostate, kidney, liver, and pancreas.
146
 
CD133 is one of the most prominent CSC surface markers. Although a multitude 
of monoclonal antibodies against CD133 have been previously described, most 
commercially available CD133 antibodies have limited applicability because they only 
recognize glycosylated CD133
+
 epitopes.
147
 Consequently, the majority of CD133 
antibodies fail to identify the entire CD133
+
 population. Nonetheless, a repertoire of 
CD133-recognizing antibodies is available for various uses. 
Clone7 is an anti-human CD133
+
 monoclonal antibody that recognizes 
glycosylated, as well as non-glycosylated, epitopes of CD133. Clone7 allows for 
multiple experiments with CD133 to be performed regardless of post-translational 
glycosylation status. Clone7 can be utilized in Western blotting, immunofluorescence, 
flow cytometry, and immunohistochemistry applications.
148
 
Single-walled carbon nanotubes functionalized with anti-CD133 antibodies to 
actively target CD133
+
 have been developed by Wang et al. Selective uptake of the 
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nanotubes was observed only in the CD133
+
 population, and phototherapy eradication of 
the CD133
+
 cells bearing the nanotubes was achieved by absorption of 808-nm near IR 
light.
149
 This study has yielded a potential photothermal approach to selectively target 
CD133
+
 glioblastoma cells. 
Lipid nanocapsules functionalized with anti-CD133 antibodies have been shown 
to target CD133
+
 CSCs, in recent work by Bourseau-Guilmain et al. Selective uptake by 
the CD133
+
 population was observed by fluorescence of Nile red, which was loaded into 
the lipid nanocapsules. Loading of hydrophobic drugs into the lipophilic cores of the 
nanocapsules is now being tested for the direct therapeutic targeting of CD133
+
 tumors 
with the goal of diminished side effects.
150
 
 Targeting of EpCAM. Epithelial cell adhesion molecules (EpCAM) are 
single transmembrane glycoproteins that play major roles in cell-cell adhesion, both 
constructively and disruptively.
151
 EpCAM is specifically expressed on epithelial 
cancers such as breast, colorectal, pancreatic, liver and ovarian tumors and can interfere 
with cell-cell adhesion in various ways. One interference method is the disruption of the 
bonding of α-cadherin and F-actin, which translates into a loss of E-cadherin-mediated 
cell-cell adhesion.
152
 Alternatively, EpCAM was originally observed to prevent cell 
scattering due to cellular adhesion characteristics.
153
 Because of this dual role in 
adhesion of cells, EpCAM expression is both tumor promoting as well as tumor 
suppressive. The role EpCAM takes within a tumor is dependent on the tumor type.
151
 
Catumaxomab (Removab®, developed by Fresenium Biotech GmbH and Trion 
Phama) is a rat–mouse hybrid monoclonal and tri-functional antibody against EpCAM, 
CD3 antigen in T cells, and antigen-presenting cells (APC; such as microphages, natural 
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killer cells, and dendritic cells).
154,155
 Its capability of binding three different types of 
cells comes from its unique structure: It is a heterozygous antibody with one chain of 
mouse anti-EpCAM antibody and one chain of rat anti-CD3 antibody. The heavy-chain 
Fc region of both chains can bind to the Fc receptors on APCs. Catumaxomab is more 
than 1,000-fold more potent than a monospecific anti-EpCAM antibody in killing cancer 
cells.
154,155
 Catumaxomab does not require the utilization of any additional reagent(s) to 
stimulate the immune response. The different specificities of the antigen binding sites of 
the two antibody chains enable simultaneous recognition of both tumor cells (especially 
CSCs) and T cells, and the functionalized heavy chain Fc domain is able to recruit and 
stimulate APC, resulting in the initiation of complex immune reactions. In a pivotal 
phase II/III clinical study, Catumaxomab treatment lead to activation of peritoneal T 
cells and a completion elimination of CD133
+
/EpCAM
+
 cells from the peritoneal fluid of 
malignant ascites patients.
156,157
 Catumaxomab was approved in the European Union in 
2009 and is undergoing Phase III clinical trials in the United States for the treatment of 
malignant ascites, ovarian cancer, and gastric cancer.
158
 In addition to Catumaxomab, 
there are other bi-functional or trifunctional EpCAM-targeting antibodies undergoing 
preclinical studies or clinical trials. 
MT110 (developed by Micromet GmbH) belongs to a class of single-chain 
antibodies called bispecific T cell engager or BiTE. MT110 was constructed by coupling 
the antigen binding domains of α-CD3 and α-EpCAM monoclonal antibodies, yielding a 
hybrid antibody with specificity for both EpCAM and CD3.
159
 A BiTE antibody enables 
the generation of a cytolytic synapse between a cytotoxic T cell and a target cell that 
binds to the BiTE antibody.
160
 In the case of MT110, the target cell is a tumor cell that 
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expresses the EpCAM cell surface marker. The formation of the cytolytic synapse 
induces T cells for redirected lysis of the EpCAM+ target cell at pico- to femtomolar 
concentrations.
159
 MT110 has been shown to have high antitumor activity in various 
animal models
159,161
 and is capable of completely eliminating colorectal CSCs in cell 
culture and in animal models.
162
 MT110 is currently in Phase I clinical trials in the 
United States for lung and gastrointestinal cancers.
163
 
Edrecolomab (Mab17-1A, Panorex®, developed by Cancer and Leukemia Group 
B) was one of the first monoclonal antibodies administered to humans for cancer 
therapy. Edrecolomab is a low-affinity murine IgG2a monoclonal antibody that targets 
the cell-surface glycoprotein EpCAM. Because of the extensive basal level expression of 
EpCAM molecules on normal epithelial cells,
164
 the toxicity of EpCAM-targeting 
antibodies was viewed as a potential obstacle for the development of this class of 
therapies,
165
 Since the expression level of EpCAMon the surface of CSCs is much 
higher than it is on the surface of normal epithelial cells, the designed low-affinity 
edrecolomab decreases the possibility of off-target effects while maintaining efficacy for 
targeting CSCs, which makes edrecolomab a well-tolerated drug with a relatively wide 
therapeutic window.
165
 Edrecolomab, which is thought to eliminate tumor cells by 
antibody-dependent cell-mediated cytotoxicity (ADCC) and/or complement-dependent 
cytotoxicity (CDC),
166,167
 underwent Phase II–III clinical trials in the United States as a 
potential postoperative adjuvant treatment of stage II colon cancer. However, the clinical 
trial was terminated in 2005 because of lack of improvement of overall or disease-free 
survival.
168
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Adecatumumab (MT201, developed by Micromet GmbH) is a fully humanized, 
recombinant IgG1 monoclonal antibody that specifically binds to EpCAM with low 
affinity. It was designed to retain the safety profile, yet improve the antitumor potency 
of edrecolomab. MT201 exhibited EpCAM-specific CDC with potency similar to that of 
edrecolomab, but the efficacy of ADCC induction of MT201 was twofold greater than 
that of edrecolomab.
167
 It also has been reported that the combination of adecatumumab 
and docetaxel is safe and efficacious in heavily pretreated advanced-stage breast cancer 
patients.
169
 MT201 is now in Phase II clinical trials in the United States for the treatment 
of prostate, colorectal, and metastatic breast cancers.
167
 
 Targeting of CD44. The lymphocyte adhesion receptor CD44, first 
described in 1983,
170
 is a transmembrane glycoprotein that binds hyaluronate (HA).
171
 
CD44 was first cloned in 1989,
172
 and the binding domain was crystallized in 2004 
(PDB 1POZ),
173
 CD44 is involved in many important cellular processes, including cell 
growth, survival, differentiation, and apoptosis.
174-176
 CD44 plays a crucial role in cancer 
migration and matrix adhesion in response to the cellular microenvironment, and high 
CD44 levels are associated with increasing cellular aggregation and tumor metastatic 
potential.
171
 The importance of CD44 in cancer cells, especially in CSCs, is closely 
related to its unique structure and function. The extracellular domain of CD44, which is 
a globular structure, contains two domains: a link domain and a HA binding 
domain.
171,177
 Binding sites for microenvironment proteins, such as laminin, collagen, 
and fibronectin,
178,179
 receptors such as E- and L-selectin,
180
 and other 
glycosaminoglycans have also been characterized.
181
 The transmembrane region of 
CD44 contains a glycolipid-enriched microdomain (GEM), which is responsible for the 
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oligomerization of CD44s.
182
 The crosslinking and GEM association of CD44s, which is 
often induced by the binding of HA or other ligands, leads to a conformational change of 
the molecule and is important in CD44-mediated signal transduction.
183
 The main 
function of the cytoplasmic domain of CD44 is to recognize its partner molecules 
ankyrin, ezrin, radixin, and moesin (ERM). ERM proteins are cytoskeleton proteins that 
regulate cell migration, cell shape, and protein resorting in the plasma membrane.
184
 The 
unique structure of CD44 molecules indicates that they are functionally important to 
CSCs. CD44 regulates cancer cell adhesion and homing,
26
 cell extravasation and 
migration,
185
 the crosstalk between stem cells and their niche,
186
 epithelial mesenchymal 
transition,
187
 and the repression of cell apoptosis.
188
 Each of these functions contributes 
to the observation that CD44 is one of the most prevalent surface markers in CSCs.
189
 
CD44 is a cell surface marker extensively expressed on the surface of a large range of 
CSCs including AML, bladder, breast, colorectal, liver, ovarian, pancreatic, and prostate 
cancers (Tables 1.1 and 1.2). 
H90 is an anti-CD44 monoclonal antibody that was first reported by John Dick 
and colleagues in 2006 as a therapeutic approach to treat AML.
20
 Currently, the majority 
of leukemia chemotherapeutics are antiproliferative drugs that target rapidly cycling 
leukemic cells. However, disease relapse is observed in more than 70% of adult patients, 
indicating that quiescent AML CSCs have not been effectively removed.
190
 AML CSCs 
are more difficult to target than highly proliferative and differentiated leukemic cells due 
to their quiescent nature. However, the survival and self-renewal of AML CSCs requires 
attachment to extracellular niche proteins.
191
 Thus, targeting the interaction between 
niche proteins and AML CSCs, which is mediated by the cell surface marker CD44, may 
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provide a mechanism to eradicate AML CSCs.
192
 In vivo administration of H90 to 
NOD/SCID mice transplanted with human AML showed a significant decrease in 
leukemia repopulation.
20
 
P245 is another CD44-specific monoclonal antibody with a design and targeting 
rationale similar to H90. Administration of P245 to human breast cancer xenografts 
markedly decreased the growth of tumor cells and effectively prevented tumor relapse 
after chemotherapy-induced remission. P245 is now under preclinical study for the 
treatment of breast cancer.
193
 Both of the above CD44-specific antibodies also have the 
effect of inducing differentiation in CSCs.
26
 
 Targeting of CD33. CD33 is a myeloid cell surface antigen that is 
expressed on leukemic blasts from 85% to 90% of AML patients,
44
 and the combination 
phenotype CD34
+
/CD38
−
/CD123
+
/CD33
+
 is uniquely expressed on the surface of AML 
CSCs.
45
 CD33 is a single transmembrane protein that is activated by phosphorylation.
194
 
CD33 functions as a putative adhesion molecule of monocytic and myeloid lineage cells 
and modulates sialic acid-dependent binding and cell differentiation.
44
 In immune 
responses, CD33 acts as an inhibitory receptor of ligand bindinginduced tyrosine 
phosphorylation by recruiting cellular phosphatases to its SH2 domain and blocking 
signal transduction through hydrolysis of the phosphates of signaling molecules.
195,196
 
CD33 also induces apoptosis in acute myeloid leukemia through mechanisms that are 
not fully characterized.
197
 
Gemtuzumab ozogamicin (Mylotarg®, developed by Wyeth and Pfizer) is a 
small-molecule–anti-CD33 monoclonal antibody conjugate. The small-molecule 
component of this drug is N-acetyl γ-calicheamicin dimethyl hydrazide, a stable 
  37 
enediyne antitumor antibiotic that was identified from a screen of potent DNA 
alkylators.
198
 The antibody component is a humanized IgG4 anti-CD33 antibody 
(hP67.6) that is conjugated to calicheamicin by an acidlabile hydrazone linker. Studies 
have shown that the antibody–drug conjugate exhibits good potency, as well as 
selectivity, which is attributed to its property of only releasing the DNA alkylator in the 
acidic environment of cellular lysosomes (i.e., it is stable in blood).
199,200
 The antibody 
component of gemtuzumab ozogamicin (GO) is largely non-toxic and functions to 
facilitate the uptake of calicheamicin into CD33
+
 AML cells. Once released, 
calicheamicin undergoes rearrangement to form a diradical metabolite that is capable of 
binding DNA and initiating single- and double-stranded DNA breaks, which results in 
cell cycle arrest or apoptosis.
201
 GO was marketed as an AML therapeutic from 2000 to 
2010 but was voluntary withdrawn from the market in June 2010 when postclinical trials 
showed an increasing number of deaths and a lack of benefit compared with other 
conventional cancer therapies.
202
 Currently, the combination of GO and other 
chemotherapeutics are under various stages of clinical investigations.
203
 
 Targeting of CD34 HSC antigen. CD34 is a single transmembrane 
glycoprotein and belongs to the CD34 family of proteins.
204
 CD34 was first identified as 
a surface marker of immature lymphohematopoietic progenitor cells in 1984.
205
 Four 
years later, Berenson et al. reported that, following the transplantation of CD34
+
 human 
marrow cells, hematopoietic systems were able to reconstitute in lethally irradiated 
baboons.
206
 CD34 has been widely used as a surface marker for the identification of non-
cancerous hematopoietic stem cells for over three decades
207
 and, more recently, has 
been identified as a CSC marker for multiple diseases (vide supra). Besides 
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hematopoietic and leukemic stem and progenitor cells, CD34 is also widely expressed 
on the surface of vascular endothelial cells and mast cells.
207
 In spite of the functional 
importance of CD34, the crystal structure of this protein remains unsolved. As a result, 
the structure and function of CD34 is not as wellstudied as CD44. The extracellular 
domain of CD34 contains a serine-, threonine- and proline-rich domain that is 
extensively glycosylated and sialylated.
208,209
 Moreover, a juxtamembrane stalk region, a 
cysteine-bonded globular domain, and a putative N-glycosylation site were also 
identified in the extracellular section of CD34.
204
 The most well-known intercellular 
binding partner of CD34 is L-selectin, which is a cellular adhesion molecule expressed 
on the surface of leukocytes.
210
 Other potential ligands of CD34 are also under 
exploration. In addition, each CD34 protein comprises a single transmembrane helix and 
a cytoplasmic domain that contains highly conserved phosphorylation sites and a C-
terminal PDZ (postsynaptic density protein) binding motif.
208,211
 The PDZ binding motif 
of CD34 recognizes Crk-like protein, which is an adaptor protein that further interacts 
with the N terminus of NHERF (Na(+)/H(+) exchange regulatory cofactor) scaffolding 
proteins. The C terminus of NHERFs contains an ERM binding domain, which 
facilitates the indirect interaction of actin cytoskeleton with other binding partners of 
NHERF proteins.
212
 CD34 has been proposed to be involved in enhancing 
proliferation,
208
 blocking differentiation,
213
 promoting lymphocyte adhesion,
209
 and the 
trafficking of hematopoietic cells.
204,214
 Because of the ubiquitous expression pattern of 
CD44 on the surface of both cancerous and normal cells, it has not been utilized for drug 
delivery to CSCs. 
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 Targeting of ABCB5. ABCB5 (ATP-binding cassette sub-family B 
member 5) is a member of ABC transporter proteins that contains two transmembrane 
domains and two nucleotide binding domains.
215
 ABC transporter proteins are part of the 
pglycoprotein family and are responsible for the transport of a large array of substrates 
across cellular membranes. Due to these characteristics, ABC transporter proteins are 
responsible for the multidrug resistance profiles of cancer cells due to their ability to 
export drugs from cells. ABCB5 exists in two isoforms, α and β, and is a cell surface 
marker that is currently known to be expressed on skin cancer cells and is closely 
associated with the chemoresistance of malignantmelanoma-initiating cells (MMICs).
216
 
3C2-1D12 is a monoclonal anti-ABCB5 antibody. Systematic administration of 
3C2-1D12 into nude mice revealed an increase in ADCC in ABCB5
+
 MMICs, as well as 
tumor-inhibitory effects.
106
 This anti-ABCB5 monoclonal antibody has not yet reached 
preclinical testing status. 
 Targeting of CD13. CD13 (alanine aminopeptidase N) is a 967-amino 
acid single-transmembrane peptidase, consisting of a small N terminus and a large C 
terminus that contains the active site.
217
 CD13 is found ubiquitously in various organs, 
such as the kidneys, small intestines, and the liver. CD13 plays an important role in 
antigen processing for the immune response and is expressed in T and B cells as well as 
macrophages.
218
 CD13 has been reported as a diagnostic cell surface marker in liver 
CSCs.
93
 
Ubenimex is a small molecule inhibitor of CD13. Ubenimex (bestatin) is a 
dipeptide isolated from Streptomyces olivoreticuli
219
 and is known to have antitumor 
effects through augmentation of the host immune system.
220,221
 Ubenimex is a 
  40 
competitive protease inhibitor and deters the growth of lung cancer and leukemic cell 
lines.
222,223
 A mechanism of action has been proposed by the co-crystallization of 
ubenimex with leukotriene A4 hydrolase (PDB 1HS6),
224
 which is structurally 
homologous to cell surface antigen CD13.
225
 Studies have shown that, in mouse xeno-
graft models, the combination of CD13 inhibitor and anti-proliferation agent fluorouracil 
dramatically reduces tumor size, as well as tumor progression, as compared with either 
single agent therapy.
93
 Ubenimex is not under clinical investigation at the present time. 
 Targeting of CD123. CD123 is the α subunit of the interleukin-3 cell 
surface receptor. It has been elucidated as a CSC marker in AML
42
 but also has been 
identified as a marker of normal hematopoietic stem cells, where it plays an important 
role in proliferation.
226
 Structural information for CD123 is not well established. 
7G3 is a monoclonal anti-CD123 antibody. Targeting of CD123 by this antibody 
has been shown to significantly reduce CD34
+
/CD38
−
 AML CSC cell populations and 
tumor engraftment in NOD/SCID mice. However, the efficacy of the antibody in 
established AML disease treatment models is still limited, and optimization is required 
before this strategy is suitable for clinical investigations. The proposed mechanism of 
anti-CD123 antibodies (e.g., 7G3) includes the inhibition of AML CSC homing to bone 
marrow and prevention of activation of human CD123 by IL-3.
227
 To our knowledge, 
molecules of this class are not yet in clinical trials. 
 Targeting of CD47. The leukocyte surface antigen CD47 plays an 
important role in cell adhesion by acting as a platelet adhesion receptor.
228
 CD47 is 
widely expressed at low levels in many tissues and highly expressed on AML CSCs, 
where increased CD47 expression is indicative of poor prognosis.
51
 One functional 
  41 
ligand of CD47 is signal regulatory protein-α (SIRPα), which is expressed on 
phagocytes. The interaction between CD47 and SIRPα activates a signal transduction 
cascade that results in the inhibition of phagocytosis.
229
 The ecto-domain of CD47 was 
crystallized in 2008 (PDB 2JJS).
230
 
Clone B6H12.2 is a monoclonal antibody that blocks the interaction between 
CD47 and SIRPα. It has been demonstrated that B6H12.2 enables phagocytosis of 
human AML CSCs in vitro and has therapeutic potential.
51
 In NOD/SCID mice, 
B6H12.2 treatment depleted AML cells in peripheral blood.
231
 In a preclinical in vivo 
mouse treatment model with high levels of engraftment, treatment with anti-CD47 
antibodies resulted in the rapid clearance of AML and targeting of the CSC 
population.
51,231
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Antibody/Agents Description Cancer Indication Reference 
Clone7 
 
Monoclonal antibody against 
CD133 
Brain 
 
[148] 
CD133 targeted 
carbon nanotubes 
 
 
Single walled carbon nanotubes 
functionalized with anti-CD133 
monoclonal antibodies 
Brain 
 
 
 
[149] 
 
 
CD133 targeted lipid 
nanocapsules 
 
 
Lipid nanocapsules functionalized 
with anti-CD133 monoclonal 
antibodies 
Colorectal 
 
 
 
[150] 
 
 
 
Catumaxomab 
 
 
Monoclonal trifunctional antibody 
against EpCAM, CD3 and APCs 
Malignant ascites, 
ovarian and gastric 
 
[158] 
 
 
MT110 
 
 
Monoclonal single chain bispecific 
antibody against EpCAM and CD3 
Colorectal, lung, gastric 
 
 
[163] 
 
 
Edrecolomab 
 
Monoclonal antibody against 
EpCAM 
Colorectal 
 
[168] 
 
Adecatumumab  
(MT201) 
Monoclonal antibody against 
EpCAM 
Breast, colorectal, 
prostate 
[167] 
 
H90 
 
 
Monoclonal antibody against 
CD44 
 
Acute myelogenous 
leukemia 
 
[20] 
 
 
P245 
 
Monoclonal antibody against 
CD44 
Breast 
 
[193] 
 
Gemtuzumab 
ozogamicin (GO) 
 
Small molecule-anti-CD33 
antibody conjugate 
 
Acute myelogenous 
leukemia 
 
[199, 200] 
 
3C2-1D12 
 
Monoclonal antibody against 
ABCB5 
Melanoma 
 
[106] 
Ubenimex 
 
Dipeptide small molecule inhibitor 
of CD13 
Liver 
 
[93] 
 
7G3 
 
Monoclonal antibody against 
CD123 
Acute myelogenous 
leukemia 
[227] 
 
Clone B6H12.2 
 
Monoclonal antibody against 
CD47 
Acute myelogenous 
leukemia 
[51] 
 
 
Table 1.3: Targeting of CSC populations by antibodies and small molecules. 
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CSC marker 
 
Other common names 
 
Cancerous tissue 
where expressed 
A2B1 α2β1 Integrin; a2b1 integrin; CD49b Prostate 
A2B5 α2β5 Integrin; a2b5 integrin brain 
ABCB5 
ABCB5 P-gp; ATP-binding cassette sub-family B member 
5 
melanoma 
ABCG2 ABC transporter G family member 2 skin, bladder 
CD4 Leu-3; T4 ALL 
CD7 GP40; Leu-9; TP41 ALL 
CD9 
BTCC-1; DRAP-27; MIC3; MRP-1; TSPAN-29; 5H9 
antigen; p24 
ALL 
CD10 Atriopeptidase; CALLA; Enkephalinase; Neprilysin; SFE ALL 
CD13 Aminopeptidase N; Alanyl aminopeptidase; gp150; Lap1 liver 
CD19 B-lymphocyte surface antigen B4; Leu-12 ALL 
CD24 Small cell lung carcinoma cluster 4 antigen 
breast, colorectal, 
ovarian, pancreatic 
CD25 Interleukin-2 receptor subunit alpha; TAC antigen; p55 AML 
CD29 
Integrin beta-1; Fibromectin receptor subunit beta; VLA-4 
subunit beta 
breast 
CD32 Low affinity IgG Fc receptor II-b; CDw32; Fc-gamma RIIb AML 
CD33 Siglect-3; gp67 AML, ALL 
CD34 Hematopoietic progenitor cell antigen CD34 AML, ALL, CML 
CD38 ADP-ribosyl cyclase 1; cADPr hydrolase 1; T10 AML, ALL, CML 
CD44 
CDw44; Epican; ECMR-III; GP90 receptor; HUTCH-I; 
Heparan sulfate proteoglycan; Hermes antigen; PGP-1; 
Hyaluronate receptor 
AML, bladder, breast, 
colorectal, liver, ovarian, 
pancreatic, prostate 
CD45 
Receptor-type tyrosine-protein phosphatase C; Leukocyte 
common antigen; T200 
AML, liver 
CD47 
Leukocyte surface antigen CD47; antigenic surface 
determinant 
protein OA3; integrin-associated protein; MER6 
AML, bladder 
CD49f Integrin alpha-6; VLA-6 
breast, colorectal, 
prostate 
CD71 Transferrin receptor protein 1; T9; p90 AML, breast, liver 
CD90 Thy-1 membrane glycoprotein ALL, AML, breast, liver 
CD96 
T cell surface protein tactile; T cell-activated increased late 
expression protein 
AML 
 
Table 1.4. Alternative names of CSC surface markers that appear in this chapter. 
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CSC 
marker 
 
Other common names 
 
Cancerous tissue where 
expressed 
CD110 
Thrombopoietin receptor; Myeloproliferative leukemia 
protein; 
Proto-oncogene c-Mpl 
ALL 
CD117 
Mast/stem cell growth factor receptor kit; Piebald trait 
protein; c-kit; p145; 
Tyrosine-protein kinase kit 
AML, ovarian 
   
CD133 Prominin-1; antigen AC133; Prominin-like protein 1 
ALL, brain, breast, 
colorectal, liver, lung, 
melanoma, ovarian, 
pancreatic, prostate 
CD166 Activated leukocyte cell adhesion molecule colorectal 
CD173 H2 breast 
CD174 Lewis Y breast 
CD176 Thomsen-Friedenreich antigen (TF) breast, liver, lung 
CD201 Endothelial protein C receptor; PROCR; APC receptor breast 
CK20 Cytokeratin-20; Protein IT bladder 
CK5 
Type II keratin Kb5; Cytokeratin-5; 58 kDa cytokeratin; 
Keratin-5; 
Type II cytoskeletal 5 
bladder 
CLL-1 
C-type lectin domain family 12 member A; DCAL-2; 
MICL 
AML 
CXCR4 
FB22; Fusin; HM89; LCR1; LESTR; NPYRL; SDF-1 
receptor; CD184; 
C-X-C chemokine receptor type 4 
pancreatic 
Cytokeratin Keratin breast 
EMA 
Epithelial membrane antigen; MUC-1; CD227; PEM; 
PUM; KL-6; H23AG; 
Episialin; Carcinoma-associated mucin; Breast 
carcinoma-associated 
antigen DF3 
bladder 
EpCAM 
CD326; GA733-2; KSA; KS1/4 antigen; ESA; EGP314; 
EGP-2; Adenocarcinoma-associated antigen; Cell surface 
glycoprotein Trop-1 
breast, colorectal, liver, 
ovarian, pancreatic 
HLA-DR CD74; p33; Ia antigen-associated invariant chain AML 
L1CAM CD171 brain 
Lin Cell lineage protein 
AML, bladder, breast, 
prostate 
OV6 - liver 
Sca-1 Stem cell antigen-1 prostate 
SSEA-1 Stage-specific embryonic antigen-1; CD15 brain 
 
Table 1.4 (continued). Alternative names of CSC surface markers that appear in this 
chapter. 
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1.4 Summary and conclusions 
Numerous studies have reported the existence of tumor cell populations with 
abilities to self-renew, differentiate, and potently initiate tumorigenesis. These cell 
populations, termed cancer stem cells (CSCs), are strongly implicated in disease 
propagation and, if not addressed during drug therapy, can facilitate disease relapse. 
Consequently, there is a significant and unmet need to better characterize the unique 
biology of CSCs as well as develop therapies to eradicate them. CSC markers, which are 
macromolecules (e.g., proteins, carbohydrates, etc.) that are uniquely expressed on the 
surface or in the cytoplasm of CSCs, are essential for the isolation and characterization 
of CSC populations. Additionally, these CSC markers provide targets for the specific 
delivery of therapeutic molecules into CSCs. In this article, we reviewed those cell 
surface macromolecules that are presented on the surfaces of many tumor CSCs, 
described the unique chemical and structural features of the most common markers, and 
reported recent efforts to target CSC surface markers as part of drug delivery efforts. 
Clearly, the field of CSC biology is still in its infancy and even less advanced are efforts 
to target those cells with therapeutic molecules. However, given that the elimination of 
CSCs may result in significantly enhanced therapy outcomes in patients, the focus of 
cancer drug discovery scientists should shift, at least in part, to designing next 
generation drugs that target CSC populations. 
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Chapter 2. Elucidating the Cellular Targets of the Anticancer 
Natural Product Parthenolide  
 
2.1 Introduction 
Cancer is the leading cause of death worldwide, and the second leading cause of 
death in the United States, only after heart diseases. It accounts for 7.6 million deaths 
(around 13% of all deaths) in 2008 worldwide
232
 as well as 565,469 deaths in the US.
233
 
Massive amount of research has been carried out to study the growing patterns of tumor 
cells, in pursuit of effective therapeutic methods against this malignant disease. 
Currently, there are two well-developed theories interpreting the patterns of cancer cell 
growth. The first one is the traditional stochastic model of cancer cell growth, which 
assumes that every tumor cell has the equal potential to develop into a new tumor, and 
their variable activities are fully or partially determined mathematically by stochastic 
models.
234
 The other theory is hierarchical model (Figure 2.1), which predicts that 
cancer stem cells (CSCs), which are also known as tumor-propagating cells or tumor-
 
Figure 2.1: Depiction of the CSC hierarchy model of cancer growth with cells 
undergoing self-renewal or differentiation into discrete tumor cell types. Graphic from 
1
.  
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initiating cells, represent a biologically unique subpopulation within the total malignant 
cell population, although it is not necessary that CSCs are genetically or functionally 
homogeneous.
235
 CSCs are undifferentiated, highly tumorigenic cells found within bulk 
tumors. CSCs have the ability to self-renew, differentiate, and generate a phenotype-
identical copy of the tumor from which they were isolated. Accordingly, CSCs reside at 
the apex of the tumor cell hierarchy and can differentiate into all of the cell types that 
comprise the host tumor. Besides CSCs, all other cells in the cancer cell hierarchy have 
only limited proliferative capacity.
1-8
 CSC theory directly challenges the traditional 
stochastic model of cancer cell growth; however, the rapid advances of cancer research 
and development of relative technologies have provided more and more evidence for the 
existence of CSCs. For example, with fluorescence-activated cell sorting (FACS) 
techniques, John Dick and colleagues provided the first seminal evidence for CSC by 
isolating the CD34
+
/CD38
−
 fraction of human donor acute myeloid leukemia (AML) 
cells and engrafting those cells into severe combined immunodeficient (SCID) mice, 
which resulted in the development of identical disease to that of the donor.
9,10
 Isolation 
of the AML CSC population (CD34
+
/CD38
−
) from the recipient mouse, followed by 
serial transplantation into a secondary recipient mouse yielded the same disease, thereby 
demonstrating the self-renewal properties of the initially engrafted CD34
+
/CD38
−
 AML 
cell fraction. On the other hand, the engraftment of other leukemic cell population, such 
as CD34
+
/CD38
+
 cells or CD34
-
 cells did not result in the occurrence of AML,
10
 which 
is another critical evidence of the hierarchy model of tumor heterogeneity.  
The clinical impact of the CSC hierarchy model of cancer growth is that the 
eradication of CSCs inevitably results in the death of tumors; on the other hand, the 
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failure to do so raises the possibility of disease relapse. A realized example of this 
concern has been documented with patients receiving the targeted BCR-ABL tyrosine 
kinase antagonist imatinib (Gleevec®) for chronic myelogenous leukemia (CML). 
Although imatinib effectively converts CML into a chronically managed disease,
22,23
 
withdrawing from imatinib treatment ultimately results in disease relapse in most 
patients because the drug does not eliminate CML CSCs.
24,25
  
However, drug targeting of CSCs is extremely challenging from two aspects. 
First of all, under standard biological conditions, CSCs are quiescent, which means their 
replication rate is lower than differentiated cancer cells.
18,19
 As a result, CSCs are 
resistant to most chemotherapeutic drugs that target the replication process of tumor 
cells. Other reported mechanisms of the drug resistance of CSCs include their expression 
of anti-apoptotic proteins,
16
 and the up-regulation of ABC multidrug resistance 
transporter proteins.
16,17
 The concern of drug resistance of CSCs is underscored by the 
example of cytarabine. Cytarabine is a front-line small molecule drug (nucleoside 
analogue) for the treatment of AML, which is designed to induce apoptosis in rapidly 
dividing cancer cells.
236
 However, recent data have demonstrated that cytarabine 
actually facilitates the entry of AML CSCs into their G0/G1 phase, thereby promoting 
cell cycle quiescence and providing a mechanism that allows AML CSCs to evade 
chemotherapy.
21
 Consequently, viable strategies to eradicate CSC populations are 
clearly needed if curative cancer therapies are to be developed.  
The second barrier towards the development of cytotoxic agents of CSCs is the 
structural and functional similarity between CSCs and normal stem cells. Considering 
the critical function of normal stem cells, to maintain their population and viability is 
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very important during the drug targeting of CSCs. For example, AML CSCs and normal 
hematopoietic stem cells (HSCs), whose differentiation yields the individual cells in the 
blood, share the same cell surface antigen profile CD34
+
/CD38
−
.
42
 Both cell types 
express Bmi1 and PTEN, which are involved in pathways that governs their self-renewal 
capability,
237,238
 and both of them are highly quiescent.
239
 Despite the highly 
biochemical similarity between AML CSCs and HSCs, some unique features of AML 
CSCs have recently been reported. For example, AML CSCs failed to express the known 
characteristic HSC cell surface antigen CD90 and CD117.
39,41
 On the other hand, the 
expression of CD123 (IL-3 receptor alpha chain) on the surface of AML CSCs has not 
been found in HSCs.
42
 In addition, elevated activity and over expression of transcription 
factor NF-κB has been observed in primitive human AML cells, including the quiescent 
CSC subpopulation; however, the NF-κB activity in HSCs generally remains in basal 
levels.
240,241
 Considering the known relationship between the NF-κB activity and its 
involvement in trigging apoptosis and inflammation in cancerous cells,
242,243
 the 
modulation of NF-κB signaling pathway may present a valuable and novel target for the 
eradication of AML CSCs.  
NF-κB (nuclear factor-κB)244 is an inducible dimeric transcription factor that 
consists of the combinations of p50, p52, p65, c-Rel and RelB proteins. NF-κB has been 
found in almost all animal cells and activates the expression of genes associated with 
numerous cellular processes such as differentiation, proliferation and cellular responses 
to stimuli, including pathogens, cytokins, stress, free radicals and so on.
245
 Playing a key 
role in the regulation of cellular inflammatory and immune responses, the activity level 
of NF-κB is coordinated by complex modulation mechanisms. In the canonical NF-κB 
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signaling pathway (Figure 2.2), a dimeric NF-κB (normally a p50-p65 heterodimer) is 
retained in the cytoplasm via interaction with its inhibitor protein IκBα. In response to 
various extracellular stress signals or pathogens, the IKKα/IKKβ/NEMO complex (IKK 
complex) phosphorylates IκBα protein and induces its ubiquitination and subsequent 
degradation by the 26S proteasome.
245-247
 The degradation of IκBα causes the p50/p65 
heterodimer to relocate from cytoplasm to nucleus
248
 and bind to NF-κB response 
elements to upregulate the expression of genes that involved in the enabling of cell 
proliferation, activation of cell invasion, secretion of anti-apoptotic proteins and so 
on.
245,249,250
 
Due to the crucial role NF-κB signaling pathway plays in the CSCs, a spectrum 
of known small molecule inhibitors of NF-κB signaling pathway has been screened by 
the Jordan laboratory (University of Rochester) as potential anti-CSC agents. Among the 
evaluated compounds, the natural product parthenolide (PTL, 1, Figure 2.3) was 
identified as a selective cytotoxic agent against AML CSCs, while sparing normal 
HSCs.
19
 PTL is sesquiterpene lactone isolated from Mexican Indian medicinal herb 
Tanacetum parthenum (feverfew plant),
251
 which has been used for over a century for 
the treatment of various common inflammatory conditions such as arthritis, asthma, 
 
Figure 2.2: The canonical NF-κB signaling pathway. 
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fever, and migraine.
252,253
 PTL has been extensively studied as an anticancer agent, 
showing significant efficacy towards a wide spectrum of human cancer cells, such as 
brain cancer,
254
 prostate cancer,
255,256
 breast cancer,
257,258
 chronic lymphocytic 
leukemia,
259
 and pancreatic cancer.
260
 As introduced above, in 2005, the identification of 
PTL as the first stand-alone and selective cytotoxic compound against AML CSCs 
further heightened its therapeutic potential.
19
 Besides AML, PTL was demonstrated to 
effectively inhibit the survival of CSCs in other cancer types, including breast cancer
261
 
and prostate cancer.
262
 In addition, the modification of PTL to a dimethylamino 
derivative of parthenolide (LC-1, 2, Figure 2.3) has yielded a water-soluble analogue, 
which exhibit in vivo (canines) therapeutic efficacy against AML CSCs and progenitor 
cells,
263
 and is now in a phase I clinical trial for the treatment of AML in the United 
Kingdom. 
In spite of the promising anticancer activity of PTL, the mechanism of action by 
which it eliminates CSCs has not been fully understood. As introduced above, the 
inhibitory of NF-κB signaling is so far the most widely accepted molecular mechanism 
of its biological activity. In previous studies, Crews and co-workers demonstrated that 
PTL inhibited NF-κB signaling via covalent modification of IKKβ kinase;264 Garcia-
Pineres and co-workers reported that the anticancer activity of PTL was achieved by the 
covalent modification of p65 protein.
265
 Both of the above studies believed that the 
inhibition of NF-κB signaling pathway was responsible for the biological activity of 
 
Figure 2.3: Structure of Parthenolide (1) and LC-1 (2). 
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PTL, and their theories were supported by the protein pull-down results reported by 
Nasim and coworkers in 2011,
266
 where both IKKβ and p65 were identified as cellular 
targets of PTL affinity probes by western blots. However, published results from Jordan 
and co-workers indicated that the inactivation of NF-κB pathway in primary AML cells 
via the introduction of an IκB superrepressor allele, which completely blocks NF-κB 
signaling by the expression of a degradation-resistant IκBα protein, only partially 
abolishes AML CSCs viability.
241
 This result questions the importance of inhibiting NF-
κB pathway when targeting CSCs. In addition, experimental results from our lab, which 
will be shown below (Figure 2.6), indicated that PTL does not inhibit NF-κB related 
kinases, including IKKβ, to a significant extent, at a concentration well above its IC50 
value in vitro. On the other hand, PTL has also been implicated to affect a wide range of 
other cellular processes, including the inhibition of HDAC1,
267
 alkylation of p65,
268
 the 
targeting of cell surface thiols,
269
 inhibition of Hsp70,
270
 activation of p53 and cellular 
caspases,
271
 and etc. The extents to which any or all of the above cellular processes 
affect the toxicity of PTL against CSCs have not been investigated. 
As a result, we proposed to utilize a “click chemistry” based protein pull-down 
strategy to design small molecule probes suitable for cellular target identification studies 
of PTL. As well known, the copper (I) - catalyzed Hüisgen 1,3-dipolar cycloaddition 
reaction, click chemistry,
272
 proceeds readily and rapidly between an alkyne group and 
an azide group under mild condition. This kinetically favored reaction, because of its 
bioorthogonal characteristic, is widely utilized as a powerful tool for both in vitro and in 
vivo functionalizations of biomolecules.
273,274
 Protein pull-down is a technique to 
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selectively capture proteins of interest from solution, utilizing protein-protein or protein-
immobilized ligand interactions.
275,276
 
 
2.2 Project Design 
As it has been introduced in the above section, PTL is a promising anticancer 
natural product because it selectively targets AML CSCs without inhibiting the growth 
of HSCs.
19
 However, the detailed molecular mechanism(s) relevant to its biological 
activity is still widely unknown. Considering the important role CSCs play in the drug 
resistance and relapse of cancers, and the lack of validated targets for CSC drug 
discovery, we hypothesized that the elucidation of the mechanism(s) of action by which 
PTL abolishes AML CSC activity will provide invaluable information and new drug 
targets for diminishing the population of CSCs. 
With this idea in mind, we sought to synthesize PTL-based affinity probes with 
varied biological functions and utilize them in click chemistry
272
 based protein pull-
down experiments to further isolate the target proteins of PTL from AML cells. Our 
design of PTL-based affinity probes is based on preliminary data from our lab (Figure 
2.4). Previously, we synthesized a reduced exocyclic methylene analogue of PTL, Red-
PTL (3), and an allylic oxidized analogue, MelB (4) and tested their toxicity in CCRF-
CEM, a commercially available leukemic cell line. The experimental results from our 
lab and others
264,277,278
 indicated that the removal of the exocyclic olefin completely 
ablated the activity of PTL, while the oxidative installation of a hydroxyl group to the 
vinyl methyl group was highly tolerated.
266
 The newly introduced hydroxyl group can 
therefore serve as a handle for the synthesis of PTL-based affinity probes. We envisaged 
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installing alkyne groups as the affinity tag, which could be easily used in following click 
chemistry conjugation to facilitate the isolation of protein targets.  
In addition, due to the innate reactivity of PTL, we predicted that a large amount 
of protein adducts would be yielded from protein pull-down experiments (which has 
been supported by our results shown below) and that to discriminate those PTL-protein 
adducts that are responsible for the AML CSC toxicity from those cellular interactions 
that result from off-target reactivity of PTL would be very challenging. As a result, 
besides the functional PTL-alkyne affinity probe that derived directly from MelB (4), we 
also designed a non-functional PTL-alkyne affinity probe, which was derived from the 
non-functional PTL analogue 3. The non-functional PTL-alkyne affinity probe was 
envisioned to not exhibit the cytotoxicity to leukemic cells as PTL, but rather, retains 
the structure of PTL and serves as a control pull-down probe. Based on the design of the 
above two probes with varied biological potencies, we proposed the comparative protein 
Me
O
O
O
Me
PTL (1)
Me
O
O
O
Me
Red-PTL (3)
O
OMe
O
OH
Mel-B (4)  
                   IC50 (μM) 4.7 ± 1.6                    >100                    5.5 ± 1.2 
 
 
Figure 2.4:  48 hr cytotoxicity dose response curve for PTL and analogues in CCRF-
CEM leukemic cells. 
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pull-down experiments (Figure 2.5). After the incubation of AML cells with each PTL-
alkyne affinity probe, the PTL-protein adducts from cell lysates would be further 
modified to introduce a biotin moiety and/or a fluorescent moiety by the utilization of 
click chemistry. The fluorescent moiety could be used to in-gel visualize the labeled 
PTL-protein adducts, while taking advantage of biotin-streptavidin interaction, the biotin 
moiety would be used to isolate the target molecules from residual unlabeled proteins. 
Candidate proteins were then analyzed by mass spectrometry, and protein fragments are 
queried against known protein databases. 
 
2.3 Results and Discussion 
2.3.1 Kinase Screening Assay of PTL against NF-κB Related Kinases. 
 
Figure 2.5: Overview of the designed comparative protein pull-down strategy to 
elucidate protein reactivity profile of PTL. “F” = functional PTL-alkyne probe; “N” = 
non-functional PTL-alkyne probe. 
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A kinase screening assay, which includes the reported NF-κB related kinases 
IKKα, IKKβ, PI3, IRAK1, IRAK4, TAK1 and cSRC was conducted (Figure 2.6) to 
further study PTL’s ability to inhibit NF-κB signaling. The kinase inhibitory activity of 
PTL was tested at two different concentrations: 2 μM and 10 μM. According to data that 
will be shown in the next chapter (Table 3.1), the 10 μM treatment is well above the 
IC50 of PTL in various cancer cell lines. However, even at the higher tested 
concentration, PTL does not show any significant inhibitory activity against NF-κB 
related kinases, including the reported PTL target IKKβ. This result suggested that the 
inhibition of NF-κB signaling pathway is not like to be the predominant mechanism by 
which PTL induces cancer cell death. 
 
2.3.2 Synthesis of Functional and Non-Functional PTL-Alkyne Probes and Testing of 
Their Cytotoxicity in AML Cells. 
 
Figure 2.6: Kinase screening assay of PTL against NF-κB related kinases. [ATP] = 
10 μM. For each data point, the concentration of tested compound (PTL) is indicated 
in the bracket; the bar indicated the relative enzymatic activity of the tested kinase and 
Mean ± SD values are shown. The screening was performed by Millipore 
KinaseProfiler Service. 
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The chemical synthesis of the proposed PTL-alkyne affinity probes commenced 
with PTL (1), which was converted into MelB (4) in 47% yield according to published 
procedure
279
 under standard allylic oxidation condition  (SeO2, t-BuOOH, Scheme 2.1). 
On the other hand, the exocyclic methylene in PTL was selectively reduced under 
carefully controlled reaction times, yielding 5 in quantitative yield.
54
 The vinyl methyl 
group of 5 was oxidized as described above to give 6 in 68% yield. With 4 and 6 in 
hand, the synthesis towards alkyne substituted PTL probes could then proceed. Several 
different conditions to install the alkyne tag were examined, however, the primary allylic 
hydroxyl group in 4 and 6 were far less reactive than we expected, possibly due to steric 
hindrance. Harsh conditions such as strong bases or heating resulted in the degradation 
of the starting material, but milder alkylation conditions failed to accomplish the desired 
transformation. After the screening of several direct nucleophilic substitution reactions, 
we determined that substrates 4 and 6 were both reactive and stable enough under 
O
OMe
O
O
O
OMe
O
Me
O
b
a
O
OMe
O
Me
OH
c
O
O
PTL(1)
7
8
MelB (4)
Red-PTL(5)
6
a c
 
Scheme 2.1: Synthesis of PTL-alkyne affinity probes. Reagents and Conditions: a) 
SeO2, t-BuOOH, DCM, 40 °C, 6 hr, 47% for 4 and 68% for 6; b) Pd/C, H2 (1 atm), 
EtOH, RT, 15 min, quant.; c) DIAD, PPh3, 4-pentynoic acid, THF, 0 °C, 83% for 7 and 
84% for 8. 
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Mitsunobu conditions,
280
 and we successfully coupled them with 4-pentynoic acid to 
obtained PTL affinity probes 7 and 8 in 83% and 84% yields, respectively.  
With compound 7 and 8 in hand, their cytotoxicity in HL-60 cells (AML cell 
line) was further tested (Figure 2.7). Consistent with our prediction, functional PTL 
probe 7 exhibited similar IC50 value (7.5 ± 1.2 μM) compared to PTL (9.3 ± 3.8 μM), 
and non-functional PTL probe 8 exhibited minimal cytotoxicity against HL-60 cells 
(IC50 > 500 μM). See section 2.5.4.2 for detailed procedure. 
 
2.3.3 Synthesis of Fluorescent Probes. 
Three fluorescent probes, rhodamine azide adduct (Rh-N3, 9), rhodamine biotin 
azide adduct (Rh-Bio-N3, 10) and Cy5.5 biotin azide adduct (Cy-Bio-N3, 11) were 
synthesized for their use as clickable fluorescent reagents to the PTL alkyne probes. 
Although Rh-N3 (9) and Rh-Bio-N3 (10) has been previously reported,
281
 these reagents 
were not commercially available and required synthesis. We prepared these two 
compounds according to reported procedures with minor modifications (Scheme 2.2, 
Scheme 2.3). Briefly, mono-Boc-protected diamine 13 was obtained in 88% yield by 
carefully adding Boc2O into excess equivalents of 1,6-diaminohexane (12)
282
. The 
solvolysis of bromoacetyl bromide 14 in MeOH yielded the corresponding methyl ester, 
                   
Figure 2.7: 48 hr cytotoxicity dose response curve for probe 7 and 8 in HL-60 cells. 
Mean ± SD values are shown. 
 
7 (IC 50 = 7.5 ± 1.2 μM) 
8 (IC 50 = 9.3 ± 3.8 μM) 
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which was converted to 15 in a SN2 reaction. Compound 15 was saponified to yield the 
carboxylate acid intermediate, which was coupled to N-hydroxysuccinimide under 
standard condition to give 16. The substitution reaction between 13 and 16 took place 
spontaneously to yield 17. From compound 12 to 17, only one column purification was 
performed, and the overall yield was 32% over 5 steps. Following the cleavage of Boc 
group in 17, the coupling of commercially available carboxy-tetramethyl-rhodamine N-
succinimidyl ester (Rh-NHS, 19)
283
 with compound 18  delivered the target molecule 
Rh-N3 (9) in 45% yield. 
In addition to the bi-functional fluorescent probe 9, a Rhodamine-Biotin-N3 tri-
functional probe (10) was also synthesized according to a reported procedure
284
 with 
minor modifications. Compound 10 (Scheme2.3) was synthesized on Siever amide resin 
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Scheme 2.2: Synthesis of Rh-N3 fluorescent probe 9. Reagents and Conditions: a) 
Boc2O, dioxane/H2O = 1:1, 88%; b) MeOH, 0 °C; c) NaN3, DMF, RT, overnight; d) 
KOH, THF/H2O = 4:1, 40 °C, 3 hr; e) DCC, NHS, DMF, RT, 4 hr; f) DMF, RT, 
overnight, 32% (over 5 steps); g) Conc. HCl, EtOAc, RT, 2 hr; h) DMF, RT, overnight, 
45% (over 2 steps). 
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using standard 9-fluorenylmethoxycarbonyl (Fmoc) solid phase synthesis strategy. Fmoc 
protected resin was deprotected with piperidine/N-methylpyrrolidinone (NMP) for 
multiple times and washed (with NMP, 3x; DCM, 3x; NMP, 3x) to remove the excess 
reagents. Then Fmoc-Lys(Biotin)-COOH was coupled to the resin under standard 
condition (EDCI, HOBt, DIPEA) to yield 20. The resin was washed and deprotected to 
reveal the primary amine, which was subsequently coupled to Fmoc-Lys(N3)-COOH to 
deliver compound 21. After subsequent wash and deprotection as described above, 
rodamine was appended to the compound 22 upon reaction with Rh-NHS (19). The final 
cleavage was accomplished under mild acidic conditions (3% TFA in DCM) to yield 
Rh-Bio-N3 (10), which was further purified by preparative HPLC. The overall yield was 
27%. 
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Scheme 2.3: Solid phase synthesis of tri-functional probe Rh-Bio-N3 (10). Reagents 
and Conditions: a) 15% piperidine, NMP, 10 min, RT, 3x; b) Fmoc-Lys(Biotin)-
COOH, EDCI, HOBt, DIPEA, NMP, RT, 2 hr; c) Fmoc-Lys(N3)-COOH, EDCI, 
HOBt, DIPEA, NMP, RT, 2 hr; d) Rh-NHS, TEA, NMP, RT, overnight; e) 3% TFA, 
DCM, RT, 30 min, 5x, overall yield: 27%. 
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Rhodamine is a widely used fluorophore in protein and DNA labeling. It is bright 
and water soluble, with an excitation wavelength of 543 nm and an emission wavelength 
of 576 nm. Due to the potential drawbacks of the Rhodamine fluorophore (heat and 
photo-stability), a Cy5.5-Biotin-N3 tri-functional probe (11, Scheme 2.4) was also 
prepared. Cy5.5 allows for more sensitive detection of covalently modified proteins, and 
is less light sensitive and has greater stability at elevated temperature. In addition, 
considering the importance of water solubility of the probe under biological conditions, 
a poly ethylene glycol (PEG) linker was also introduced.  
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Scheme 2.4: Solid phase synthesis of tri-functional probe Cy-Bio-N3 (11). Reagents and 
Conditions: a) 15% piperidine, NMP, 10 min, RT, 3x; b) Fmoc-Lys(Biotin)-COOH, 
HBTU, HOBt, DIPEA, NMP, RT, 2 hr; c) Fmoc-Lys(Alloc)-OH, HBTU, HOBt, 
DIPEA, DCM, RT, overnight; d) Pd(PPh3)4, DCM/AcOH/NMA = 37 : 2 : 1, RT, 2 hr; e) 
N3-PEG-COOH, HBTU, DIPEA, NMP, RT, overnight; f) Cy5.5-NHS, TEA, NMP, RT, 
overnight; g) 3% TFA, DCM, 30 min, RT, 5x. 
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Probe 11 was synthesized on Siever amide resin using standard Fmoc solid phase 
strategy as well. Fmoc protected resin was deprotected with piperidine/N-
methylpyrrolidinone (NMP) multiple times and washed as descripted above to remove 
the excess reagents. Then Fmoc-Lys(Biotin)-COOH was coupled to the resin under 
standard amide coupling  condition to give 20. The resin was washed and deprotected to 
reveal the primary amine, which was subsequently coupled to Fmoc-Lys(Alloc)-OH to 
yield 23. After the cleavage of Alloc protection group under the catalyze of 
tetrakis(triphenylphosphine)palladium, the resulting terminal amine was coupled to N3-
PEG-COOH to install the azide moiety in 24. After wash, the resin was deprotected and 
readily coupled to the NHS ester of Cy5.5 to yield resin bound 11. After cleavage under 
mild acidic conditions, 11 was obtained after HPLC purification, with 29% overall yield. 
The structure was confirmed by HRMS. 
 
2.3.4 Proof of Concept Experiments of Protein Pull-Down. 
With both the function and non-functional PTL-alkyne affinity probes (7 and 8) 
and fluorescent probes 9-11 in hand, some proof of concept assays were conducted to (I) 
demonstrate the feasibility of the designed project and (II) optimize the experimental 
conditions in a relatively simple system with relatively less variables before the 
performance of any experiments in biological systems. 
2.3.4.1 Click chemistry template reaction. A click chemistry proof of concept 
study was carried out to evaluate the ability of probes 7 and 8 to be captured by azide-
based reagents under Cu-catalyzed conditions (see section 2.5.4.2 for detailed 
procedure). The major reason we chose in situ click chemistry approach to introduce the 
affinity tag, as opposed to dosing cells with PTL-biotin conjugates
266
 is that comparing 
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to biotin (molecular weight of PTL-Biotin: 687; PTL: 248), the appending of small 
alkyne groups (molecular weight of probe 7: 316) is less likely to perturb the recognition 
of the PTL derivatives by their target proteins.  
In the template reaction (Scheme 2.5), DMSO solutions of Rh-N3 (9) and PTL 
affinity probes (7 or 8) were added to RIPA buffer (used for cell lysis), followed by the 
addition of aqueous solutions of sodium ascobate, ligand (see Scheme 2.5 for structure) 
and CuSO4. The reaction was conducted in an aqueous condition to mimic the biological 
environment. The template reactions were performed in 1 mg scale and monitored by 
analytical HPLC at 595 nm (the characteristic UV absorption of rhodamine) and were 
found to finish within 20 min (Figure 2.8). In these reactions, excess amount of PTL 
probes were used, so we define the completion of the reactions as the disappearance of 
Rh-N3 peak. The major products of the two template reactions were isolated and 
characterized by mass spectrometry. The mass data was found to be consistent with the 
molecular weight of our proposed click chemistry product. The above template reactions 
demonstrated that the coupling between the alkyne group of PTL affinity probes and the 
azide group of fluorescent probe is kinetically fast. Furthermore, the clear conversion 
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Scheme 2.5: Click chemistry template reaction. 
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from starting materials to product makes us confident to transfer the reaction from a 
simple organic reaction vessel to a complicated biological system. 
 
2.3.4.2 In gel fluorescent labeling assay of cell lysates (see section 2.5.4.4 for 
detailed procedure). In this project, we proposed to dose and label live cells and observe 
the molecular targets of PTL. In order to achieve this objective, the synthesized PTL 
affinity probes must penetrate the cell membranes and label their target proteins without 
killing the cells. Considering the complexity of the whole process, we decided to 
conduct the fluorescent labeling in cell lysates first to test the feasibility of fluorescent 
labeling, as well as to optimize the labeling conditions (Figure 2.9). First of all, HL-60 
cell lysates were generated by treating HL-60 cells with RIPA lysing buffer. Then the 
incubation of PTL affinity probe (7 or 8, 0.7 mM) and HL-60 cell lysate (0.5 mg/mL) 
A.                                                       B. 
     
C. 
     
Figure 2.8: HPLC traces of template click chemistry with the reaction time of 20 min 
under 595 nm. A: HPLC trace of starting material 9; B: the reaction between 7 and 9; 
C: the reaction between 8 and 9. 
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facilitated the formation of covalent small molecule-protein adducts, which were then 
tagged by the fluorescent probe 9 using click chemistry method. The protein sample was 
then analyzed by SDS-PAGE. The resulting gel was detected for Rhodamine 
fluorescence (shown in Figure 2.9, panel B). The gel indicated clear fluorescent labeling 
of multiple proteins by probe 7.  
 In addition, a time course assay of the in gel fluorescent labeling of HeLa cell 
lysates with functional probe 7 (Figure 2.10) was also conducted to determine the 
kinetic profile of the PTL labeling of its target proteins. In this assay, excess probe 7 
(0.7 mM) was incubated with same concentration of HeLa cell lysates (0.5 mg/mL) for a 
time span from 10 min to 50 min before the performance of click chemistry step. The 
result of this assay reveals a fast kinetic property of the covalent modification of proteins 
 
Figure 2.9: In gel fluorescent labeling of HL-60 cell lysate by PTL probe 7. A: 
Overview of in gel fluorescent labeling; B: SDS-PAGE showing the functional 
labeling results. 
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by PTL: fluorescent labeling could be observed as soon as 10 min, and the extent of 
labeling did not change significantly after 30 min.  
 
2.3.5 Protein Pull-Down Experiments. 
After getting positive results from a series of proof of concept experiments 
showing that the covalent binding of proteins by PTL analogues is kinetically fast and 
relatively robust, we then began investigating pull-down studies of PTL-bound proteins. 
Taking advantage of the high affinities between biotin and streptavidin, we originally 
proposed to use streptavidin resin to enrich proteins that were tagged with biotin from 
those that were not (Figure 2.11, see section 2.5.4.5 for detailed procedure); however, 
this affinity separation condition failed to yield any enrichment of proteins. Briefly, HL-
60 cells were lysed by RIPA buffer to generate cell lysates, which were treated with PTL 
affinity probe 7 or 8 to facilitate the binding of the PTL probes with their target proteins. 
The tri-functional probe 10 was used in the click conjugation step, enabling the 
introduction of a fluorescent rhodamine tag, which could be used to visualize the bound 
 
Figure 2.10: Time course assay of the in gel fluorescent labeling of HeLa cell lysates 
with 7. From the first lane to the last lane, HeLa cell lysates were incubated with 7 for 
0, 10, 20, 30, 40, 50 min respectively, before the performance of click chemistry. The 
gel was scanned for Rhodamine fluorescence. 
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proteins, as well as a biotin tag, which would be associated with streptavidin resin to 
enable affinity separation. After the incubation of protein samples, probe 10 and click 
chemistry reagents, the samples were then treated with streptavidin resin. The unbound 
proteins were washed away and the bound proteins were eluted from the resin under 
standard conditions (2% SDS in PBS, 96 °C, 20 min). The eluted protein samples were 
collected and analyzed by SDS-PAGE gel electrophoresis. However, no protein signals 
were observed either for fluorescent signals or after silver staining (a total protein stain). 
The affinity separation assay did not yield the desired result because one or more of the 
following steps likely went wrong: 1) protein labeling; 2) click chemistry; 3) enrichment 
and/or 4) elution (Figure 2.11). According to the preliminary assays, our experimental 
conditions for step 1 and 2 were robust. In addition, the possibility that step 3 was 
problematic is low, because the association of biotin and streptavidin is very tight (Kd ~ 
10
-14 
mol/L) and almost the strongest non-covalent interactions known in nature.
285
 As a 
result, we turned our attention to the elution step.  
 
Figure 2.11: Proposed strategy to pull-down PTL target proteins from HL-60 cells (or 
cell lysates). 
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The elution of biotinylated molecules from streptavidin coated solid supports 
sometimes presents problems in protein pull-down studies, and as a result, various 
elution conditions with different recovery yields have been developed.
286
 After the 
screening of multiple elution condition, we found that only the following harsh condition 
gave us a partially positive result: 2% SDS, 3 mM biotin, 2 M urea, 6 M thiourea in 
PBS, 96 °C, 20 min. After the performance of this elution condition, the eluted protein 
samples were analyzed by SDS-PAGE gel electrophoresis (Figure 2.12). Although no 
fluorescent signals were observed, we were delighted to find that differential labeled 
protein showed up clearly after silver staining. We hypothesized that the absence of 
fluorescent signals resulted from the loss of the rhodamine moiety of the protein-PTL-
Rh-Biotin complex under the harsh elution condition we used. It has also been reported 
that PTL is not stable under either basic or acidic conditions.
287
  
 
Figure 2.12: Pull-down of PTL-protein adducts from HL-60 cell lysates. The SDS-
PAGE was visualized after silver staining. Lane 1: protein ladder; 2: HL-60 whole cell 
lysate; 3: proteins from functional pull-down (probe 7); 4: proteins from non-functional 
pull-down (probe 8). 
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In order to prove this hypothesis, a stability assay of Michael adducts of PTL 
was conducted (Scheme 2.6; Table 2.1, see section 2.5.4.6 for detailed procedure). In 
this assay, small molecule methyl thioglycolate (26) was used to mimic the cysteine 
residues of proteins. The Michael addition product 27 formed readily and instantly upon 
the mixture of PTL and 26. After chromatography purification, the stability of 27 was 
tested under diverse conditions (Table 2.1). 27 was proved to be stable under 
thermodynamic condition; however, after incubated in the elution buffer at 96 °C for 20 
min and then extracted by CDCl3, compound 27 was not observed in NMR, indicating 
the degradation of the compound. The result echoed our hypothesis that although we 
were able to pull-down the target proteins of PTL by streptavidin resin based affinity 
separation, the PTL moiety of the PTL-protein adduct decomposed under the harsh 
condition of elution, and led to the loss of fluorescent signals by SDS-PAGE.  
Due to the lack of stability of PTL-protein adduct under brutal conditions, we 
purchased several modified (strept)avidin coated solid supports, assuming that the 
decreased affinities of these solid supports for biotin allow milder elution conditions. 
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Scheme 2.6: Synthesis of PTL Michael adduct 27. 
 
 Conditions Result 
Thermodynamic 
conditions 
CDCl3, 55 °C, 120 min Stable 
d6-DMSO, 100 °C, 
120 min 
Stable 
Elution condition 
2% SDS, 3 mM Biotin, 2 
M urea, 6 M thiourea in 
PBS, 96 °C, 20 min 
Decomposed 
Table 2.1: Conditions and results of the stability assay of 27. 
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After a screening of conditions, it turned out that the elution condition of monomeric 
avidin resin (Pierce) was compatible with PTL-protein adducts (Figure 2.13). 
Streptavidin is a homo-tetramer and each subunit binds biotin with equal affinity. 
Multivalency is another reason of its high binding affinity to biotin.
285
 On the other 
hand,  monomeric avidin is a recombinant form of streptavidin with mutations to break 
the tetramer into a monomer, with a higher Kd of 10
-7
 to 10
-8
 mol/L.
288
 As a result, the 
binding between monomeric avidin and biotin can be dissociated under neutral 
conditions at room temperature.
289
  
 
Figure 2.13: Modified strategy of comparative and competitive pull-down of PTL 
protein targets from HL-60 cells. A: Overview of strategy to elucidate the protein 
reactivity profile of PTL with chemical probes; B: SDS-PAGE (silver stain) showing the 
labeling results. Lane 1: protein ladder; 2: protein from functional pull-down (probe 7); 
3: protein from non-functional pull-down (probe 8); 4: protein from competitive pull-
down (PTL then probe 7); 5: HL-60 whole cell lysate. 
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 In the modified strategy of affinity separation (Figure 2.13, see section 2.5.4.7 
for a detailed description of experimental details), HL-60 AML cells were treated with 
probe 7 or 8 before lysed by RIPA buffer. The incubation time (8 hr) and the 
concentration (40 μM) was determined in a series of cytotoxicity assay, so that highest 
concentration of PTL probes were used to maximize the labeling without significant 
cellular cytotoxicity (< 15 % cell death). After adjusted to an appropriate concentration, 
the cell lysates were incubated and clicked with Biotin-N3 probe 28. The protein samples 
were then loaded to a monomeric avidin resin columns to achieve the affinity separation. 
Briefly, the protein samples were allowed to incubate with the columns for 30 min to 
facilitate the binding of biotin to the resin. The non-bound proteins were removed from 
columns by amine free PBS buffer. The columns were then thoroughly washed by 
elution buffer (3 mM biotin in amine free PBS) to elute the bound proteins and 
regenerated by 0.1 M glycine solution (pH = 2.8). Both the elution and regeneration 
buffers were collected, neutralized by TrisHCl buffer (pH = 9.5) and concentrated by 3 
KDa molecular weight cut-off centrifugal filter units to yield crude samples of eluted 
proteins. The crude samples were precipitated by TCA to remove the extra detergents 
and analyzed by both SDS-PAGE and mass spectrometry. In addition to the above 
functional pull-down by probe 7 and non-functional pull-down by probe 8, a competitive 
pull-down assay was also conducted to narrow down the target proteins of PTL. In the 
competitive assay, HL-60 cells were incubated with free PTL (20 μM) for 4 hours to 
occupy the active sites of target proteins, and then labeled with functional PTL probe 7 
(20 μM). As a result, all the labeled proteins in competitive assay are the result from 
redundant or non-specific bindings that are actually not the target proteins of PTL, and 
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can be de-prioritized from the list of candidate PTL protein targets. Figure 2.12B shows 
the SDS-PAGE result of the affinity separation of functional, non-functional and 
competitive pull-down of HL-60 cells by PTL probes after silver staining. Analysis of 
the gel clearly shows the capability of probe 7 and 8 to form protein adducts, and 
differential labeling patterns were observed between functional, non-functional and 
competitive pull-down.  
The above proteins samples from monometric avidin affinity separation have 
been analyzed by mass spectrometry (by contract to the Taplin Mass Spectrometry 
laboratory, Harvard University). In this proteomic study, proteins in each sample were 
digested by trypsin and the resulting peptide fragments were analyzed and sequenced by 
microcapillary LC/MS/MS techniques. In order to identify proteins from a sample, the 
peptides information obtained from the above experiment was then compared to IPI 
databases (International Protein Index). Any protein with three or more unique peptide 
matches compared to a known protein is considered confidently identified. Proteins with 
less than three matches are not considered confidently identified without further 
inspection of the data. In order to obtain more accurate results, multiple replicates of 
protein pull-down and affinity separation was performed (6 replicates for functional, 6 
for non-functional and 5 for competitive) and all protein samples were analyzed by mass 
spectrometry in the same manner. The final data were grouped (group I: functional, 
group II: non-functional and group III: competitive. Table 2.2) and proteins that did not 
show enough replicates (observed for less than two times in the same group between 
biological replicates) were removed from the list. The candidates PTL protein targets 
were considered to be those identified in group I, but not appeared in either group II or 
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group III. The protein count data from the mass spectrometry analysis of all replicates 
has been included in Table 2.2. The identified protein targets were listed in Table 2.3, 
and their function and significances will be discussed in the next section.  
 
2.3.6 Annotation of Protein Pull-Down Results.  
Upon analysis of proteomic data, a total of 33 proteins have been identified as 
potential cellular protein targets of PTL. Specifically, proteins identified in non-
functional pull-down assays and in competition experiments were excluded from 
proteins found in assays with functional probe. Those candidate proteins obtained by this 
method of prioritization that appeared at least two out of six times were kept for future 
study, yielding 33 candidate protein targets. The protein attributes, major functions and 
involvements in diseases of those potential targets that were observed for no less than 
three times will be discussed below. 
Trial 
Number of Proteins Oberserved 
Group I Group II Group III 
1 174 57 149 
2 548 79 304 
3 222 323 262 
4 163 320 252 
5 223 209 219 
6 177 297 NA 
Table 2.2: Number of proteins identified in each protein pull-down assay. Six 
biological data were performed. Group I: functional pull-down using probe 7; Group 
II: non-functional pull-down using probe 8; Group III: competitive pull-down using 
PTL then probe 7. NA: not available. 
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Protein 
ID 
Protein Name 
Times 
observed 
Protein 
ID 
Protein Name 
Times 
observed 
GSN Isoform 1 of Gelsolin 4 GSPT1 
Eukaryotic peptide 
chain release factor 
GTP-binding subunit 
ERF3A 
2 
SMC3 
Structural maintenance 
of chromosomes 
protein 3 
4 GSTO1 
Glutathione S-
transferase omega-1 
2 
CAPZB 
F-actin-capping 
protein subunit beta 
3 HNRNPAB 
Heterogeneous 
nuclear ribo-
nucleoprotein A/B 
2 
GNB2 
Guanine nucleotide-
binding protein subunit 
beta-2 
3 
IPI-
00453476.2 
- 2 
HDGF 
Hepatoma-derived 
growth factor 
3 NARG1 
Isoform 2 of NMDA 
receptor-regulated 
protein 1 
2 
HNRNPH1 
Heterogeneous nuclear 
ribonucleoprotein H 
3 PCNA 
Proliferating cell 
nuclear antigen 
2 
KCNAB2 
Isoform 1 of Voltage-
gated potassium 
channel subunit beta-2 
3 PGAM2 
Phosphoglycerate 
mutase 2 
2 
LOC-
131691 
Peptidyl-prolyl cis-
trans isomerase-like 1 
3 PRDX5 
Peroxiredoxin-5, 
mitochondrial 
2 
RAB1A 
Isoform 1 of Ras-
related protein Rab-1A 
3 PRG2 
Bone marrow 
proteoglycan 
2 
RPS7P4 
40S ribosomal protein 
S7 
3 PSMA6 
Proteasome subunit 
alpha type-6 
2 
ALDOC 
Fructose-bisphosphate 
aldolase C 
2 PSMA7 
Proteasome subunit 
alpha type-7 
2 
ARPC1B 
Actin-related protein 
2/3 complex subunit 
1B 
2 SEPT7 Isoform 1 of Septin-7 2 
CAND1 
Cullin-associated 
NEDD8-dissociated 
protein 1 
2 TXNL1 
Thioredoxin-like 
protein 1 
2 
CLTCL1 
Isoform 1 of Clathrin 
heavy chain 2 
2 UBE2I 
SUMO-conjugating 
enzyme UBC9 
2 
EIF3G 
Eukaryotic translation 
initiation factor 3 
subunit G 
2 UPF1 
Isoform 1 of regulator 
of nonsense 
transcripts 1 
2 
ERLIN1 
ER lipid raft associated 
1 
2 WDR1 
WD repeat-containing 
protein 1 
2 
ERP44 
Endoplasmic reticulum 
resident protein ERp44 
2    
Table 2.3: Identified protein targets by mass spectrometry. Protein ID: the abbreviated 
protein name in IPI database; Protein name: recommended name in IPI database; 
Times observed: the number of times the protein showed up in functional pull-down 
(out of 6 assays). 
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1. GSN (Gelsolin, also known as actin-depolymerizing factor or brevin, observed 
4 times in pull-down) is a calcium-regulated, actin-modulating protein that binds to the 
ends of actin monomers or filaments, preventing monomer exchange (end-blocking or 
capping). It can promote the assembly of monomers into filaments (nucleation) as well 
as sever filaments already formed.
290
 Defects in GSN are the cause of amyloidosis type 
5
291
 and were found in breast and colorectal cancers.
292
 This protein has also been 
reported to involve in aging, regulation of cell adhesion and tissue regeneration.
293,294
 
2. SMC3 (structural maintenance of chromosomes protein 3, also known as 
Chondroitin sulfate proteoglycan 6 or Chromosome-associated polypeptide, observed 4 
times in pull-down) is a nuclear protein and the central component of cohesin, a complex 
required for chromosome cohesion during the cell cycle. The cohesin complex may form 
a large proteinaceous ring within which sister chromatids can be trapped. At anaphase, 
the complex is cleaved and dissociates from chromatin, allowing sister chromatids to 
segregate. Cohesion is coupled to DNA replication and is involved in DNA repair. The 
cohesin complex plays also an important role in spindle pole assembly during mitosis 
and in chromosomes movement.
295,296
 Defects in SMC3 are the cause of Cornelia de 
Lange syndrome.
297
 Because of the important role SMC3 plays in cell cycle and DNA 
repair, it presents a good target of anti-cancer of anti-CSC therapy. 
3. CAPZB (F-actin-capping protein subunit beta, observed 3 times in pull-down) 
is a cytoskeleton protein that binds in a Ca
2+
-independent manner to the fast growing 
ends of actin filaments, thereby blocking the exchange of subunits at these ends. Unlike 
other capping proteins (such as gelsolin and severin), these proteins do not sever actin 
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filaments. Plays a role in the regulation of cell morphology and cytoskeletal 
organization.
298
 Interestingly, this protein has been reported recently to involve in the 
differentiation of human embryonic stem cells.
299
 
4. GNB2 (Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-2, 
observed 3 times in pull-down) is a cytoplasmic protein that locates in perinuclear 
region. Guanine nucleotide-binding proteins (G proteins) are involved as a modulator or 
transducer in various transmembrane signaling systems. The beta and gamma chains are 
required for the GTPase activity, for replacement of GDP by GTP, and for G protein-
effector interaction.
300
 
5. HDGF (Hepatoma-derived growth factor, observed 3 times in pull-down) is an 
acidic heparin-binding protein, with mitogenic activity for fibroblasts. It is also a 
transcription factor that stimulates cell proliferation when binding to DNA.
301
 As a 
growth factor, HDGF stimulates the growth of endothelial cells, vascular smooth muscle 
cells and hepatoma cells. It is highly expressed in a variety of human cancers and is 
critical in tumorigenesis.
302
  
6. HNRNPH1 (Heterogeneous nuclear ribonucleoprotein H, observed 3 times in 
pull-down) is a nuclear protein and a component of the heterogeneous nuclear ribo-
nucleoprotein (hnRNP) complexes, which provide the substrate for the processing events 
that pre-mRNAs undergo before becoming functional mRNAs in the cytoplasm. 
Mediates pre-mRNA alternative splicing regulation.
303
 Together with CUGBP1, it also 
inhibits insulin receptor (IR) pre-mRNA exon 11 inclusion in myoblast.
304
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7. KCNAB2 (Voltage-gated potassium channel subunit beta-2, observed 3 times 
in pull-down) is an accessory potassium channel protein that modulates the activity of 
the pore-forming alpha subunit and involved in synaptic transmission.
305
 
8. LOC131691 (Peptidyl-prolyl cis-trans isomerase-like 1, also known as PPIase, 
observed 3 times in pull-down) accelerates the folding of proteins. It catalyzes the cis-
trans isomerization of proline peptide bonds in oligopeptides. May be involved in pre-
mRNA splicing. PPIase is most abundant in heart and skeletal muscle.
306
 
9. RAB1A (Ras-related protein, observed 3 times in pull-down) is required for 
transit of protein from the endoplasmic reticulum through Golgi compartment. It binds 
GTP and GDP and possesses intrinsic GTPase activity. 
10. RPS7P4 (40S ribosomal protein S7, observed 3 times in pull-down) is a 
cytoplasmic protein that is required for rRNA maturation.
307
 
 
2.4 Conclusions and Future Direction 
In conclusion, in order to identify the cellular protein targets of the anticancer 
natural product parthenolide and elucidate the mechanism of action of its cytotoxicity 
against CSCs, we designed and synthesized two PTL-alkyne affinity probes with diverse 
biological activity. Their capabilities of coupling with secondary probes using click 
chemistry and differential labeling proteins in vitro were demonstrated in a series of 
proof of concept experiments, including a click chemistry template reaction, the in-gel 
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fluorescent labeling assay and time course assays. When conducting the pull-down 
experiment, we experienced some difficulties in recovering the bound protein from 
affinity separation, due to the lack of stability of PTL-protein complex under elution 
conditions of streptavidin resin. The issue was successfully addressed by switching to 
monomeric avidin resin, which presents lower affinity to biotin and allows milder 
elution conditions than streptavidin resin. Utilizing the modified strategy, multiple 
replicates of comparative and competitive protein pull-down experiments were 
conducted. The eluted protein samples were analyzed by SDS-PAGE as well as mass 
spectrometry. Thirty-three potential protein targets were identified according to mass 
spectrometry data. Among the identified proteins, the most promising one is HDGF 
(Hepatoma-derived growth factor), which is a transcription factor and has been reported 
to be critical in tumorigenesis and highly expressed in a variety of human cancers.
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To further validate the protein targets of PTL, western blot experiments using 
antibodies against each identified proteins should be performed. In addition, we will 
utilize RNA interference (RNAi) technology to knockdown individual candidate 
proteins in AML cells and then test their viability. As a result, the knockdown of 
protein(s) that yields most reduction in AML CSC viability will likely be the cellular 
protein target that is responsible for the cytotoxicity of PTL against CSCs. 
 
2.5 Experimentle 
2.5.1 General   
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All reactions were performed under an anhydrous nitrogen atmostphere unless 
otherwise noted.  Parthenolide was purchased from Enzo Life Sciences and repurified by 
SiO2 chromatography prior to biological studies. Commercial grade reagents (Aldrich, 
Acros, Alfa Aesar) were used without further purification unless otherwise noted. 
Tetrahydrofuran and dichloromethane were rendered anhydrous by passing through the 
resin column of a solvent purification system. Benzene was purified by fractional 
distillation. Methanol, 1,2-dimethoxyethane, and N,N-dimethylformamide were 
purchased as anhydrous. All reactions were monitored by thin-layer chromatography 
(TLC) using silica gel 60-F254 TLC plates (Merck), and visualized using either iodine or 
charring with para-Anisaldehyde stain.  Column chromatography employed Silicycle 
SiliaFlash® P60 (40-  silica gel. SiO2 column purification was performed using a 
CombiFlash® Rf 200 instrument using pre-packed silica gel column or Redisep Rf Gold 
High-Performance silica gel columns (Teledyne-Isco). HPLC purification was 
performed using an Agilent 1200 series instrument (preparative scale) equipped with a 
Zorbax (Agilent) preparatory column (21.2 x 250 mm, 7 μm).  Analysis of compound 
purity was conducted on the aforementioned HPLC, using a Zorbax analytical column 
(4.6 x 150 mm, 5 μm). Nuclear magnetic resonance (NMR) spectroscopy employed a 
Bruker 400 Ultrashield 400 MHz spectrometer.  Internal solvent peaks were referenced 
in each case.  Mass spectral data was obtained from the University of Minnesota mass 
spectrometry lab, employing a Bruker Biotof II instrument. 
2.5.2 Synthesis of Parthenolide Affinity Probes 
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Melampomagnolide B (4): MelB was prepared based on a previous literature 
report.
279
 
1
H NMR (CDCl3, 400 MHz):  6.22 (d, J = 3.5 Hz, 1H), 5.64 (t, J = 8.2 Hz, 
1H), 5.54 (d, J = 3.2 Hz, 1H), 4.15 (d, J = 12.6 Hz, 1H), 4.07 (d, J = 12.6 Hz, 1H), 3.84 
(t, J = 9.3 Hz, 1H), 2.83 (m, 2H), 2.41 (m, 3H), 2.21 (m, 3H), 1.66 (m, 2H), 1.54 (s, 3H), 
1.08 (t, J = 12.4 Hz, 1H). 
 
O
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O
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Melampomagnolide B alkyne 7: MelB (4, 12 mg, 0.045 mmol), pentynoic acid 
(8.9 mg, 0.091 mmol) and PPh3 (26 mg, 0.10 mmol) were weighted out in a 50 mL RBF 
and dried over high vac for 2 hrs. To a stirred solution of the above material in dry THF 
(3 mL) was injected DIAD (20 L, 0.10 mmol) dropwise at 0 C under N2. The reaction 
was slowly warmed to room temperature and allowed to stir overnight. THF was 
removed under reduced pressure and the residue was dissolved in CH2Cl2 (40 mL) and 
washed with brine (15 mL, 3x). The combined aqueous layer was extracted with EtOAc 
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(40 mL, 2x). The organic layers were collected, dried over anhydrous Na2SO4 and 
concentrated in vacuo. The crude material was subjected to SiO2 column purification 
(gradient 5%-60% EtOAc in hexanes over 16 min) to yield the product (13 mg, 83%) as 
white solid. 
1
H NMR (CDCl3, 400 MHz):  6.26 (d, J = 3.5 Hz, 1H), 5.71 (t, J = 8.1 Hz, 
1H), 5.55 (d, J = 3.2 Hz, 1H), 4.72 (d, J = 12.4 Hz, 1H), 4.49 (d, J = 12.4 Hz, 1H), 3.85 
(t, J = 9.3 Hz, 1H), 2.86 (m, 2H), 2.54 (m, 4H), 2.30 (m, 6H), 1.98 (t, J = 2.4 Hz, 1H), 
1.76 (m, 1H), 1.55 (s, 3H), 1.11 (t, J = 12.4 Hz, 1H). 
13
C NMR (CDCl3, 100 MHz): 
171.5, 169.3, 138.7, 134.8, 130.9, 120.3, 82.3, 81.0, 69.2, 67.0, 63.3, 59.9, 42.7, 36.6, 
33.3, 25.7, 24.4, 23.8, 18.0, 14.4. HRMS (ESI
+
) m/z calcd for [C20H24O5+Na]
+
 367.1521; 
found 367.1537. 
 
O
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O
O
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Reduced Melampomagnolide B alkyne 8: compound 6 (12.8 mg, 0.48 mmol), 
pentynoic acid (10 mg, 0.096 mmol) and PPh3 (28 mg, 0.11 mmol) were weighted out in 
a 50 mL RBF and dried over high vac for 2 hrs. To a stirred solution of the above 
material in dry THF (3 mL) was injected DIAD (21 L, 0.11 mmol) dropwise at 0 C 
under N2. The reaction was slowly warmed to room temperature and allowed to stir 
overnight. THF was removed under reduced pressure and the residue was dissolved in 
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CH2Cl2 (40 mL) and washed with brine (15 mL, 3x). The combined aqueous layer was 
extracted with EtOAc (40 mL, 2x). The organic layers were collected, dried over 
anhydrous Na2SO4 and concentrated in vacuo. The crude material was subjected to SiO2 
column purification (gradient 5%-60% EtOAc in hexanes over 16 min) to yield the 
product (14 mg, 84%) as white solid. 
1
H NMR (CDCl3, 400 MHz):  5.67 (t, J = 8.1 Hz, 
1H), 4.71 (d, J = 12.5 Hz, 1H), 4.46 (d, J = 12.5 Hz, 1H), 3.83 (t, J = 9.5 Hz, 1H), 2.75 
(d, J = 9.4 Hz, 1H), 2.55 (m, 5H), 2.30 (m, 6H), 1.98 (t, J = 2.5 Hz, 1H), 1.91 (m, 1H), 
1.60 (m, 1H), 1.55 (s, 3H), 1.29 (d, J = 6.9 Hz, 3H), 1.08 (t, J = 12.8 Hz, 1H). 
13
C NMR 
(CDCl3, 100 MHz): 177.7, 171.4, 135.0, 130.1, 82.3, 81.0, 69.2, 66.4, 63.5, 59.8, 46.3, 
41.5, 36.8, 33.4, 26.7, 24.3, 23.7, 17.9, 14.4, 13.1. HRMS (ESI
+
) m/z calcd for 
[C20H26O5+K]
+
 385.1417; found 385.1412. 
 
2.5.3 Synthesis of Fluorescent Probes 
H2N
NHBoc
 
tert-butyl (6-aminohexyl)carbamate (13):282 to a stirred solution of 1,6-
diaminohexane (2.0 g, 17.2 mmol) in 1,4-dioxane (100 mL) at 0 °C was added dropwise 
the solution of Boc2O (0.94 g, 4.3 mmol) in deionized H2O (100 mL) through an 
addition funnel. The reaction was stirred overnight and 1,4 – dioxane was removed 
under reduced pressure. The aqueous solution was extracted by EtOAc (100 mL, 3x), 
and the combined organic layers were dried over anhydrous Na2SO4 and concentrated in 
vacuo to yield compound 12 (crude, 820 mg, 88%). 
1
H NMR (CDCl3, 400 MHz):  4.53 
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(br s, 1H), 3.09 (m, 2H), 2.67 (td, J = 3.08 Hz, J = 6.8 Hz, 2H), 1.47 (m, 11H), 1.32 (m, 
4H), 1.12 (br s, 4H). 
 
O
O
N3
 
α-azidoacetic acid (15):308 Anhydrous MeOH (15 mL) was added slowly to 
bromoacetyl bromide (0.74 mL, 8.5 mmol) at 0 °C. The reaction was stirred for 2 hrs at 
0 °C before slowly quenched by water (15 mL). MeOH was removed under reduced 
pressure with caution, because the product methyl 2-bromoacetate is volatile (bp: 50 °C 
at 15 mmHg). The resulting aqueous solution was neutralized by NaHCO3 (saturated aq., 
15 mL) and extratcted by CH2Cl2 (60 mL, 3x). The organic layers were collected, dried 
over anhydrous Na2SO4 and concentrated in vacuo to yield crude product of methyl 2-
bromoacetate. To a stirred solution of methyl 2-bromoacetate in DMF (5 mL) was added 
NaN3 (600 mg, 9.2 mmol). The reaction was allowed to stir at room temperature 
overnight. After the removal of DMF under reduced pressure, the residue was suspended 
in H2O (40 mM) and extracted by CH2Cl2 (60 mM, 3x). The organic layers were 
collected, dried over anhydrous Na2SO4 and concentrated in vacuo to yield 15 (678 mg, 
69%). This material was used crude in the reaction to prepare 18. 
 
H2N
H
N
O
N3
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N-(6-aminohexyl)-2-azidoacetamide (18):281 To a stirred solution of the 15 (678 
mg, 5.9 mmol) in THF (5 mL) was added dropwise KOH aqueous solution (15%, 2 mL). 
The reaction was stirred at 45 °C for 3 hr. THF was removed under reduced pressure. 
The remaining aqueous solution was diluted with deionized H2O to 40 mL and washed 
by ether (20 mL, 2x). The aqueous layer was neutralized by conc. HCl and extracted by 
EtOAc (60 mL, 3x). The combined organic layers were dried over anhydrous Na2SO4 
and concentrated in vacuo to yield azidoacetic acid (404 mg, 68%). 
1
H NMR (CDCl3, 
400 MHz):  10.40 (s, 1H), 3.97 (s, 2H). To a stirred solution of N-hydroxyl-
succinimide (56 mg, 0.48 mmol) and DCC (99 mg, 0.48 mmol) in DMF (2 mL) was 
added the solution of azidoacetic acid (40 mg, 0.39 mmol) in DMF (1 mL). After stirring 
at room temperature for 4 hr, the reaction was filtered and the filtrate was concentrated 
to give 16. Crude 16 was added to a solution of 13 (95 mg 0.44 mmol) in DMF (2 mL). 
The reaction was allowed to stir overnight. DMF was then removed under reduced 
pressure. The residue was suspended in deionized H2O (15 mL) and extracted by CH2Cl2 
(40 mL, 3x). The combined organic layers were dried over anhydrous Na2SO4 and 
concentrated in vacuo. The crude compound was purified by SiO2 chromatography 
(gradient 5%-80% EtOAc in hexanes over 16 min) to yield 17 (105 mg, 89%). To a 
stirred solution of the 17 (105 mg, 0.35 mmol) in EtOAc (10 mL) was added dropwise 
conc. HCl under 0 °C until pH = 2. The reaction was warmed to room temperature and 
stirred for 2 hr before quenched by deionized H2O (10 mL), the water layer was 
neutralized by KOH solution (3 M in H2O, 10 mL) and extracted by EtOAc (40 mL, 3x). 
The combined organic layers were dried over anhydrous Na2SO4 and concentrated in 
vacuo to yield compound 18 (54 mg, 77%). 
1
H NMR (d4-MeOH, 400 MHz):  3.86 (s, 
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2H), 3.37 (s, 1H), 3.22 (t, J = 8.0 Hz, 2H), 2.69 (t, J = 7.2 Hz, 1H), 1.54 (m, 4H), 1.37 
(m, 4H). 
 
ON N
COO
ON
H
H
N
N3
O  
Rh-N3 (9):
281 To a stirred solution of 18 (12 mg, 0.060 mmol) in DMF was added 
Rh-NHS (19, 19 mg, 0.030 mmol). The reaction was stirred overnight. DMF was 
removed under reduced pressure and the crude material was purified by preparative 
HPLC (gradient 10% to 100% acetonitrile in H2O containing 0.1% TFA over 40 min, 
then 100% acetonitrile for 15 min) to yield 9 (10 mg, 45%). 
1
H NMR (D2O, 400 MHz): 
 8.76 (d, J = 1.6 Hz, 1H), 8.25 (dd, J = 1.6 Hz, J = 7.8 Hz, 1H), 7.51 (d, J = 7.9 Hz, 
1H), 7.13 (m, 2H), 7.05 (dd, J = 2.3 Hz, J = 9.4Hz, 2H), 6.97 (d, J = 2.2 Hz, 2H), 3.86 
(s, 2H), 3.46 (t, J = 6.9 Hz, 2H), 3.30 (s, 12H), 3.23 (t, J = 6.9 Hz, 2H), 1.69 (m, 2H), 
1.55 (m, 2H), 1.44 (m, 4H). 
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Rhodamine-Biotin-N3 (10): the compound was prepared as previously 
described.284 
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Cy5.5-Biotin-N3 (11): The compound was prepared using a modification of the 
protocol published by Cravatt and coworkers to synthesize 10.284 Cy5.5-biotin-N3 was 
synthesized on Sieber Amide resin (Novabiochem) using standard 9-
fluorenylmethoxycarbonyl (Fmoc) solid phase synthesis. Fmoc protected resin (80 mg, 
0.035 mmol) was transferred into a reaction vessel, deprotected with 15% piperidine/N-
methylpyrrolidinone (NMP, 2 mL, 10 min, 3x) and washed (NMP, 2 mL, 3x; CH2Cl2, 2 
mL, 3x; NMP, 2 mL, 3x) to remove excess reagents. Then Fmoc-Lys(Biotin)-COOH 
(Novabiochem, 104 mg, 0.175 mmol) was coupled to the resin (2.5 hr) using HBTU (68 
mg, 0.174 mmol), HOBt (28 mg, 0.175 mmol) and DIPEA (50 μL, 0.28 mmol) in NMP 
(2 mL) to yield 20. The resin was then washed and deprotected as described above. 
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Fmoc-Lys(Alloc)-OH was coupled to the resin using same equivalents of reagents 
overnight to yield 23. After subsequent wash as described above, the alloc group was 
cleaved (2 hr) using Pd(PPh3)4 (8 mg, 0.07 mmol) in mixed solvent DCM/AcOH/NMA 
(N-methylaniline) = 37 : 2 : 1 (0.8 mL). After washing, N3-PEG-COOH was coupled to 
the resin using the same equivalents of coupling reagents overnight to give 24. 
Following the subsequent wash and cleavage of Fmoc as described above, Cy5.5 was 
appended to the free amine upon reaction with Cy5.5-succinimidyl ester (Lumiprobe, 15 
mg, 0.021 mmol) using TEA (100 μL, 0.70 mmol) in NMP (2 mL) overnight to give 25. 
The resin was then thoroughly washed (NMP, 2 mL, 3 x; CH2Cl2, 2 mL, 3 x; MeOH, 2 
mL then 50% CH2Cl2/MeOH until wash was clear). Compound 11 was cleaved off resin 
with dilute TFA (3% in CH2Cl2, 3 mL, 10 min, 5x). Toluene was added to the dark red 
solution, and the solvent was removed under reduced pressure. The crude material was 
then purified by preparative HPLC (gradient 10% to 40% acetonitrile in H2O over 10 
min, gradient 40% to 100% acetonitrile in H2O over 45 min, then 100% acetonitrile for 5 
min, all solvent contains 0.1% TFA) to give compound 10 (8 mg, overall yield 29%). 
HRMS (ESI
+
) m/z calcd for [C79H101N12O10S+Na]
++
 680.3689; found 680.3714. 
Analytical HPLC (700 nm): 
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2.5.4 Procedures for Biochemical Experiments 
2.5.4.1 Kinase screening assay (section 2.3.1). The experiments were performed 
by Millipore KinaseProfiler Service. For protocol, see 
https://www.millipore.com/techpublications/tech1/pf3036. 
2.5.4.2 Protocol for Cell Culture Cytotoxicity Assays (section 2.3.2). A 
protocol for these experiments was previously published by Hexum et al.
309
 HL-60 
(ATCC, CCL-240) were maintained in a humidified 5% CO2 environment at 37 °C in 
culture flasks (Corning) and cultured in IMDM media (Cellgro) supplemented with 20% 
FBS (Gibco), penicillin (100 I.U./mL), and streptomycin (100 µg/mL, ATCC). Cells 
were cultured at a density of 10,000 cells/well in cell culture media (50 µL) in standard 
96-well plates (Costar) 24 h prior to treatment. Controls used were Blank (no cells) wells 
and control (vehicle control treated) wells and were prepared for every experiment. 
Tested compounds (7 and 8) were serially diluted in pre-warmed media and dosed to 96 
well plates (final volume/well = 100 µL; final DMSO concentration = 0.5%). 
Approximately 1-3 h before the end of the treatment period (48 h), Alamar Blue 
(Invitrogen) cell viability reagent was added to the 96 well plates (10 µL). A quantitative 
measure of cell viability can be achieved from evaluating the ability of metabolically 
active cells (which are proportional to the number of living cells) to convert resazurin 
(non-fluorescent dye) to red-fluorescent resorufin. Fluorescence data were obtained on a 
Molecular Devices SpectraMax M2 plate reader. Background fluorescence (no cell 
controls) was subtracted from each well and cellular viability values following 
  89 
compound treatment were normalized to vehicle-only treated wells (control wells only 
treated with aqueous DMSO, which were arbitrarily assigned 100% viability). Individual 
IC50 curves were generated by fitting data to the sigmoidal (dose response) function of 
varied slope in GraphPad Prism (v. 5.0) software. Only curve fits with R
2
 > 0.95 were 
deemed sufficient. Each experiment was performed in biological triplicate and mean 
IC50 values were calculated from the individual IC50 values obtained from each replicate. 
Standard deviation was calculated from the individual IC50 values obtained for each 
biological replicate.  
2.5.4.3 click chemistry template reaction (section 2.3.4.1): the following stock 
solutions were made beforehand: probe 7 (10 mM in DMSO), probe 8 (10 mM in 
DMSO), tris[(1-benyl-1H-1,2,3-triazol-4-yl)methyl]amine (ligand, 10 mM in DMSO), 
RhN3 (9, 10 mM in DMSO), (+)sodium L-ascobate (50 mM in H2O), CuSO4 (50 mM in 
H2O). In the template reaction, sterilized PBS buffer (150 μL), probe 7 (or probe 8, 10 
μL), RhN3 (9, 8 μL), ligand (10 μL) and sodium ascobate (20 μL) were added 
subsequently into a 1.5 mL Eppendorf tube. The sample was gently vortexed at room 
temperature, and the reaction was initiated by the addition of CuSO4 (20 μL). Each 
reaction was monitored by analytic HPLC at 595 nm every 10 min until the 
disappearance of RhN3 peak. 
2.5.4.4 General protocol for RIPA lysis of HL-60 cells: HL-60 cells (ATCC, 
CCL-240) were cultured in IMDM media (Cellgro, supplemented with 20% FBS 
(Gibco), penicillin (100 I.U./mL), and streptomycin (100 µg/mL, ATCC)) in a 
humidified 5% CO2 environment at 37 °C in culture flasks (Corning, 75 cm
2
, 20 mL 
media/flask). After the concentration reached 1 million/mL, HL-60 cells were 
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transferred to a 50 mL falcon tube and centrifuged down at 2500 x g to form a cell 
pellet. After the supernatant cell media was decanted, the cell pellet was suspended in 
cold PBS buffer (1 mL) and transferred to a 1.5 mL eppendorf tube. Again, cells were 
centrifuged down at 2500 x g to form a cell pellet. The supernatant was removed with a 
pipette. RIPA buffer (Pierce, pre-chilled, 1.1 mL) was pre-mixed with protease inhibitor 
(25x, generated from Roche complete EDTA-free protease inhibitor cocktail tablets) 
and added to the cell pellet. The mixture was pipetted up and down to suspend the cells 
and then shaken gently for 15 min on ice and vortexed every 5 min.  The sample was 
centrifuged at 14000 x g for 15 min at 4 
o
C to pellet the cell debris, which was removed 
by a p200 pipette. The protein concentration of HL-60 cell lysate was determined by 96 
well-plate BCA (bicinchoninic acid) assay (Pierce BCA protein assay kit) and adjusted 
to 1 mg/mL by adding extra RIPA buffer. The final protein lysates were kept at -20 °C 
until use.  
2.5.4.5 In gel fluorescent labeling and time course assay (section 2.3.4.2): HL-
60 cell lysate (20 μL, 1 mg/mL) and PTL probe 7 (or 8, 3 μL, 10 mM in DMSO) were 
agitated at room temperature in an 1.5 mL eppendorf tube for 60 min. Following the 
incubation, RhN3 (9, 3 μL, 10 mM in DMSO), ligand (3 μL, 10 mM in DMSO) and 
sodium ascobate (6 μL, 50 mM in H2O) were added subsequently to each sample. The 
samples were gently vortexed, and the reactions were initiated by the addition of CuSO4 
(6 μL, 50 mM in H2O). The tubes were agitated gently at room temperature for 30 min 
before the proteins were denatured by LDS loading buffer (Invitrogen, NuPAGE, 15 
μL, 4x concentrated) and reducing agent DTT (Invitrogen, NuPAGE, 6 μL, 10x 
concentrated) at 96 °C for 5 min. After the samples were cooled down to room 
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temperature, 20 μL of each sample were loaded to a gel (Invitrogen NuPAGE Bis-Tris 
minigel, 1 mm, 10 wells, 4%-12%), together with protein ladder and denatured whole 
cell lysate as control. The gel electrophoresis was performed at 185 V for 35 min, and 
the fluorescent signals were recorded in a GE FLA7000 Typhoon biomolecular imaging 
system with a R710 filter, and 650 nm excitation wavelength. In the time course assay, 
five tubes of HeLa cell lysates (purchased, 1 mg/mL, 20 μL) were incubated with probe 
7 (3 μL, 10 mM in DMSO) 50 min, 40 min, 30 min, 20 min or 10 min before the 
initiation of click chemistry. All the following steps were the same as described above. 
2.5.4.6 Streptavidin affinity purification (section 2.3.5): HL-60 cell lysates 
(200μL, 1 mg/mL) and PTL probe 7 (or 8, 3 μL, 10 mM in DMSO) were agitated at 
room temperature in an 1.5 mL eppendorf tube for 60 min. Following the incubation, 
Rh-Bio-N3 (10, 4 μL, 10 mM in DMSO), ligand (4 μL, 10 mM in DMSO) and sodium 
ascobate (8 μL, 50 mM in H2O) were added subsequently to each sample. The samples 
were gently vortexed, and the reactions were initiated by the addition of CuSO4 (8 μL, 
50 mM in H2O). After 1 hr, the labeled protein samples were transferred to tubes with 
streptavidin agarose (Pierce, 100 μL) and agitated for 1 hr at room temperature. The 
samples were centrifuged at 1400 x g for 3 min to remove the supernatant. The residue 
agarose was washed by PBS (1 mL, 3x), 0.2% SDS/PBS (1 mL, 3x) and deionized H2O 
(1 mL, 3x) to thoroughly remove the unbound protein. At last, 150 μL of 2% SDS/PBS 
(or 2% SDS, 3 mM Biotin, 2 M urea, 6 M thiourea in PBS) was added to the agarose and 
heated to 96 °C for 20 min to release the bound protein. The resin was pelleted down by 
centrifugation (300 x g, 1 min), and the supernatants were collected and incubated with 
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reducing agent DTT (Invitrogen, NuPAGE, 10x) before the performance of SDS-
PAGE. 
2.5.4.7 Stability assay (section 2.3.5): Compound 7 (10 mg, 0.029 mmol) was 
added to a stirred solution of methyl thioglycolate (26, 10 mg, 0.094 mmol) in DMF (1 
mL). The reaction was stirred at room temperature for 1 hr. DMF was removed under 
reduced pressure and the residue was purified by SiO2 chromatography (gradient 5%-
80% EtOAc in hexanes over 16 min) to give compound 27 (13 mg, 99%).  Compound 
27 (6 mg) was dissolved in CDCl3 (1 mL) and heated to 55 °C for 2 hr. The NMR did 
not show any change to the 
1
H spectrum. CDCl3 was removed under reduced pressure, 
and the material was re-dissolved in DMSO-d6. The DMSO solution was heated to 100 
°C for 2 hr, the NMR did not show any change to the 
1
H spectrum.  Compound 27 (7 
mg) was dissolved in DMSO (50 μL) and incubated with elution buffer of streptavidin 
(2% SDS, 3 mM Biotin, 2 M urea, 6 M thiourea in PBS, 0.5 mL) at 96 °C for 20 min. 
After cooling down, the above system was extracted by CDCl3. Compound 27 was not 
observed in NMR, presumably because of the degradation of 27 under the elution 
conditions. 
2.5.4.8 Modified affinity separation strategy (section 2.3.5): 
a) Functional pull-down: HL-60 cells were grown in a T-75 corning flask in 20 
mL media until the concentration reached 1 x 10
6
 cells/mL. The cells were incubated 
under 37 
o
C with functional PTL probe (7, 40 μM, the probe was pre-dissolved in 
DMSO to form a 10 mM stock solution) for 8 hrs and then lysed by RIPA buffer. The 
protein concentration of the lysates was determined by BCA assay. In most cases, the 
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concentration is between 1.1 to 1.3 mg/mL. The concentration was adjusted to 1 mg/mL 
by adding extra RIPA buffer. 
To functional labeled HL-60 cell lysate (1 mg/mL, 0.5 mL) was added Biotin-N3 
probe (28, 10 mM in DMSO, 3.3 μL), ligand (10 mM in DMSO, 3.8 μL), sodium 
ascorbate (50 mM in H2O, 7 μL) and CuSO4 (50 mM in H2O, 7 μL) subsequently. The 
mixture was allowed to gently agitate at room temperature for 2.5 hr before loading to a 
monomeric avidin agrose column. The column contains 2 mL agrose and was washed 
with blocking buffer (10 mL, 2 mM D-biotin in PBS), regeneration buffer (12 mL, 0.1 
M glycine, pH2.8) and amine free PBS buffer (12 mL, generated from pierce BupH™ 
Phosphate Buffered Saline pack) before using. After loaded, the protein sample was 
incubated the monomeric avidin column for 0.5 hr at room temperature and then, the 
column was washed with amine free PBS buffer (12 mL) to remove non-bound protein, 
blocking buffer (12 mL) to elute labeled protein and regeneration buffer (12 mL) to elute 
and regenerate the resin for further use. The fractions from both the blocking buffer and 
regeneration buffer were collected to a 15 mL centrifugal filter unit (Millipore, amicon 
ultra 15, PL membrane, 3 KDa) and neutralized with TrisHCl buffer (1 mL, pH 9.5). 
The filter unit was centrifuged at 4000 x g for 45 min to centrifuge the sample to about 
300 μL. An aliquot of the final protein sample was analyzed by SDS-PAGE (Invitrogen 
NuPAGE Bis-Tris minigel, 1 mm, 10 wells, 4%-12%, 185 V, 35 min), followed by 
silver staining. The protein sample was precipitated by 10% TCA (procedure see below) 
to remove salt and analyzed by mass spectrometry (at Taplin Mass Spectrometry 
Facility, Harvard Medical School). 
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b) Non-functional pull-down: HL-60 cells were grown in a T-75 corning flask in 
20 mL media until the concentration reached 1 x 10
6
 cells/mL. The cells were incubated 
under 37 
o
C with non-functional PTL probe (8, 40 μM, the probe was pre-dissolved in 
DMSO to form a 10 mM stock solution) for 8 hrs and lysed by RIPA buffer. The protein 
concentration was determined by BCA assay (Pierce BCA protein assay kit). In most 
cases, the concentration is between 1.4 to 1.6 mg/mL. The concentration was adjusted to 
1 mg/mL by adding extra RIPA buffer. 
To non-functional labeled HL-60 cell lysate (1 mg/mL, 0.5 mL) was added 
Biotin-N3 probe (15, 10 mM in DMSO, 3.3 μL), ligand (10 mM in DMSO, 3.8 μL), 
sodium ascorbate (50 mM in H2O, 7 μL) and CuSO4 (50 mM in H2O, 7 μL) 
subsequently. The mixture was allowed to gently agitate at room temperature for 2.5 hr 
before loading to a monomeric avidin agrose column. The column separation process 
was the same as described above. An aliquot of the protein sample was analyzed by 
SDS-PAGE (Invitrogen NuPAGE Bis-Tris minigel, 1 mm, 10 wells, 4%-12%, 185 V, 35 
min), followed by silver staining. The protein sample was precipitated by 10% TCA to 
remove salt and analyzed by mass spectrometry (at Taplin Mass Spectrometry Facility, 
Harvard Medical School). 
 
c) Competitive pull-down experiment: HL-60 cells were grown in a T-75 corning 
flask in 20 mL media until the concentration reached 1 x 10
6
 cells/mL. The cells were 
firstly incubated under 37 
o
C with PTL (20 μM, the probe was pre-dissolved in DMSO 
to form a 10 mM stock solution) for 4 hrs and then, with functional PTL probe (7, 20 
μM) for another 3 hrs. Cells were lysed by RIPA buffer and protein concentration was 
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determined by BCA assay (Pierce BCA protein assay kit). In most cases, the 
concentration is between 1.1 to 1.3 mg/mL. The concentration was adjusted to 1 mg/mL 
by adding extra RIPA. 
To competitively labeled HL-60 cell lysate (1 mg/mL, 0.5 mL) was added 
Biotin-N3 probe (15, 10 mM in DMSO, 3.3 μL), ligand (10 mM in DMSO, 3.8 μL), 
sodium ascorbate (50 mM in H2O, 7 μL) and CuSO4 (50 mM in H2O, 7 μL) 
subsequentially. The mixture was allowed to gently agitate at room temperature for 2.5 
hrs before loading to a monomeric avidin agrose column. The column separation process 
was the same as described above. An aliquot of the protein sample was analyzed by 
SDS-PAGE (Invitrogen NuPAGE Bis-Tris minigel, 1 mm, 10 wells, 4%-12%, 185 V, 35 
min), followed by silver staining. The protein sample was precipitated by 10% TCA to 
remove salt and analyzed by mass spectrometry (at Taplin Mass Spectrometry Facility, 
Harvard Medical School). 
 
d) TCA (Trichloroacetic acid) protein precipitation: After concentration by filter 
units, the protein samples were diluted to 400 μL using cold deionized H2O. After the 
addition of 100 μL 100% TCA solution (prepared by dissolving 10 g TCA to a total 
volume of 10 mL in deionized H2O), the protein samples were incubated on ice until a 
white cloudy precipitation was observed (about 20 min). The samples were centrifuged 
at 14000 x g at 4 C for 20 min to yield the protein pellets. After careful removal TCA 
solution, 200 μL cold acetone was added to each protein pellet. The samples were 
votexed and centrifuged again for 10 min at 14000 x g at 4 C and the acetone was 
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removed with precaution. At last, the residual acetone was dried in speed-vac over night 
to yield the final protein pellets that were ready for mass spectrum analysis. 
 
e) Mass spectrometry analysis: the above mentioned protein samples were 
analyzed at Taplin Mass Spectrometry Facility, Harvard Medical School 
(https://taplin.med.harvard.edu/intro). Briefly, proteins in each sample were digested by 
trypsin and the resulting peptide fragments were analyzed and sequenced by 
microcapillary LC/MS/MS techniques. In order to identify proteins from a sample, the 
peptides information obtained from the above experiment was then compared to IPI 
databases (International Protein Index). Any protein with three or more unique peptide 
matches compared to a known protein is considered confidently identified. Proteins with 
less than three matches are not considered confidently identified without further 
inspection of the data. 
  97 
2.6 NMR Spectrum 
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Chapter 3. Semi-Synthesis and Biological Evaluation of 
Parthenolide Analogues. 
3.1 Introduction 
 The natural product Parthenolide (PTL, 1, figure 3.1) is a sesquiterpene lactone 
isolated from the Mexican Indian medicinal herb Tanacetum parthenum (feverfew 
plant),
251
 which has been used for over a century for the treatment of various common 
diseases such as arthritis, asthma, fever, and migraine.
252,253
 PTL has been extensively 
studied as an anticancer agent, showing significant efficacy towards a wide spectrum of 
human cancer cells, such as brain cancer,
254
 prostate cancer,
255,256
 breast cancer,
257,258
 
chronic lymphocytic leukemia,
259
 and pancreatic cancer.
260
 In 2005, the identification of 
PTL as the first stand-alone cytotoxic compound against leukemia stem cells (LSCs) 
further heightened its therapeutic potential. In addition, PTL exhibits selective 
cytotoxicity for LSCs versus normal hematopoietic stem cells (HSCs).
19
 After the 
discovery of PTL’s promising inhibitory activity against the LSCs, the study of the anti-
cancer activity of PTL has entered a new prosperous era. Besides leukemia, PTL was 
demonstrated to inhibit the survival of cancer stem cells (CSCs) in other types of 
cancers, including breast cancer
261
 and prostate cancer.
262
 
Despite the striking biological activity of PTL, two hurdles still prevent its 
further development. The first hurdle is the modest biological potency of PTL. Although 
 
Figure 3.1: Structure of parthenolide and LC-1. 
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PTL is considered a covalent modifier of cancer cells, it only exhibits anti-cancer 
activity of low micromolar level,
19
 indicating safety concerns associated with the 
required high dosing schedule. However, the task of boosting the anticancer activity of 
PTL is challenging. On one hand, PTL and PTL analogues must be reactive enough to 
be able to alkylate the functional target proteins to realize the anticancer activity; on the 
other hand, in order to diminish the off target effects to the largest extent, the reactivity 
of PTL analogues should be specific enough to retain the selective cytotoxicity of cancer 
cells over normal cells. In other words, the modification of healthy, non-cancerous cells, 
which may present very similar molecular targets as cancer cells or CSCs, leads to 
undesired toxicity and should be avoided. The second hurdle to the clinical utilization of 
PTL is its poor water solubility and thus, poor in vivo bioavailability. In 2004, a Phase I 
dose escalation trial of feverfew plant extract, which contained at least 0.2% 
parthenolide, was conducted to evaluate the pharmacokinetics and toxicity of feverfew 
plant extract as an anticancer agent. In this study, oral doses of up to 4 mg of PTL into 
healthy human volunteers did not yield any detectable concentration of the drug in the 
plasma, which was attributed to the poor water solubility of the compound.
310
 In order to 
address this issue, a water-soluble PTL analogue, the fumarate salt of dimethylamino-
parthenolide (DMAPT, LC-1, 2, figure 3.1) was developed and exhibited efficacy 
against acute myeloid leukemia (AML) stem and progenitor cells in vivo (canines) 
263,311
. 
A phase I clinical trial with LC-1 has been initiated in the United Kingdom in 2007 for 
the treatment of AML; however, results have not been reported. Bearing a 
dimethylamino group, which can be protonated to increase water solubility, and 
removed in cells metabolically to recover the α-methylene-γ-butyrolactone functionality, 
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LC-1 is a prodrug of PTL, with 1000-times better water solubility and equipotent anti-
proliferative activity as PTL in vitro.
263,311
 The metabolism process in which LC-1 was 
converted back to PTL likely involves the N-oxidation of dimethylamino group, and the 
subsequent Cope elimination of the N-oxide group.
263
 However, this process has not yet 
been explicitly elucidated to the best of our knowledge. Due to the involvement of 
metabolic activation, it is possible that the cellular concentration of PTL may vary in 
different patients. 
 
3.2 Project Design 
The aim of the project is to overcome the two hurdles mentioned above, that is, 
to develop PTL analogues with better anticancer potency, less off-target effects, and 
better in vivo bioavailability. It has been demonstrated by our lab and others that as a 
covalent modifier, the “warhead” of PTL is the α-methylene-γ-butyrolactone moiety, 
and removing of that pharmocophore abolishes most of the biological activities.
263,264
 
However, other reactive functionalities, such as C1-C10 endocyclic olefin and 
electrophilic epoxide also exist in the structure of PTL. We hypothesized that the innate 
reactivity of these structural features may erode both the target specificity and contribute 
in part to PTL’s side-effects (such as the anti-proliferative effect to normal cells and 
contact allergic responses
312
). However, after an examination of previous literatures, we 
found that efforts have not been performed to the best of our knowledge to determine 
whether all of these reactive groups on PTL (e.g. endocyclic olefin, epoxide) are 
essential for its anticancer activity. As a result, we proposed that a systematic removal of 
the reactive moieties from PTL’s architecture would result in the identification of the 
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minimal PTL skeleton that confers its cytotoxicity against cancer cells and CSCs, which 
is beneficial in tuning the reactivity of this covalent drug. In addition, we also aimed at 
developing new types of water-soluble PTL prodrugs that does not involve metabolic 
activation. 
 
3.3 Results and Discussion 
3.3.1 Synthesis and Biological Evaluation of Cyclopropyl Parthenolide Analogues.  
Previously in our lab, we synthesized the allylic oxidized PTL, 
Melampomagnolide B (MelB, 3, see Scheme 2.1 for preparation) according to a 
reported procedure
279
 and demonstrated that it has anti-cancer activity in various cancer 
 PTL (1) MelB (3) 
HL-60 9.3 ± 3.8 7.5 ± 3.0 
CCRF-CEM 4.7 ± 1.6 5.5 ± 1.2 
GBM6 3.4 ± 1.1 3.5, 6.6 
HeLa 44.1 ± 6.4 36.1 ± 3.2 
DU-145 8.9 ± 4.6 14.1 ± 5.7 
U-87 MG 5.8 ± 2.3 16.3 ± 6.8 
MCF-7 9.7 ± 2.8 9.5 ± 1.9 
NCI/Adr-Res 57.6 ± 8.9 17.8 ± 4.3 
Vero 12.4 ± 0.6 15.6 ± 3.5 
Table 3.1. Half maximal inhibitory concentration (IC50 in μM) of PTL (1) and MelB 
(3) in nine different cell lines. IC50 values are averages (n > 3) ± Standard deviation. 
For MelB in GBM6 cells, only duplicate data has been obtained. 
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cell lines similar to PTL (Table 3.1). Cancer cell lines investigated were HL-60 
(promyelocytic leukemia), CCRF-CEM (acute lymphoblastic leukemia), GBM6 
(glioblastoma multiforme), HeLa (cervical cancer), DU-145 (prostate cancer), U-87MG 
(glioblastoma, astrocytoma), MCF-7 (breast cancer), and NCI-ADR-RES (multidrug-
resistant ovarian cancer
313
). Vero cells (African green monkey epithelial kidney cells) 
were utilized to gauge cytotoxicity against normal cells. This result indicated that the 
geometry of the endocyclic olefin and the conformation of the 10-membered ring in 
PTL were not crucial for the biological activity of the compound. Based on the above 
observation, we modified the C1-C10 endocyclic olefin in PTL by Simmons-Smith 
cyclopropylation reaction
314
 and developed the cyclopropyl PTL analogues (Scheme 
3.1). The hypothesis behind this modification is that cyclopropyl group is a well-known 
bioisostere of olefin. Due to the presence of ring strain, the sp
3
 carbons in cyclopropyl 
group share some characteristics with sp
2
 carbons, so that the molecule retains the 
original conformation to a large extent; however, the transformation from sp
2
 carbons to 
sp
3
 carbons abolishes the innate chemical reactivity of olefin, which may result in some 
of the off-target effects of the parent compound. This modification has been previously 
used in the synthesis of selective retinoid
315
, as well as in the improvement of chemical 
and metabolic stability of anticancer nature product Epothilones (Epothilone A
316,317
 and 
Epothilone B
316,318
). 
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Cyclopropyl PTL (4) was prepared by treating PTL (1) with an in situ generated 
reagent Zn(CH2I)2·DME. Compound 4 is the only detectable product of the reaction, 
with the recovery of 41% of PTL starting material. The regio- and stereo-selectivity of 
the reaction were confirmed by both NMR spectroscopy and X-ray crystallography 
(Appendix A) of compound 4. With the similar strategy to prepare LC-1 (2) from PTL 
(1), we synthesized the fumarate salt of dimethylamine derivative (compound 5) to 
improve water solubility. 
With cyclopropyl PTL analogues 4 and 5 in hand, we tested their anticancer 
activity in five different cell lines to probe the effect of this modification (Table 3.2). 
From the result, we can reach the conclusion that the modification of the endocyclic 
 PTL LC-1 4 5 
HL-60 9.3 ± 3.8 7.1 ± 0.4 4.4 ± 1.3 6.5 ± 2.7 
GBM6 3.4 ± 1.1 3.5 ± 1.1 2.3 ± 0.5 2.2 ± 0.8 
DU-145 8.9 ± 4.6 8.4 ± 4.5 14.8 ± 6.7 TBD 
U-87 MG 5.8 ± 2.3 8.8 ± 1.9 7.4 ± 1.6 TBD 
Vero 12.4 ± 0.6 15.6 ± 7.8 TBD 22.2 ± 1.3 
Table 3.2. Half maximal inhibitory concentration (IC50 in μM) of PTL (1), LC-1 (2) 
and cyclopropyl PTL analogues 4 and 5 in five different cell lines. IC50 values are 
averages (n > 3) ± Standard deviation. TBD = to be determined. 
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Scheme 3.1. Reagents and Conditions: a) ZnEt2, CH2I2, DME, DCM, 0 °C to RT, 
40%; b) i. dimethylamine, MeOH, overnight; ii. Fumaric acid, Et2O, overnight, 85% 
over 2 steps. 
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olefin does not attenuate the anticancer activity of PTL. The synthesized PTL analogues 
possess comparable and sometimes better anti-proliferative activity than PTL in the 
tested cancer cells lines. For example, in HL-60 cell line, the IC50 of compound 4 (4.4 ± 
1.3 μM) is lower than that of PTL (9.3 ± 3.8 μM) and LC-1 (7.1 ± 0.4 μM), and in 
normal Vero cells, compound 5 possesses a slightly higher IC50 value (22.2 ± 1.3 μM) 
comparing with PTL (12.4 ± 0.6 μM) or LC-1 (15.6 ± 7.8 μM) indicating less off-target 
toxicity. In other tested cancer cell lines, the cytotoxicity of the four compounds are not 
significantly different. 
As a result of these positive results, we further invested the cytotoxicity of the 
synthesized compounds in murine primary AML cell lines, B117H, B117P, B140H and 
B140P (Table 3.3). Among these four cell lines, B117P and B140P are murine AML 
cell lines isolated from a BXH-2 mice strain that develops AML.
319
 These two cell lines 
are cytarabine (an FDA approved chemotherapeutic drug for AML) sensitive. 
Continuous low dosing of cytarabine to these two cell lines yielded B117H and B140H, 
respectively, which are cytarabine resistant.
319,320
 Notably, in B117P cell line, cell 
surface molecules such as CD34 and c-kit, which are well-established markers for 
 PTL LC-1 5 
B117H 2.0 ± 0.1 2.8 ± 1.8 4.4 ± 0.7 
B117P 1.1 ± 0.2 1.5 ± 0.4 1.9 ± 1.8 
B140H 3.6 ± 0.9 5.7 ± 1.8 4.1 ± 1.3 
B140P 2.9 ± 0.6 4.1 ± 1.2 4.2 ± 1.2 
Table 3.3. Half maximal inhibitory concentration (IC50 in μM) of PTL (1), LC-1 (2) 
and compound 5 in various murine AML cell lines. IC50 values are averages (n > 3) ± 
Standard deviation. Data from Sue Rathe from Dr. David Largaespada’s lab, UMN. 
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cancer stem and progenitor cells in AML, are highly expressed, indicating cancer stem 
and progenitor characteristics of the cell line. In this experiment, all tested compounds, 
PTL, LC-1 and compound 5 showed low micromolar level of cytotoxicity (between 2 to 
6 μM) towards both cytarabine sensitive and cytarabine resistant AML cell lines. For 
example, the IC50 of compound 5 in B117H (4.4 ± 0.7 μM) is less than two fold higher 
than that of PTL (2.0 ± 0.1 μM) and LC-1 (2.8 ± 1.8 μM), and in other three tested cell 
lines, the difference between the three compounds are not significant. The above result 
reiterated the therapeutic potency of PTL analogues in leukemia cells.  
Due to the good in vitro anticancer activity of cyclopropyl PTL analogues, we 
further tested the in vivo pharmacokinetic properties of the water-soluble compounds 
LC-1 and 5 in a normal mouse model. In this study, healthy CD-1 male mice were 
provided a single dose of tested compound by body weight via oral gavage at 100 mg/kg 
(the tested compounds were formulated in 0.5% methylcellulose to 10 mg/mL). Animals 
were sacrificed and blood and brain samples were collected 1 hour or 4 hours after the 
dosing to analyze the concentration of LC-1 and 5, as well as their parent compounds 
(elimination products), PTL and 4 in plasma (Table 3.4) and perfused brain (Table 3.5) 
by mass spectrometry. As a reference, 2964 ng/mL concentration equals 10.1 μM LC-1 
in plasma, and 446 ng/mL equals 1.4 μM of compound 5. The plasma concentration of 
each compound includes both the prodrug (LC-1 or 5) and the bioactive metabolite 
(PTL or 4). As a result, both tested compounds were detected in micromolar 
concentration in plasma at 1 hour, which is about or above their IC50 values, and 
dropped significantly at 4 hours. Notably, these measurements only considered the free 
drug and do no account for drug that has been bounded by protein. As a result, although 
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it appeared that compound 5 accumulated to a lower level than LC-1 in plasma, it is 
possible that compound 5 has a faster kinetic properties of metabolism and target 
binding, yielding less free drug in plasma and larger amount of drug at its cellular targets 
by the time of testing.  
In this pharmacokinetic study, the brain penetration of LC-1 and 5 were also 
tested. Strikingly, both LC-1 and 5 were found at high concentration in perfused brain. 
An average of 6250 ng/g of LC-1, which equals 21 μM concentration, and an average of 
1316 ng/g of 5, which equals 4.3 μM concentration were detected in brain tissue after 1 
hr (assuming 1 g/mL brain density). These values are well above their IC50 values for 
anti-proliferative activity in the tested brain cancer cell lines (GBM6 and U-87 MG). 
The permeability issue of drugs to penetrate the blood-brain barrier (BBB) is a major 
issue of many promising molecules towards the development of chemotherapeutic 
Compound 
Time 
(hour) 
Product 
Measured 
(ng/mL) 
Elimination 
Product 
Measured 
(ng/mL) 
LC-1 1 2964 2142
 
 
LC-1 4 115 211 
5 1 446 104
 
 
5 4 8 11 
Table 3.4 Concentration of LC-1, 5 and their metabolites in mouse plasma. Values are 
averages (n = 2 or 3). 
Compound 
Time 
(hour) 
Product 
Measured 
(ng/g) 
Elimination 
Product 
Measured 
(ng/g) 
LC-1 1 6250  2402
 
 
LC-1 4 342 113 
5 1 1316
 
 106
 
 
5 4 26 <LLOQ
a
 
Table 3.5 Concentration of LC-1, 5 and their metabolites in mouse brain. Values are 
averages (n = 2 or 3). a: LLOQ: Lower limit of quantitation. 
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agents for various brain cancers.  The BBB consists of tight junctions all along the brain 
capillaries and excludes almost 100% of large molecule drugs and over 98% of small 
molecule drugs from the brain circulation.
321
 The above pharmacokinetic results support 
the continued development of PTL analogues as next generation chemotherapeutic 
agents against brain tumors. 
In conclusion, two cyclopropyl PTL analogues were developed. In in vitro 
assays, they exhibited comparable or even better anticancer activity than their parent 
compound PTL in various cancer cell lines, including murine drug-resistant AML cell 
lines. Notably, the in vivo pharmacokinetic study indicated not only high serum 
concentration, but also brain penetration of the compounds, validating the future 
development of this class of molecules for various cancers. 
 
3.3.2 Synthesis and Biological Evaluation of Rearranged Parthenolide Analogues. 
Taking advantage of the reactivity of the endocyclic olefin and epoxide under 
acidic condition, we synthesized various PTL analogues with 5-7-5 ring systems 
(Scheme 3.2). Rearrangements of PTL (1) using BF3OEt in toluene according to 
literature procedure yielded Micheliolide (6) as the major product, and compound 7 as 
the minor product. The structure and stereochemistry of 6 are confirmed by comparing 
to published data
322
 as well as small molecule X-ray crystallography (Appendix B).  
a
O
Me
Me OH
O
H
PTL (1)
6 (67% yield)
+
Me H
HO
O
O
7 (23% yield)  
Scheme 3.2. Reagents and Conditions: a) BF3Et2O, toluene, 1 hr. 
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With rearranged PTL analogues 6 and 7 in hand, we tested their anticancer 
activities in seven different cancer cell lines, as well as in Vero cells, to probe the effect 
of this modification (Table 3.6, see section 3.3.1 for the description of cell lines). The 
synthesized PTL analogues possess the same level of anti-proliferative activity as PTL 
in many cancer cells lines. For example, in HL-60, CCRF-CEM and HeLa cell lines, the 
three tested compounds exhibited very similar cytotoxicity. In GBM6 cells, PTL (IC50 = 
3.4 ± 1.1 μM) is about two fold more active than rearranged PTL analogues (IC50 of 6 = 
8.7 ± 0.6 μM, IC50 of 7 = 8.4 ± 1.8 μM). In DU-145 cells, PTL  (IC50 = 8.9 ± 4.6 μM) is 
almost two fold more active than rearranged PTL analogues (IC50 of 6 = 14.8 ± 4.0 μM, 
IC50 of 7 = 13.9 ± 3.7 μM). In MCF-7 cells, PTL (IC50 = 9.7 ± 2.8 μM) and compound 6 
(IC50 = 9.6 ± 1.0 μM) have similar cytotoxicity, but compound 7 is significantly less 
active (IC50 of  = 25.0 ± 4.3 μM). What makes the result more meaningful is that in Vero 
cells, which are healthy kidney epithelial cells from the African monkey, rearranged 
PTL analogues 6 (IC50 = 36.1 ± 9.4 μM) and 7 (IC50 = 54.5 ± 3.0 μM) are less active 
than the parent compound PTL (IC50 = 12.4 ± 0.6 μM), indicating decreased toxicity 
against normal cells. Compared to PTL, compound 6 is approximately 2-fold less 
potent; however, it bears the structural advantage of an introduced tertiary alcohol, 
which is amenable to chemical manipulation, and its further modification will be 
introduced in section 3.3.3. Furthermore, compound 6 and 7 do not contain the pendent 
epoxide group, which is an unneglectable advantage from the perspective of drug 
design, because epoxide groups are notoriously reactive under biological conditions. 
From the above results, we can reach the conclusion that the modification of the 
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endocyclic olefin, the removal of the electrophilic epoxide, and the alteration of ring 
structure do not abolish the anticancer activity of PTL.  
Based on the above preliminary data, we further tested the anti-proliferative 
potency of PTL, LC-1 and compound 6 in four murine AML cell lines: B117H, B117P, 
B140H and B140P (Table 3.7, see section 3.3.1 for the description of cell lines). In this 
experiment, all tested compounds, PTL, LC-1 and 6 exhibited low micromolar level of 
cytotoxicity towards both cytarabine sensitive (B117P and B140P) and cytarabine 
resistant (B117H and B140H) cell lines. However, in all four tested cell lines, compound 
6 is about three to six fold less active the PTL and LC-1. For example, in B117 H cells, 
IC50 of 6 is 6.5 ± 1.0 μM, which is about five fold less active than PTL (IC50 = 1.1 ± 0.2 
μM) or LC-1 (IC50 = 1.5 ± 0.4 μM). 
 PTL 6 7 
HL-60 9.3 ± 3.8 7.1 ± 1.3 11.6 ± 0.2 
CCRF-CEM 4.7 ± 1.6 5.2 ± 1.8 4.8 ± 1.5 
GBM6 3.4 ± 1.1 8.7 ± 0.6 8.4 ± 1.8 
HELA 44.1 ± 6.4 35.6, 34.0 44.2 
DU-145 8.9 ± 4.6 14.8 ± 4.0 13.9 ± 3.7 
U-87 MG 5.8 ± 2.3 16.2 ± 3.6 29.3 ± 3.0 
MCF-7 9.7 ± 2.8 9.6 ± 1.0 25.0 ± 4.3 
Vero 12.4 ± 0.6 36.1 ± 9.4 54.5 ± 3.0 
Table 3.6. Half maximal inhibitory concentration (IC50 in μM) of PTL (1), and 
rearranged PTL analogues 6 and 7 in eight different cell lines. IC50 values are 
averages (n > 3) ± Standard deviation (SD).  For 6 or 7 in HeLa cells, only duplicate 
or single data has been obtained. 
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In conclusion, a series of rearranged PTL analogues with 5-7-5 ring systems 
were developed. In in vitro assays, they exhibited comparable anticancer activity with 
their parent compound PTL in various cancer cell lines, including murine drug-resistant 
AML cell lines.  
 
3.3.3 Synthesis and Biological Evaluation of Parthenolide Phosphate Prodrugs. 
In the above two sections, our efforts towards systematical removal of reactive 
functional groups of PTL were discussed. We synthesized two series of PTL analogues 
with comparable anticancer activities and less reactive groups than PTL, and 
demonstrated that they either have prominent in vivo pharmacokinetic properties or less 
extent off-target toxicity. In the meantime, we also synthesized the fumarate salts of the 
dimethylamino PTL analogues to increase the water solubility. However, as it has been 
introduced above, the limitation of the dimethylamino prodrugs is that they require 
metabolic activation to generate their active parent compounds. Due to the lack of 
knowledge of the process in which LC-1 was converted back to PTL, and the enzyme(s) 
involved in this transformation, it is possible that the cellular concentration of the active 
 PTL LC-1 6 
B117H 2.0 ± 0.1 2.8 ± 1.8 6.4 ± 1.0 
B117P 1.1 ± 0.2 1.5 ± 0.4 8.8 ± 1.7 
B140H 3.6 ± 0.9 5.7 ± 1.8 10.0 ± 0.4 
B140P 2.9 ± 0.6 4.1 ± 1.2 9.3 ± 1.5 
Table 3.7. Half maximal inhibitory concentration (IC50 in μM) of PTL, LC-1 and 
compound 6 in various murine AML cell lines. IC50 values are averages (n > 3) ± 
Standard deviation. Data from Sue Rathe from Dr. David Largaespada’s lab, UMN. 
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compounds vary in patients with different levels of drug metabolizing enzymes. In order 
to bypass this activation process, we designed and synthesized a new class of water-
soluble PTL analogues, using another prodrug strategy. 
As it has been introduced above, MelB (3) and Micheliolide (6) are two PTL 
analogues with micromolar anticancer activity. They have different chemical scaffolds, 
but the structural similarity is that both of them are bearing hydroxyl groups that can be 
further modified. Taking advantage of the hydroxyl groups, we synthesized the 
phosphate salts of MelB and Micheliolide (Scheme 3.3). This is hypothesized to be a 
better way to develop water-soluble PTL analogues, because it avoids the necessity of in 
vivo bioactivation. 
Starting from MelB (3) and Micheliolide (6), phosphoramidite chemistry was 
carried out to realize the transformation from 3 and 6 to 9 and 11, respectively, after a 
screen of phosphorylation conditions. In this step, the bis(2-cyanoethyl) 
diisopropylphosphoramidite (8), which is an unstable reagent, was synthesized 
according to a reported procedure
323
 and used within four weeks after it is made. 
Compound 8 was coupled to the hydroxyl group in compound 3 or 6 to yield the 
phosphites, which were acid labile and used in situ without any purification. The 
phosphite intermediates were oxidized to phosphates by mCPBA under careful control 
of reaction time and temperature (otherwise the olefins in the molecule would be 
epoxidized) to yield phosphates 9 and 11. The overall yield of the phosphorylation of 
compound 6 (57%) is lower than compound 3 (81%), presumably because of the steric 
hindrance of the tertiary alcohol in 6. At last, the cyanoethyl protection groups were 
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removed under basic condition (DBU, ion-exchange chromatography) to yield the water-
soluble phosphate salts 10 (47%) and 12 (37%).  
In order to compare the biological and pharmacokinetic properties of the 
synthesized phosphate salts 10 and 12 to the conventional dimethylamino prodrug of 
PTL analogues, the fumarate salts of dimethylamino MelB (13) and dimethylamino 
Micheliolide (14)
322
 were also synthesized (Scheme 3.4) using procedures described 
above.  
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Scheme 3.4. Reagents and Conditions: a) i. dimethylamine, MeOH, overnight; ii. 
Fumaric acid, Et2O, overnight, yield over 2 steps: 53% for 13, 96% for 14. 
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Scheme 3.3. Reagents and Conditions: a) i. Bis(2-cyanoethyl) diisopropyl-
phosphoramidite (8), tetrazole, 4 Å MS, MeCN, overnight; ii. mCPBA, 1 hr, 0 °C; 
yields over 2 steps: 81% for 9, 57% for 11; b) DBU, DCM, RT, overnight, followed by 
ion-exchange chromatography, 47% for 10, 37% for 11. 
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With compound 10, 12 - 14 in hand, we further tested their anticancer activity in 
different cell lines (Table 3.8). The anti-proliferative testing is still underway. The 
current data indicated that the modification of compound 6 to its phosphate salt 12 was 
not tolerated (IC50 of 12 in HL-60 cells is > 250 μM); while the phosphate salt of MelB 
(compound 10, IC50 in HL-60 = 22.5 ± 2.2 μM) is more active than the fumarate salt of 
the same parent compound (compound 13, IC50 in HL-60 = 36.2 ± 6.1 μM). However, it 
is possible that the decreased in vitro anticancer activity of phosphate compounds 
resulted from the lack of phosphate diesterases in cell models, and the synthesized 
parthenolide phosphates would be active in vivo. In the presence of phosphate 
diesterases in vivo, the negatively charged phosphate prodrugs of parthenolide analogues 
would be converted back to parent compounds (MelB or rearranged PTL) before they 
penetrating the negatively charged cell membrane, likely leading to higher concentration 
of drugs in cells.  
In addition, the theoretical distribution coefficient values (cLogD) of compound 
10, 12 - 14, as well as MelB (3), Micheliolide (6), LC-1 (2) and PTL (1) were also 
calculated using Marvin Sketch 5.11.5. software manufactured by ChemAxon (Table 
3.9). Distribution coefficient represents the ratio of the sum of the concentrations of all 
forms of the compound (ionized and un-ionized) in hydrophobic and hydrophilic phases. 
 10 12 13 14 
HL-60 22.5 ± 2.2 > 250 36.2 ± 6.1 32.3 ± 10.4 
Vero 50.0 > 250 21.1 ± 1.2 48.7 ± 5.9 
Table 3.8. Half maximal inhibitory concentration (IC50 in μM) of compound 10, 12, 
13 and 14 in HL-60 and Vero cell lines. IC50 values are averages (n > 3) ± Standard 
deviation (SD). For compound 10 in Vero cells, only single data has been obtained. 
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cLogD strongly affects how easily the tested compound can reach its intended target in a 
biological system. Under neutral condition (pH = 7.4), PTL (cLogD = 3.07), MelB 
(cLogD = 1.79) and Micheliolide (cLogD = 1.97) exhibited high LogD values, 
indicating their hydrophobic property. On the other hand, the fumarate prodrugs LC-1 
(cLogD = 0.50), compound 13 (cLogD = -0.78) and 14 (cLogD = -0.60) had low LogD 
values, indicating their moderate water solubility. The synthesized phosphate PTL 
analogues 10 (cLogD = -1.29) and 12 (cLogD = -1.34) exhibited even lower LogD 
values, indicating their good water-solubility, which is consistent with our experiment 
observation.  
 
3.4 Conclusions and Future Direction 
 cLogD7.4 
PTL 3.07 
LC-1 0.50 
MelB 1.79 
Micheliolide 1.97 
10 -1.29 
12 -1.34 
13 -0.78 
14 -0.60 
 Table 3.9. Calculated LogD values (pH7.4) of compound 10, 12, 13, 14, PTL, LC-
1, MelB and Micheliolide. Calculated by Marvin Sketch 5.11.5. software 
manufactured by ChemAxon 
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In conclusion, a library of PTL analogues have been synthesized and 
biologically evaluated to elucidate the importance of various functional groups to the 
cytotoxicity profile of PTL and to purse PTL analogues with increased anticancer 
potencies. The methods we employed to modify PTL included acidic rearrangement, 
cyclopropylation and phosphorylation. The modified functional groups included the 
endocyclic olefin, the vinyl methyl group, the epoxide, the exocyclic olefin and the 10-
membered ring structure of PTL. In addition, phosphate prodrugs of hydroxyl 
containing PTL analogues were synthesized in pursuit of water-soluble PTL analogues 
that do not need to be bioactivated in vivo. 
Our results revealed that minor modifications of PTL were well tolerated across 
all tested cancer cell lines, indicating large space for future modification. Among the 
analogues we synthesized, cyclopropyl PTL analogues exhibited better activity when 
compared to PTL in some cancer cell lines. The outstanding pharmacokinetic properties 
of 5 in serum and perfused brain validated the future development of this class of 
molecules for leukemia and brain cancers. Rearranged PTL analogues 6 and 7 also 
displayed interesting biological activity. Exhibiting similar level of activity as PTL in 
most cancer cell lines, they are demonstrated to be less cytotoxic against normal cell line 
Vero. Both compounds had up to a 5-fold loss in activity against Vero, indicating 
decreased off-target toxicity. In addition, both the rearranged and cyclopropyl PTL 
analogues were demonstrated to be effective in inhibiting the proliferation of murine 
drug resistant leukemia cells, iterating the important role PTL analogues will play in the 
future development of therapeutic agents of leukemia. 
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3.5 Experimentle 
3.5.1 General 
All reactions were performed under an anhydrous nitrogen atmostphere unless 
otherwise noted.  Parthenolide was purchased from Enzo Life Sciences and repurified by 
SiO2 chromatography prior to biological studies. Commercial grade reagents (Aldrich, 
Acros, Alfa Aesar) were used without further purification unless otherwise noted. 
Tetrahydrofuran and dichloromethane were rendered anhydrous by passing through the 
resin column of a solvent purification system. Benzene was purified by fractional 
distillation. Methanol, 1,2-dimethoxyethane, and N,N-dimethylformamide were 
purchased as anhydrous. All reactions were monitored by thin-layer chromatography 
(TLC) using silica gel 60-F254 TLC plates (Merck), and visualized using either iodine or 
charring with para-Anisaldehyde stain.  Column chromatography employed Silicycle 
SiliaFlash® P60 (40-63 m) silica gel. SiO2 column purification was performed using a 
CombiFlash® Rf 200 instrument using pre-packed silica gel columns or Redisep Rf 
Gold High-Performance silica gel columns (Teledyne-Isco). HPLC purification was 
performed using an Agilent 1200 series instrument (preparative scale) equipped with a 
Zorbax (Agilent) preparatory column (21.2 x 250 mm, 7 μm).  Analysis of compound 
purity was conducted on the aforementioned HPLC, using a Zorbax analytical column 
(4.6 x 150 mm, 5 μm). Nuclear magnetic resonance (NMR) spectroscopy employed a 
Bruker 400 Ultrashield 400 MHz spectrometer.  Internal solvent peaks were referenced 
in each case.  Mass spectral data was obtained from the University of Minnesota mass 
spectrometry lab, employing a Bruker Biotof II instrument. X-ray diffraction was 
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performed by Dr. Victor G. Young, Jr., at the X-ray Crystallographic Laboratory at the 
University of Minnesota. 
 
3.5.2 Synthesis of Parthenolide Analogues 
Me
O
O
O
Me
NMe2
HOOC
COOH
 
Dimethylamino Parthenolide Fumarate salt (DMAPT, LC-1, 2): This 
compound was prepared as previously described.
263
 Briefly, to a stirred solution of 
parthenolide (126 mg, 50.7 mmol) in MeOH (4 mL) was added dimethylamine solution 
(2 M in MeOH, 1 mL). The reaction was allowed to stir at room temperature overnight, 
and then the solvent was removed under reduced pressure. The residue was dissolved in 
CH2Cl2 (50 mL), and washed with deionized H2O (20 mL, 1x) and saturated aq. 
NaHCO3 (20 mL, 1x). The combined aqueous solution was washed with CH2Cl2 (50 
mL, 2x). The organic layers were collected, dried over anhydrous Na2SO4 and 
concentrated in vacuo. The crude material was subjected to SiO2 chromatography 
(gradient 0%-50% EtOAc in hexanes over 10 min, then gradient 0%-15% MeOH in 
CH2Cl2 over 15 min) to yield the dimethylamino product (130 mg, 87%) as colorless oil. 
To the stirred solution of dimethylamino product (130 mg, 0.44 mmol) in ether (3 mL) 
was added fumaric acid (51.4 mg, 0.44 mmol). The reaction was allowed to stir at room 
temperature overnight until a white powder precipitated out. The solvent was removed 
under reduced pressure to yield LC-1 (181 mg, quant.). Spectral data matches that 
previously reported.
263
 
1
H NMR (DMSO-d6, 400 MHz):  6.61 (s, 2H), 5.21 (d, J = 10.0 
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Hz, 1H), 3.97 (t, J = 9.1 Hz, 1H), 2.79 (d, J = 9.1 Hz, 1H), 2.62 (m, 3H), 2.35 (m, 1H), 
2.19 (m, 8H), 1.98 (m, 4H), 1.66 (m, 4H), 1.20 (s, 3H), 1.12 (td, J = 5.8 Hz, J = 12.9 Hz, 
1H). 
 
O
Me
Me
O O
  
Cyclopropyl parthenolide 4: A 0.20 M solution of Zn(CH2I)2·DME complex
314 
was made in the following manner: To a stirred solution of diethyl zinc (1.0 M solution 
in hexanes, 4.0 mL, 4 mmol) in CH2Cl2 (20 mL) and DME (0.50 mL) at 0 °C was added 
diiodomethane (0.80 mL, 9.92 mmol) under N2. The mixture was stirred for 10 minutes. 
This Zn(CH2I)2·DME complex was added dropwise over 10 minutes to a solution of 
parthenolide (90 mg, 0.36 mmol) in CH2Cl2 (3 mL) at 0 °C. The reaction was stirred for 
1 hour at 0 °C, and the stirring was continued overnight with gradual warming to room 
temperature.  The crude material was quenched by pouring into NH4Cl (saturated, aq., 
20 mL) and then extracted with CH2Cl2 (20 mL, 4x). The combined organic layers were 
washed with NaHCO3 (saturated aq., 20 mL), brine (saturated aq., 20 mL) and then dried 
over Na2SO4. The crude material was purified using SiO2 chromatography (gradient 10-
30% EtOAc in hexanes over 15 minutes) to yield the product (36 mg, 40%) as a 
colorless oil and recovered parthenolide (37 mg, 41%). 
1
H NMR (400 MHz, CDCl3) δ: 
6.28 (d, J = 3.7 Hz, 1H), 5.57 (d, J = 3.3 Hz, 1H), 3.96 (t, J = 9.1 Hz, 1H), 2.98 (d, J = 
9.0 Hz, 1H), 2.67 (m, 1H), 2.39 (dd, J = 8.0 Hz, J = 14.7 Hz, 1H), 2.19 (dd, J = 2.3 Hz, J 
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= 8.3 Hz, 1H), 1.95 (m, 2H), 1.70 (m, 1H), 1.40 (s, 3H), 1.28 (m, 2H), 1.09 (s, 3H), 0.85 
(dd, J = 11.1 Hz, J = 14.7,  1H), 0.64 (td, J = 6.0 Hz, J = 9.5 Hz, 1H), 0.39 (dd, J = 4.3 
Hz, J = 9.4 Hz, 1H), -0.08 (dd, J = 4.6 Hz, J = 5.6 Hz, 1H).
 13
C NMR (100 MHz, CDCl3) 
δ: 169.4, 139.9, 120.5,. 82.7, 65.5, 60.6, 48.0, 42.3, 38.4, 25.7, 24.5, 22.3, 20.4, 18.8, 
18.5, 17.1.  HRMS (ESI
+
) m/z calcd for [C16H22O3+Na]
+
 285.1467; found 285.1470. The 
structure of 4 was further confirmed by small molecule X-ray crystallography (see 
Appendix A). 
 
O
Me
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O
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Dimethylamino cyclopropyl-Parthenolide fumarate salt 5: To a stirred 
solution of 4 (9 mg, 0.034 mmol) in MeOH (2 mL) was added dimethylamine solution 
(2M in MeOH, 1.5 mL). The reaction was stirred overnight at RT. MeOH was removed 
under reduced pressure and the residue was purified by Si2O chromatography (gradient 
0%-50% EtOAc in hexanes over 10 min, then gradient 0%-25% MeOH in CH2Cl2 over 
15 min) to yield the dimethylamino product as a white solid (9 mg, 0.024 mmol, 85%). 
To a stirred solution of dimethylamino product in Et2O (5 mL) was added fumaric acid 
(3.4 mg, 0.029 mmol). A white precipitate was observed after stirring overnight at room 
temperature.  Et2O was removed under reduced pressure to give the fumarate salt as 
white solid (12.4 mg, quant.). 
1
H NMR (DMSO-d6, 400 MHz):  6.61 (s, 2H), 4.09 (t, J 
= 9.5 Hz, 1H), 3.04 (d, J =9.2 Hz, 1H), 2.64 (m, 3H), 2.24 (s, 6H), 2.14 (m, 2H), 2.05 
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(m, 1H), 1.78 (m, 2H), 1.59 (m, 1H), 1.31 (s, 3H), 1.19 (m, 2H), 1.02 (s, 3H), 0.74 (m, 
2H), 0.28 (dd, J = 3.8 Hz, J = 9.2 Hz, 1H), -0.18 (t, J = 4.8 Hz, 1H). 
13
C NMR (DMSO-
d6, 100 MHz): 176.6, 166.1, 134.1, 81.8, 64.3, 60.3, 57.2, 47.4, 45.6, 45.3, 41.7, 38.0, 
24.2, 24.0, 21.6, 20.1, 18.4, 18.3, 16.7. HRMS (ESI
+
) m/z calcd for [C18H30NO3+H]
+
 
308.2226; found 308.2216. 
 
O
Me
Me OH
O
H
 
Me H
HO
O
O  
Micheliolide (6),
324
 rearranged parthenolide analogue 7
325
: These two 
compounds were prepared as previously described.
324, 325
 Briefly, to a stirred solution of 
parthenolide (30 mg, 0.12 mmol) in toluene (1 mL) was added BF3Et2O (7 L, 0.072 
mmol) dropwise. The reaction was allowed to stir at room temperature for 1 hr before 
being quenched by NaHCO3 (saturated aq., 15 mL).  The aqueous solution was extracted 
by CH2Cl2 (40 mL, 3x). The combined organic layers were dried over anhydrous 
Na2SO4 and concentrated in vacuo. The crude material was subjected to SiO2 column 
purification (gradient 10%-50% EtOAc in hexanes over 16 min) to yield 6 (20 mg, 67%) 
as white solid, 
1
H NMR (CDCl3, 400 MHz):  6.21 (d, J = 3.3 Hz, 1H), 5.50 (d, J = 3.1 
Hz, 1H), 3.81 (t, J = 10.3 Hz, 1H), 2.74 (d, J = 10.7 Hz, 1H), 2.66 (m, 2H), 2.40 (dd, J = 
8.4 Hz, J = 16.3 Hz, 1H), 2.22 (m, 3H), 2.09 (ddd, J = 2.3 Hz, J = 3.9 Hz, J = 13.6 Hz, 
1H), 1.81 (m, 2H), 1.68 (s, 3H), 1.34 (m, 4H); and less polar rearrangement product 7 (7 
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mg, 23%) as a white solid, 
1
H NMR (CDCl3, 400 MHz):  6.12 (d, J = 3.5 Hz, 1H), 5.48 
(d, J = 3.2 Hz, 1H), 5.14 (s, 1H), 5.06 (s, 1H), 4.01 (d, J = 9.7 Hz, 1H), 2.96 (m, 1H), 
2.61 (m, 1H), 2.32 (m, 5H), 2.02 (m, 1H), 1.79 (m, 2H), 1.56 (m, 2H), 1.06 (d, J = 7.1 
Hz, 3H). The structure of 6 was further confirmed by small molecule X-ray 
crystallography (see Appendix B). The structure of 7 was confirmed by comparing to 
reported NMR data.
325
 
 
N
P O
O
CN
CN
 
Bis(2-cyanoethyl) diisopropylphosphoramidite (8): Reagent 8 was prepared 
according to reported procedure.
323
 Diisopropylphosphoramidous dichloride (505 mg, 
2.5 mmol) was added dropwise to a stirred solution of cyanoethenol (356 mg, 5 mmol) 
and DIPEA (1.3 mL, 7.5 mmol) in anhydrous THF (3 mL) at 0 °C. The reaction mixture 
was warmed to room temperature and stirring was continued for 1 hr or until a white 
powder precipitated. The reaction mixture was filtered through celite and THF was 
removed from filtrate. The concentrated filtrate was redissolved in EtOAc (80 mL) and 
washed with H2O (20 mL, 2x). The combined aqueous solution was washed with EtOAc 
(80 mL, 2x). The organic layers were collected, dried over anhydrous Na2SO4 and 
concentrated in vacuo. The crude material was subjected to SiO2 column purification 
(gradient 0%-40% EtOAc in hexanes containing 1.5% Et3N over 20 min) to yield 
product (307 mg, 45%) as colorless oil. The phosphoramidite product is not stable and 
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extremely sensitive to acid, such as silica gel. It could be stored at -20 °C for no more 
than 1 month. When NMR is taken in the solvent, CDCl3 should be neutralized with 
Na2CO3 beforehand. 
1
H NMR (CDCl3, 400 MHz):  3.82 (m, 4H), 3.62 (5d, J = 6.8 Hz, 
J = 10.4 Hz, 2H), 2.65 (t, J = 6.3 Hz, 4H), 1.20 (d, J = 6.8 Hz, 12H). 
31
P NMR (CDCl3, 
162 MHz):  -246.6. 
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O
O
P O
O O
CN
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Bis(2-cyanoethyl) Melampomagnolide B phosphate 9: Compound 3 (30 mg, 
0.11 mmol) and phosphoramidite (8, 31 mg, 0.11 mg) were weighted out in a round 
bottom flask and dried under high vac for 2 hr. The dried material was dissolved in 
anhydrous acetonitrile (5 mL) under N2 stream. Two 4Å molecular sieves were added. 
After the injection of tetrazole (0.47 M in acetonitrile, 0.47 mL, 0.22 mmol), the reaction 
was stirred overnight at room temperature. The second day, mCPBA (61 mg, 0.27 
mmol) was added to the reaction, which was quenched after 2 hrs by the addition of 
NaHCO3 (saturated aq., 5 mL). Acetonitrile was removed under reduced pressure. The 
aqueous residue was diluted with deionized H2O (15 mL) and extracted by CH2Cl2 (30 
mL, 3x). The organic layer was combined, dried over anhydrous Na2SO4, and 
concentrated in vacuo. The crude material was purified by SiO2 column chromatograpy 
(gradient 5%-100% EtOAc in hexanes over 7 min, 100% EtOAc over 8 min, then 
gradient 0%-15% MeOH in CH2Cl2 over 15 min) to yield the product (40 mg, 81%) as a 
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colorless oil. 
1
H NMR (CDCl3, 400 MHz):  6.26 (d, J = 3.4 Hz, 1H), 5.81 (t, J = 8.3 
Hz, 1H), 5.62 (d, J = 3.1 Hz, 1H), 4.69 (t, J = 10.4 Hz, 1H), 4.55 (dd, J = 6.1 Hz, J = 
11.5 Hz, 1H), 4.29 (m, 4H), 3.85 (t, J = 9.3 Hz, 1H), 2.80 (m, 6H), 2.32 (m, 6H), 1.71 (t, 
J = 9.6 Hz, 1H), 1.55 (s, 3H), 1.12 (t, J = 13.1 Hz, 1H). 
31
P NMR (CDCl3, 162 MHz):  -
2.05. HRMS (ESI
+
) m/z calcd for [C21H27N2O7P+Na]
+
 473.1454; found 473.1466. 
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O
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Melampomagnolide B phosphate disodium salt 10: To a stirred solution of 
compound 9 (25 mg, 0.056 mmol) in CH2Cl2 (5 mL) was injected N,O-
Bis(trimethylsilyl) acetamide (205 L, 0.82 mmol) and DBU (84 L, 0.56). The reaction 
was stirred overnight under N2 and quenched by the addition of MeOH. After the 
removal of solvent under reduced pressure, the residue was dissolved in deionized H2O 
and separated by reverse phase column chromatography (Biotage isolute XL-C18 
column, eluant: 100% H2O 5 mL, 75% H2O in MeOH 5 mL, 25% H2O in MeOH 5 mL, 
then 100% MeOH 5 mL). Every fraction that stained blue under p-anisaldehyde in TLC 
was collected to yield the crude product, which contained both acid form and DBU-salt 
form of the product and some leftover of DBU. The crude product was acidified by 
Dowex 50WX8 resin (pre-acidified by HCl and washed by H2O until eluate was neutral) 
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for 1 hr at room temperature in H2O/MeOH 3:1. The resin was removed by filtration and 
the filtrate was concentrated and stirred with triethylammonium acetate buffer (1 M, 5 
mL) overnight to give di-TEA salt of the product. The triethylammonium acetate buffer 
was removed under reduced pressure and loaded to an ion exchange column 
(Dowex50WX8-Na
+
, eluant: H2O). All fractions were collected and concentrated. The 
residue was further purified by reverse phase C-18 column (100% H2O, then 75% H2O 
in MeOH) to yield pure product. The product was lyophilized overnight to give white 
powder (10 mg, 47%). 
1
H NMR (D2O, 400 MHz):  6.25 (d, J = 3.4 Hz, 1H), 5.84 (d, J 
= 3.1 Hz, 1H), 5.76 (t, J = 8.1 Hz, 1H), 4.45 (dd, J = 7.0 Hz, J = 11.8 Hz, 1H), 4.26 (m, 
2H), 3.23 (d, J = 9.6 Hz, 1H), 3.09 (m, 1H), 2.52 (m, 1H), 2.39 (m, 3H), 2.23 (m, 2H), 
1.76 (t, J = 11.4 Hz, 1H), 1.63 (s, 3H), 1.14 (t, J = 12.3 Hz, 1H). 
31
P NMR (D2O, 162 
MHz):  1.08. HR-MS (ESI) m/z calcd for [C15H20O7P]
-
 343.0952; found 343.0940. 
 
O
Me
Me O
O
H
P
OO
O
CN
CN
 
Bis(2-cyanoethyl) Micheliolide phosphate 11: Compound 6 (20 mg, 0.074 
mmol) and phosphoramidite (8, 20 mg, 0.081 mg) were weighted out in a round bottom 
flask and dried under high vac for 2 hours. The dried material was dissolved in 
anhydrous acetonitrile (5 mL) under N2 stream. Two 4Å molecular sieves were added. 
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After the injection of tetrazole (0.47 M in acetonitrile, 0.32 mL, 0.15 mmol), the reaction 
was stirred overnight at room temperature. The second day, mCPBA (37 mg, 0.16 
mmol) was added in situ to the reaction at 0 °C, which was quenched after 2 hr by the 
addition of NaHCO3 (saturated aq., 5 mL). Acetonitrile was removed under reduced 
pressure. The aqueous residue was diluted with deionized H2O (15 mL) and extracted by 
CH2Cl2 (30 mL, 3x). The organic layer was combined, dried over anhydrous Na2SO4, 
and concentrated in vacuo. The crude material was purified by SiO2 column 
chromatography (gradient 5%-60% EtOAc in hexanes over 10 min, 100% EtOAc over 
10 min) to yield the product (20 mg, 57%) as a colorless oil. 
1
H NMR (CDCl3, 400 
MHz):  6.18 (d, J = 3.3 Hz, 1H), 5.49 (d, J = 3.0 Hz, 1H), 4.33 (m, 4H), 3.85 (t, J = 
10.1 Hz, 1H), 3.24 (d, J = 5.1 Hz, 1H), 2.76 (m, 5H), 2.48 (m, 1H), 2.21 (m, 5H), 2.10 
(dd, J = 2.2 Hz, J = 13.8 Hz, 1H), 1.70 (s, 3H), 1.57 (s, 3H), 1.35 (m, 1H). 
31
P NMR 
(CDCl3, 162 MHz):  -7.50. HRMS (ESI
+
) m/z calcd for [C21H27N2O6P+Na]
+
 457.1504; 
found 451.1522. A main byproduct, which is the mCPBA-oxidized product of the 
starting material, was also obtained: 
O
Me
Me OH
O
H
O
 
Epoxidized rearranged parthenolide:
326
 
1
H NMR (CDCl3, 400 MHz):  6.19 
(d, J = 3.3 Hz, 1H), 5.48 (d, J = 3.1 Hz, 1H), 4.05 (t, J = 10.4 Hz, 1H), 2.80 (s, 1H), 2.30 
(m, 4H), 1.92 (m, 4H), 1.65 (dt, J = 7.6 Hz, J = 15.2 Hz, 1H), 1.47 (s, 3H), 1.41 (m, 1H), 
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1.30 (s, 3H). 
13
C NMR (CDCl3, 100 MHz):  169.6, 138.1, 119.5, 81.9, 79.7, 69.9, 62.2, 
55.6, 49.4, 37.3, 33.4, 29.5, 23.3, 23.3, 21.9. 
 
O
Me
Me O
O
H
P
O
O O
2Na
 
Micheliolide phosphate disodium salt 12: To a stirred solution of compound 11 
(14 mg, 0.032 mmol) in CH2Cl2 (5 mL) was injected N,O-Bis(trimethylsilyl) acetamide 
(118 L, 0.48 mmol) and DBU (47 L, 0.32). The reaction was stirred overnight under 
N2. The reaction was quenched by the addition of MeOH. After the removal of solvent 
under reduced pressure, the residue was dissolved in deionized H2O and separated by 
reverse phase column chromatography (Biotage isolute XL-C18 column, eluant: 100% 
H2O 5 mL, 75% H2O in MeOH 5 mL, 25% H2O in MeOH 5 mL, then 100% MeOH 5 
mL). Every fraction that stained blue under p-anisaldehyde in TLC was collected to 
yield the crude product, which contained both acid form and DBU-salt form of the 
product and some leftover of DBU. The crude product was acidified by Dowex 50WX8 
resin (pre-acidified by HCl and washed by H2O until eluate was neutral) for 1 hr at room 
temperature in H2O/MeOH 3:1. The resin was removed by filtration and the filtrate was 
concentrated and stirred with TEA (0.5 mL) in MeOH (5 mL) for 1 hr to give di-TEA 
salt of the product. The solvent was removed under reduced pressure and the residue was 
loaded to an ion exchange column (Dowex50WX8-Na
+
, eluant: H2O). All fractions were 
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collected and concentrated. The residue was further purified by reverse phase C-18 
column (100% H2O, then 75% H2O in MeOH) to yield pure product. The product was 
lyophilized overnight to give white powder (4.5 mg, 37%). 
1
H NMR (CD3OD, 400 
MHz):  6.12 (d, J = 3.4 Hz, 1H), 5.57 (d, J = 3.1 Hz, 1H), 3.87 (t, J = 10.1 Hz, 1H), 
3.17 (d, J = 10.3 Hz, 1H), 2.79 (td, J = 2.5 Hz, J = 10.4 Hz 1H), 2.48 (m, 1H), 2.22 (m, 
6H), 1.74 (s, 3H) 1.57 (s, 3H), 1.35 (m, 1H). 
31
P NMR (CD3OD, 162 MHz):  -0.34. 
HRMS (ESI
+
) m/z calcd for [C15H21O6P+Na]
+
 351.0973; found 351.0990. 
 
O
OMe
O
OH
N COOH
HOOH2C
.
 
Dimethylamino Melampomagnolide B fumarate salt 13: To a stirred solution 
of compound 3 (12 mg, 0.045 mmol) in MeOH (2 mL) was added a solution of 
dimethylamine (2M in MeOH, 1.5 mL). The reaction was stirred overnight at room 
temperature. MeOH was removed under reduced pressure and the residue was purified 
by SiO2 column chromatography (gradient 0%-50% EtOAc in hexanes over 10 min, then 
gradient 0%-25% MeOH in CH2Cl2 over 15 min) to yield the dimethylamino product as 
a white solid (7.4 mg, 0.024 mmol, 53%). To a stirred solution of dimethylamino 
product in Et2O (5 mL) was added fumaric acid (2.8 mg, 0.024 mmol). A white 
precipitate was observed after the reaction was stirred overnight at room temperature.  
Et2O was removed under reduced pressure to give the fumarate salt as white solid (10.2 
mg, quant.). 
1
H NMR (DMSO-d6, 400 MHz):  6.61 (s, 2H), 5.48 (t, J = 7.5 Hz, 1H), 
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4.02 (t, J = 9.5 Hz, 1H), 3.91 (q, J =13.3 Hz, 2H), 2.68 (m, 4H), 2.27 (m, 10H), 2.07 (m, 
3H), 1.57 (t, J = 9.9 Hz, 1H), 1.47 (s, 3H), 0.90 (t, J = 12.3 Hz, 1H). 
13
C NMR (DMSO-
d6, 100 MHz): 177.0, 166.2, 141.0, 134.1, 123.4, 80.4, 63.3, 63.2, 59.8, 57.3, 45.0, 43.3, 
42.6, 36.9, 25.6, 24.0, 22.9, 17.5. HR-MS (ESI) m/z calcd for [C17H28NO4+H]
+
 
310.2018; found 310.2004. 
 
 
O
Me
Me OH
O
NH
COOH
COOH
 
Dimethylamino Micheliolide fumarate salt 14: 14 was prepared according to 
the previously reported method that yielded HCl salt of the same parent compound.
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To a stirred solution of 6 (26 mg, 0.106 mmol) in MeOH (2 mL) was added 
dimethylamine solution (2M in MeOH, 1.5 mL). The reaction was stirred overnight at 
room temperature. MeOH was removed under reduced pressure and the residue was 
purified by SiO2 column chromatography (gradient 0%-50% EtOAc in hexanes over 10 
min, then gradient 0%-15% MeOH in CH2Cl2 over 15 min) to yield the dimethylamino 
product as a white solid (30 mg, 0.102 mmol, 96%). To a stirred solution of 
dimethylamino product in Et2O (5 mL) was added fumaric acid (11.8 mg, 0.102 mmol). 
A white precipitate was observed after stirring overnight at room temperature. Et2O was 
removed under reduced pressure to give the fumarate salt as white solid (41 mg, quant.). 
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1
H NMR (DMSO-d6, 400 MHz):  6.62 (s, 2H), 3.83 (t, J = 10.2 Hz, 1H), 2.82 (m, 3H), 
2.54 (m, 1H), 2.40 (s, 6H), 2.30 (m, 2H), 2.04 (m, 5H), 1.61 (m, 5H), 1.25 (m, 1H), 1.17 
(s, 3H). 
13
C NMR (DMSO-d6, 100 MHz): 176.9, 166.1, 134.0, 132.9, 130.6, 82.9, 79.4, 
57.2, 56.1, 50.8, 44.3, 44.2, 42.5, 34.5, 29.5, 26.2, 23.5, 22.5. HRMS (ESI
+
) m/z calcd 
for [C17H28NO3+H]
+
 294.2069; found 294.2072. 
 
3.5.3 Protocol for Mammalian Cell Culture  
All cell lines were maintained in a humidified 5% CO2 environment at 37 °C in 
culture flasks (Corning). Adherent cells were dissociated using 0.25% Trypsin-EDTA 
solution (Gibco). CCRF-CEM cells (ATCC, CCL-119) and NCI/ADR-RES (a gift from 
Dr. Gunda Georg’s lab, UMN) were cultured in RPMI-1640 media (Cellgro) 
supplemented with 10% fetal bovine serum (FBS, Gibco), penicillin (100 I.U./mL), and 
streptomycin (100 µg/mL, ATCC) at a density of 2 × 10
5
 - 2 × 10
6
 cells/mL. DU-145 
cells (ATCC, HTB-81), Vero cells (ATCC, CCL-81), U-87MG cells (ATCC, HTB-14), 
and HeLa cells (ATCC, CCL-2) were cultured in MEM media (Cellgro) supplemented 
with 10% FBS (Gibco), penicillin (100 I.U./mL), and streptomycin (100 µg/mL, 
ATCC). HL-60 cells (ATCC, CCL-240) were cultured in IMDM media (Cellgro) 
supplemented with 20% FBS (Gibco), penicillin (100 I.U./mL), and streptomycin (100 
µg/mL, ATCC). MCF-7 cells (ATCC, HTB-22) were cultured in MEM media (Cellgro) 
supplemented with 10% FBS (Gibco), bovine insulin (0.01 mg/mL, Sigma) penicillin 
(100 I.U./mL), and streptomycin (100 µg/mL, ATCC). GBM6 cells (a gift from Dr. John 
Ohlfest, UMN) were cultured with DMEM/F12 (1:1) with L-Glutamine, without HEPES 
(Thermo Scientific) supplemented with Normocin (100 µg/mL, Invivogen), 50X B-27 
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supplement (10 mL, Gibco), 100X N-2 supplement (5 mL, Gibco), human EGF (20 
ng/µL, Peprotech), human FGF-basic (20 ng/µL, PeproTech), penicillin (50 I.U./mL), 
and streptomycin (50 µg/mL, ATCC).  
 
3.5.4 Protocol for Cell Culture Cytotoxicity Assays  
A protocol for these experiments was previously published by Hexum et al.
309
 
CCRF-CEM and HL-60 cells were cultured at a density of 10,000 cells/well in cell 
culture media (50 µL) in standard 96-well plates (Costar) 24 h prior to treatment. DU-
145, Vero, U-87MG, GBM6, HeLa, MCF-7, and NCI/ADR-RES cells were seeded at a 
density of 5,000 cells/well in cell culture media (50 µL) in standard 96-well plates 
(Costar).  Controls used were Blank (no cells) wells and control (vehicle control treated) 
wells and were prepared for every experiment. All PTL analogues were serially diluted 
in pre-warmed media and dosed to 96 well plates (final volume/well = 100 µL; final 
DMSO concentration = 0.5%). Approximately 1-3 h before the end of the treatment 
period (48 h), Alamar Blue (Invitrogen) cell viability reagent was added to the 96 well 
plates (10 µL). A quantitative measure of cell viability can be achieved from evaluating 
the ability of metabolically active cells (which are proportional to the number of living 
cells) to convert resazurin (non-fluorescent dye) to red-fluorescent resorufin. 
Fluorescence data were obtained on either a Molecular Devices SpectraMax M2 plate 
reader or an LJL BioSystems HT Analyst plate reader. Background fluorescence (no cell 
controls) was subtracted from each well and cellular viability values following 
compound treatment were normalized to vehicle-only treated wells (control wells only 
treated with aqueous DMSO, which were arbitrarily assigned 100% viability). Individual 
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IC50 curves were generated by fitting data to the sigmoidal (dose response) function of 
varied slope in GraphPad Prism (v. 5.0) software. Only curve fits with R
2
 > 0.95 were 
deemed sufficient. Each experiment was performed in biological triplicate and mean 
IC50 values were calculated from the individual IC50 values obtained from each replicate. 
Standard deviation was calculated from the individual IC50 values obtained for each 
biological replicate. 
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Appendix A X-Ray Crystallography Data for Cycprypyl PTL (4) 
 
A.1 General Experimentle 
A crystal (approximate dimensions 0.45x 0.40 x 0.05mm3) was placed onto the tip of a 
0.1 mm diameter glass capillary and mounted on a CCD area detector diffractometer for 
a data collection at 123(2) K. A preliminary set of cell constants was calculated from 
reflections harvested from three sets of 20 frames.  These initial sets of frames were 
oriented such that orthogonal wedges of reciprocal space were surveyed.  This produced 
initial orientation matrices determined from 61 reflections.  The data collection was 
seconds and a detector distance of 4.8 cm.  A randomly oriented region of reciprocal 
space was surveyed to the extent of one sphere and to a resolution of 0.77 Å.  Four 
settings and a detector position of -
absorption and decay (SADABS). Final cell constants were calculated from 2944 strong 
reflections from the actual data collection after integration. 
The structure was solved using Bruker SHELXTL4 and refined using Bruker 
SHELXTL. The space group P21 was determined based on systematic absences and 
intensity statistics.  A direct-methods solution was calculated which provided most non-
hydrogen atoms from the E-map.  Full-matrix least squares / difference Fourier cycles 
were performed which located the remaining non-hydrogen atoms.  All non-hydrogen 
atoms were refined with anisotropic displacement parameters.  All hydrogen atoms were 
placed in ideal positions and refined as riding atoms with relative isotropic displacement 
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parameters.  The final full matrix least squares refinement converged to R1 = 0.0496 and 
wR2 = 0.1335 (F2, all data). 
There are two identical, unique molecules per asymmetric unit with Z’=2. The chirality 
is as follows: C4-R, C5-R, C6-S, and C7-S. The CheckCIF program made no assignment 
at C1 due to its geometry, but this appears to be R. There is only slight pseudo-
symmetry between the two unique molecules resulting in a pseudo 21 relationship along 
an irrational axis in the monoclinic setting. Data collection and structure solution were 
conducted at the X-Ray Crystallographic Laboratory, 192 Kolthoff Hall, Department of 
Chemistry, UMN.  All calculations were performed using Pentium computers using the 
current SHELXTL suite of programs. 
A.2 Thermal Ellipsoid Drawing of 4 
 
A.3 Crystallographic Information 
  187 
 
Table 1.  Crystal data and structure refinement for 4. 
_____________________________________________________________________________ 
Empirical formula  C16 H22 O3 
Formula weight  262.34 
Temperature  123(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P21 
Unit cell dimensions a = 11.106(2) Å  
 b = 7.9397(16) Å  
 c = 16.668(3) Å  
Volume 1426.0(5) Å3 
Z 4 
Density (calculated) 1.222 Mg/m3 
Absorption coefficient 0.083 mm-1 
F(000) 568 
Crystal color, morphology Colorless, Plate 
Crystal size 0.45 x 0.40 x 0.05 mm3 
Theta range for data collection 1.26 to 27.47° 
Index ranges -14 ≤ h ≤ 13,0 ≤ k ≤ 10,0 ≤ l ≤ 21 
Reflections collected 12785 
Independent reflections 3465 [R(int) = 0.0291] 
Observed reflections 3001 
Completeness to theta = 27.47° 98.9%  
Absorption correction Mulit-scan 
Max. and min. transmission 0.9959 and 0.9637 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3465 / 1 / 347 
Goodness-of-fit on F2 1.046 
Final R indices [I>2sigma(I)] R1 = 0.0496, wR2 = 0.1256 
R indices (all data) R1 = 0.0599, wR2 = 0.1335 
Absolute structure parameter 0.1(15) 
Largest diff. peak and hole 0.621 and -0.368 e.Å-3 
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Table 2.  Atomic coordinates(x 104) and equivalent isotropic displacement parameters 
(Å2x 103).  Ueq is defined as one third of the trace of the orthogonalized Uij tensor. 
 x y z Ueq 
_____________________________________________________________________ 
C1A 8313(3) 687(4) 520(2) 31(1) 
C2A 8620(3) 1643(5) -194(2) 38(1) 
C3A 7538(3) 2720(5) -688(2) 35(1) 
C4A 6994(3) 3875(4) -157(2) 31(1) 
C5A 5932(2) 3222(4) 137(2) 29(1) 
C6A 5669(2) 3698(4) 947(2) 29(1) 
C7A 6002(2) 2262(4) 1579(2) 29(1) 
C8A 7322(3) 2326(5) 2160(2) 42(1) 
C9A 8141(3) 814(5) 2062(2) 39(1) 
C10A 8911(2) 1022(4) 1428(2) 32(1) 
C11A 4927(3) 2308(4) 1983(2) 31(1) 
C12A 3916(3) 3269(5) 1432(2) 37(1) 
C13A 4790(4) 1644(5) 2679(2) 44(1) 
C14A 9949(3) 2292(5) 1687(2) 48(1) 
C15A 7819(3) 5283(4) 271(2) 40(1) 
C16A 9237(3) -539(5) 1021(2) 40(1) 
O17A 5732(2) 4447(3) -522(1) 39(1) 
O18A 4329(2) 3954(3) 809(1) 37(1) 
O19A 2862(2) 3477(4) 1489(2) 55(1) 
C1B 713(3) 5269(5) 3394(2) 37(1) 
C2B 395(3) 4385(5) 4116(2) 43(1) 
C3B 1423(3) 3229(5) 4589(2) 45(1) 
C4B 2643(3) 4147(5) 4866(2) 45(1) 
C5B 3465(3) 4052(4) 4296(2) 41(1) 
C6B 4357(3) 5391(4) 4187(2) 36(1) 
C7B 4056(3) 6167(4) 3317(2) 34(1) 
C8B 3290(3) 7798(4) 3200(2) 44(1) 
C9B 1898(3) 7615(5) 2807(2) 39(1) 
C10B 1037(3) 7116(4) 3346(2) 36(1) 
C11B 5342(3) 6323(4) 3156(2) 34(1) 
C12B 6199(3) 5248(4) 3765(2) 37(1) 
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C13B 5715(3) 7165(5) 2578(2) 43(1) 
C14B 1028(5) 8333(6) 4018(3) 66(1) 
C15B 2688(4) 5548(9) 5485(2) 73(2) 
C16B -212(3) 6446(6) 2883(3) 63(1) 
O17B 3732(2) 3103(4) 5061(2) 78(1) 
O18B 5573(2) 4563(3) 4291(2) 41(1) 
O19B 7271(2) 4924(3) 3817(2) 48(1) 
 
 
 
Table 3.   Bond lengths [Å]. 
C(1A)-C(16A) 1.512(4) 
C(1A)-C(2A) 1.518(4) 
C(1A)-C(10A) 1.522(4) 
C(1A)-H(1AA) 1.0000 
C(2A)-C(3A) 1.541(4) 
C(2A)-H(2AA) 0.9900 
C(2A)-H(2AB) 0.9900 
C(3A)-C(4A) 1.498(4) 
C(3A)-H(3AA) 0.9900 
C(3A)-H(3AB) 0.9900 
C(4A)-O(17A) 1.459(3) 
C(4A)-C(5A) 1.476(4) 
C(4A)-C(15A) 1.511(4) 
C(5A)-O(17A) 1.443(4) 
C(5A)-C(6A) 1.497(4) 
C(5A)-H(5AA) 1.0000 
C(6A)-O(18A) 1.465(3) 
C(6A)-C(7A) 1.536(4) 
C(6A)-H(6AA) 1.0000 
C(7A)-C(11A) 1.507(4) 
C(7A)-C(8A) 1.549(4) 
C(7A)-H(7AA) 1.0000 
C(8A)-C(9A) 1.539(5) 
C(8A)-H(8AA) 0.9900 
C(8A)-H(8AB) 0.9900 
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C(9A)-C(10A) 1.521(4) 
C(9A)-H(9AA) 0.9900 
C(9A)-H(9AB) 0.9900 
C(10A)-C(16A) 1.499(4) 
C(10A)-C(14A) 1.514(5) 
C(11A)-C(13A) 1.317(5) 
C(11A)-C(12A) 1.479(4) 
C(12A)-O(19A) 1.209(4) 
C(12A)-O(18A) 1.347(4) 
C(13A)-H(13A) 0.9500 
C(13A)-H(13B) 0.9500 
C(14A)-H(14A) 0.9800 
C(14A)-H(14B) 0.9800 
C(14A)-H(14C) 0.9800 
C(15A)-H(15A) 0.9800 
C(15A)-H(15B) 0.9800 
C(15A)-H(15C) 0.9800 
C(16A)-H(16A) 0.9900 
C(16A)-H(16B) 0.9900 
C(1B)-C(16B) 1.493(5) 
C(1B)-C(2B) 1.507(5) 
C(1B)-C(10B) 1.517(5) 
C(1B)-H(1BA) 1.0000 
C(2B)-C(3B) 1.527(5) 
C(2B)-H(2BA) 0.9900 
C(2B)-H(2BB) 0.9900 
C(3B)-C(4B)             1.509(5) 
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Table 4. Bond angles [°]. 
_____________________________________________________________________________ 
c C(16A)-C(1A)-C(2A) 120.3(3) 
C(16A)-C(1A)-C(10A) 59.2(2) 
C(2A)-C(1A)-C(10A) 124.5(3) 
C(16A)-C(1A)-H(1AA) 114.0 
C(2A)-C(1A)-H(1AA) 114.0 
C(10A)-C(1A)-H(1AA) 114.0 
C(1A)-C(2A)-C(3A) 113.7(2) 
C(1A)-C(2A)-H(2AA) 108.8 
C(3A)-C(2A)-H(2AA) 108.8 
C(1A)-C(2A)-H(2AB) 108.8 
C(3A)-C(2A)-H(2AB) 108.8 
H(2AA)-C(2A)-H(2AB) 107.7 
C(4A)-C(3A)-C(2A) 113.5(2) 
C(4A)-C(3A)-H(3AA) 108.9 
C(2A)-C(3A)-H(3AA) 108.9 
C(4A)-C(3A)-H(3AB) 108.9 
C(2A)-C(3A)-H(3AB) 108.9 
H(3AA)-C(3A)-H(3AB) 107.7 
O(17A)-C(4A)-C(5A) 58.89(18) 
O(17A)-C(4A)-C(3A) 115.4(2) 
C(5A)-C(4A)-C(3A) 116.7(3) 
O(17A)-C(4A)-C(15A) 112.2(3) 
C(5A)-C(4A)-C(15A) 123.0(3) 
C(3A)-C(4A)-C(15A) 116.5(3) 
O(17A)-C(5A)-C(4A) 59.95(18) 
O(17A)-C(5A)-C(6A) 119.2(3) 
C(4A)-C(5A)-C(6A) 123.9(3) 
O(17A)-C(5A)-H(5AA) 114.3 
C(4A)-C(5A)-H(5AA) 114.3 
C(6A)-C(5A)-H(5AA) 114.3 
O(18A)-C(6A)-C(5A) 107.9(2) 
O(18A)-C(6A)-C(7A) 106.1(2) 
C(5A)-C(6A)-C(7A) 111.4(2) 
O(18A)-C(6A)-H(6AA) 110.4 
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C(5A)-C(6A)-H(6AA) 110.4 
C(7A)-C(6A)-H(6AA) 110.4 
C(11A)-C(7A)-C(6A) 101.7(2) 
C(11A)-C(7A)-C(8A) 116.9(2) 
C(6A)-C(7A)-C(8A) 116.0(3) 
C(11A)-C(7A)-H(7AA) 107.2 
C(6A)-C(7A)-H(7AA) 107.2 
C(8A)-C(7A)-H(7AA) 107.2 
C(9A)-C(8A)-C(7A) 113.7(3) 
C(9A)-C(8A)-H(8AA) 108.8 
C(7A)-C(8A)-H(8AA) 108.8 
C(9A)-C(8A)-H(8AB) 108.8 
C(7A)-C(8A)-H(8AB) 108.8 
H(8AA)-C(8A)-H(8AB) 107.7 
C(10A)-C(9A)-C(8A) 115.8(3) 
C(10A)-C(9A)-H(9AA) 108.3 
C(8A)-C(9A)-H(9AA) 108.3 
C(10A)-C(9A)-H(9AB) 108.3 
C(8A)-C(9A)-H(9AB) 108.3 
H(9AA)-C(9A)-H(9AB) 107.4 
C(16A)-C(10A)-C(14A) 115.4(3) 
C(16A)-C(10A)-C(9A) 117.5(3) 
C(14A)-C(10A)-C(9A) 113.1(3) 
C(16A)-C(10A)-C(1A) 60.05(19) 
C(14A)-C(10A)-C(1A) 121.3(3) 
C(9A)-C(10A)-C(1A) 119.2(2) 
C(13A)-C(11A)-C(12A) 121.4(3) 
C(13A)-C(11A)-C(7A) 131.1(3) 
C(12A)-C(11A)-C(7A) 107.4(2) 
O(19A)-C(12A)-O(18A) 121.5(3) 
O(19A)-C(12A)-C(11A) 128.7(3) 
O(18A)-C(12A)-C(11A) 109.8(2) 
C(11A)-C(13A)-H(13A) 120.0 
C(11A)-C(13A)-H(13B) 120.0 
H(13A)-C(13A)-H(13B) 120.0 
C(10A)-C(14A)-H(14A) 109.5 
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C(10A)-C(14A)-H(14B)109.5 
H(14A)-C(14A)-H(14B)109.5 
C(10A)-C(14A)-H(14C) 109.5 
H(14A)-C(14A)-H(14C) 109.5 
H(14B)-C(14A)-H(14C) 109.5 
C(4A)-C(15A)-H(15A) 109.5 
C(4A)-C(15A)-H(15B) 109.5 
H(15A)-C(15A)-H(15B) 109.5 
C(4A)-C(15A)-H(15C) 109.5 
H(15A)-C(15A)-H(15C) 109.5 
H(15B)-C(15A)-H(15C) 109.5 
C(10A)-C(16A)-C(1A) 60.7(2) 
C(10A)-C(16A)-H(16A) 117.7 
C(1A)-C(16A)-H(16A) 117.7 
C(10A)-C(16A)-H(16B) 117.7 
C(1A)-C(16A)-H(16B) 117.7 
H(16A)-C(16A)-H(16B) 114.8 
C(5A)-O(17A)-C(4A) 61.15(17) 
C(12A)-O(18A)-C(6A) 110.2(2) 
C(16B)-C(1B)-C(2B) 119.0(3) 
C(16B)-C(1B)-C(10B) 60.3(2) 
C(2B)-C(1B)-C(10B) 126.6(3) 
C(16B)-C(1B)-H(1BA) 113.5 
C(2B)-C(1B)-H(1BA) 113.5 
C(10B)-C(1B)-H(1BA) 113.5 
C(1B)-C(2B)-C(3B) 113.7(3) 
C(1B)-C(2B)-H(2BA) 108.8 
C(3B)-C(2B)-H(2BA) 108.8 
C(1B)-C(2B)-H(2BB) 108.8 
C(3B)-C(2B)-H(2BB) 108.8 
H(2BA)-C(2B)-H(2BB) 107.7 
C(4B)-C(3B)-C(2B) 111.8(3) 
C(4B)-C(3B)-H(3BA) 109.3 
C(2B)-C(3B)-H(3BA) 109.3 
C(4B)-C(3B)-H(3BB) 109.3 
C(2B)-C(3B)-H(3BB) 109.3 
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H(3BA)-C(3B)-H(3BB) 107.9 
O(17B)-C(4B)-C(5B) 59.7(2) 
O(17B)-C(4B)-C(3B) 115.8(4) 
C(5B)-C(4B)-C(3B) 115.5(3) 
O(17B)-C(4B)-C(15B) 112.5(3) 
C(5B)-C(4B)-C(15B) 123.8(3) 
C(3B)-C(4B)-C(15B) 116.3(3) 
O(17B)-C(5B)-C(4B) 59.0(2) 
O(17B)-C(5B)-C(6B) 118.5(3) 
C(4B)-C(5B)-C(6B) 125.2(3) 
O(17B)-C(5B)-H(5BA) 114.3 
C(4B)-C(5B)-H(5BA) 114.3 
C(6B)-C(5B)-H(5BA) 114.3 
O(18B)-C(6B)-C(5B) 106.5(3) 
O(18B)-C(6B)-C(7B) 105.9(2) 
C(5B)-C(6B)-C(7B) 113.6(3) 
O(18B)-C(6B)-H(6BA) 110.2 
C(5B)-C(6B)-H(6BA) 110.2 
C(7B)-C(6B)-H(6BA) 110.2 
C(11B)-C(7B)-C(8B) 115.1(3) 
C(11B)-C(7B)-C(6B) 101.6(2) 
C(8B)-C(7B)-C(6B) 116.5(3) 
C(11B)-C(7B)-H(7BA) 107.7 
C(8B)-C(7B)-H(7BA) 107.7 
C(6B)-C(7B)-H(7BA) 107.7 
C(9B)-C(8B)-C(7B) 116.4(3) 
C(9B)-C(8B)-H(8BA) 108.2 
C(7B)-C(8B)-H(8BA) 108.2 
C(9B)-C(8B)-H(8BB) 108.2 
C(7B)-C(8B)-H(8BB) 108.2 
H(8BA)-C(8B)-H(8BB) 107.3 
C(10B)-C(9B)-C(8B) 119.2(3) 
C(10B)-C(9B)-H(9BA) 107.5 
C(8B)-C(9B)-H(9BA) 107.5 
C(10B)-C(9B)-H(9BB) 107.5 
C(8B)-C(9B)-H(9BB) 107.5 
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H(9BA)-C(9B)-H(9BB) 107.0 
C(14B)-C(10B)-C(16B) 116.2(3) 
C(14B)-C(10B)-C(9B) 113.5(3) 
C(16B)-C(10B)-C(9B) 115.0(3) 
C(14B)-C(10B)-C(1B) 123.1(3) 
C(16B)-C(10B)-C(1B) 59.1(2) 
C(9B)-C(10B)-C(1B) 118.4(3) 
C(13B)-C(11B)-C(12B) 122.0(3) 
C(13B)-C(11B)-C(7B) 130.1(3) 
C(12B)-C(11B)-C(7B) 107.9(3) 
O(19B)-C(12B)-O(18B) 121.5(3) 
O(19B)-C(12B)-C(11B) 129.3(3) 
O(18B)-C(12B)-C(11B) 109.2(2) 
C(11B)-C(13B)-H(13C) 120.0 
C(11B)-C(13B)-H(13D) 120.0 
H(13C)-C(13B)-H(13D) 120.0 
C(10B)-C(14B)-H(14D) 109.5 
C(10B)-C(14B)-H(14E) 109.5 
H(14D)-C(14B)-H(14E) 109.5 
C(10B)-C(14B)-H(14F) 109.5 
H(14D)-C(14B)-H(14F) 109.5 
H(14E)-C(14B)-H(14F) 109.5 
C(4B)-C(15B)-H(15D) 109.5 
C(4B)-C(15B)-H(15E) 109.5 
H(15D)-C(15B)-H(15E) 109.5 
C(4B)-C(15B)-H(15F) 109.5 
H(15D)-C(15B)-H(15F) 109.5 
H(15E)-C(15B)-H(15F) 109.5 
C(1B)-C(16B)-C(10B) 60.6(2) 
C(1B)-C(16B)-H(16C) 117.7 
C(10B)-C(16B)-H(16C) 117.7 
C(1B)-C(16B)-H(16D) 117.7 
C(10B)-C(16B)-H(16D) 117.7 
H(16C)-C(16B)-H(16D)114.8 
C(4B)-O(17B)-C(5B) 61.3(2) 
C(12B)-O(18B)-C(6B) 110.1(2) 
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Table 5.   Anisotropic displacement parameters (Å2x 103).  The anisotropic 
displacement factor exponent takes the form: - 2[ h2a*2U11 + ... + 2 h k a* b* U12 ]. 
_____________________________________________________________________________ 
 U11 U22 U33 U23 U13 U12 
_____________________________________________________________________________ 
C1A 23(1)  32(2) 35(2)  -4(1) -1(1)  2(1) 
C2A 32(2)  49(2) 36(2)  -1(2) 12(1)  3(2) 
C3A 33(2)  44(2) 29(1)  2(1) 10(1)  1(1) 
C4A 28(1)  33(2) 31(1)  7(1) 6(1)  2(1) 
C5A 22(1)  35(2) 27(1)  1(1) 0(1)  -1(1) 
C6A 19(1)  33(2) 32(1)  -1(1) 3(1)  -1(1) 
C7A 22(1)  36(2) 26(1)  -3(1) 1(1)  3(1) 
C8A 26(1)  67(2) 28(1)  -10(2) -3(1)  9(2) 
C9A 30(1)  53(2) 28(1)  9(1) -2(1)  12(2) 
C10A 21(1)  36(2) 34(1)  -2(1) -2(1)  4(1) 
C11A 29(1)  32(2) 33(1)  -6(1) 7(1)  -2(1) 
C12A 27(1)  43(2) 42(2)  -5(2) 7(1)  -1(1) 
C13A 55(2)  39(2) 41(2)  -1(2) 20(2)  3(2) 
C14A 30(2)  55(2) 50(2)  -11(2) -5(1)  -5(2) 
C15A 36(2)  35(2) 51(2)  2(2) 14(1)  -8(1) 
C16A 35(2)  40(2) 41(2)  -4(2) 1(1)  11(1) 
O17A 33(1)  45(1) 37(1)  12(1) 3(1)  8(1) 
O18A 23(1)  48(1) 39(1)  7(1) 7(1)  7(1) 
O19A 24(1)  81(2) 63(2)  1(2) 14(1)  5(1) 
C1B 27(1)  41(2) 39(2)  -2(1) -2(1)  -3(1) 
C2B 23(1)  47(2) 59(2)  10(2) 8(1)  -3(1) 
C3B 29(2)  46(2) 63(2)  18(2) 15(2)  -2(2) 
C4B 26(1)  60(2) 49(2)  25(2) 7(1)  2(2) 
C5B 26(1)  33(2) 66(2)  11(2) 18(1)  4(1) 
C6B 21(1)  33(2) 57(2)  3(2) 14(1)  3(1) 
C7B 22(1)  31(2) 48(2)  0(1) 9(1)  -2(1) 
C8B 29(2)  33(2) 70(2)  12(2) 16(2)  3(1) 
C9B 31(2)  47(2) 40(2)  16(2) 9(1)  11(1) 
C10B 27(1)  39(2) 45(2)  6(1) 11(1)  7(1) 
C11B 24(1)  34(2) 46(2)  -9(1) 12(1)  -4(1) 
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C12B 25(1)  34(2) 52(2)  -10(2) 12(1)  -3(1) 
C13B 36(2)  50(2) 48(2)  -6(2) 16(1)  -6(2) 
C14B 88(3)  43(2) 87(3)  -16(2) 58(3)  -6(2) 
C15B 70(3)  121(5) 31(2)  -8(2) 17(2)  -28(3) 
C16B 32(2)  71(3) 79(3)  29(3) -4(2)  2(2) 
O17B 33(1)  75(2) 122(3)  65(2) 11(2)  10(1) 
O18B 23(1)  41(1) 59(1)  8(1) 13(1)  5(1) 
O19B 24(1)  53(2) 68(2)  -5(1) 16(1)  2(1) 
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Table 6.   Hydrogen coordinates (x 104) and isotropic displacement parameters (Å2x 
103). 
_____________________________________________________________________ 
 x  y  z  U(eq) 
_____________________________________________________________________ 
H1AA 7431 301 411 38 
H2AA 8865 826 -574 46 
H2AB 9340 2386 25 46 
H3AA 7836 3402 -1098 42 
H3AB 6877 1963 -996 42 
H5AA 5679 2050 -49 35 
H6AA 6128 4748 1168 34 
H7AA 5938 1185 1260 34 
H8AA 7736 3374 2049 50 
H8AB 7249 2372 2740 50 
H9AA 8711 576 2606 46 
H9AB 7599 -184 1907 46 
H13A 4029 1777 2837 52 
H13B 5452 1031 3024 52 
H14A 10500 1942 2213 72 
H14B 9597 3400 1754 72 
H14C 10423 2357 1263 72 
H15A 7367 5962 593 60 
H15B 8062 5996 -143 60 
H15C 8563 4805 642 60 
H16A 8916 -1627 1173 48 
H16B 10071 -597 907 48 
H1BA 1126 4521 3058 45 
H2BA -367 3710 3910 52 
H2BB 212 5242 4501 52 
H3BA 1180 2769 5080 55 
H3BB 1524 2271 4231 55 
H5BA 3131 3359 3790 49 
H6BA 4405 6291 4613 43 
H7BA 3584 5310 2924 40 
  199 
H8BA 3390 8337 3747 52 
H8BB 3644 8573 2852 52 
H9BA 1600 8704 2543 47 
H9BB 1801 6770 2359 47 
H13C 6555 7095 2544 52 
H13D 5143 7844 2196 52 
H14D 1848 8352 4406 100 
H14E 402 7993 4311 100 
H14F 829 9458 3782 100 
H15D 3438 6223 5523 110 
H15E 2701 5064 6028 110 
H15F 1954 6266 5307 110 
H16C -944 6753 3092 76 
H16D                                   -372                   6351                  2274                      76 
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Appendix B X-Ray Crystallography Data for Rearranged PTL (6) 
 
 
B.1 General Experimentle 
A crystal (approximate dimensions 0.50 x 0.08 x 0.04 mm3) was placed onto the tip of a 
0.1 mm diameter glass capillary and mounted on a Bruker APEX-II CCD diffractometer 
for a data collection at 173(2) K.  A preliminary set of cell constants was calculated from 
reflections harvested from three sets of 20 frames.  These initial sets of frames were 
oriented such that orthogonal wedges of reciprocal space were surveyed.  This produced 
initial orientation matrices determined from 755 reflections.  The data collection was 
seconds and a detector distance of 6.0 cm.  A randomly oriented region of reciprocal 
space was surveyed to the extent of one sphere and to a resolution of 0.77 Å.  Four 
settings and a detector position of -
absorption and decay (SADABS).  Final cell constants were calculated from 2972 strong 
reflections from the actual data collection after integration.  
The data were merged as though the structure was centrosymmetric since absolute 
configuration could not be determined experimentally for lack of a heavy atom. In this 
case the Flack parameter is meaningless and the enantiomer was chosen based on known 
chiral centers. Data collection and structure solution were conducted at the X-Ray 
Crystallographic Laboratory, 192 Kolthoff Hall, Department of Chemistry, UMN.  All 
calculations were performed using Pentium computers using the current SHELXTL suite 
of programs. 
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B.2 Thermal Ellipsoid Drawing of 6 
 
 
B.3 Crystallographic Information 
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Table 1.  Crystal data and structure refinement. 
__________________________________________________________________________ 
Empirical formula  C15 H20 O3 
Formula weight  248.31 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  C2221 
Unit cell dimensions  a = 7.4777(9) Å  
 b = 15.4839(18) Å  
 c = 22.319(3) Å  
Volume 2584.2(5) Å3 
Z 8 
Density (calculated) 1.276 Mg/m3 
Absorption coefficient 0.087 mm-1 
F(000) 1072 
Crystal color, morphology colourless, Needle 
Crystal size 0.50 x 0.08 x 0.04 mm3 
Theta range for data collection 2.63 to 27.52° 
Index ranges 0 ≤ h ≤ 9, 0 ≤ k ≤ 19, 0 ≤ l ≤ 29 
Reflections collected 12579 
Independent reflections 1686 [R(int) = 0.0415] 
Observed reflections 1475 
Completeness to theta = 27.52°  99.6%  
Absorption correction Multi-scan 
Max. and min. transmission 0.9965 and 0.9576 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 1686 / 0 / 166 
Goodness-of-fit on F2 1.042 
Final R indices [I>2sigma(I)]  R1 = 0.0373, wR2 = 0.0958 
R indices (all data) R1 = 0.0442, wR2 = 0.1008  
Absolute structure parameter 4.3(16) 
Largest diff. peak and hole              0.179 and -0.192 e.Å-3 
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Table 2.  Atomic coordinates (x 104) and equivalent isotropic displacement parameters 
(Å2x 103 ). Ueq is defined as one third of the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________  
 x  y  z     Ueq 
_________________________________________________________________________ 
C1 2832(3) 1293(1) 3111(1) 30(1) 
C2 2644(4) 403(2) 2828(1) 41(1) 
C3 3409(4) -224(2) 3288(1) 41(1) 
C4 2964(3) 189(1) 3891(1) 33(1) 
C5 3338(3) 1158(1) 3769(1) 27(1) 
C6 2429(3) 1782(1) 4188(1) 27(1) 
C7 3078(3) 2712(1) 4148(1) 28(1) 
C8 2203(4) 3210(1) 3642(1) 36(1) 
C9 2909(4) 2940(2) 3027(1) 43(1) 
C10 2634(3) 2027(2) 2804(1) 34(1) 
C11 2755(3) 3021(1) 4776(1) 30(1) 
C12 2813(3) 2242(1) 5162(1) 32(1) 
C13 2389(3) 3796(2) 4989(1) 42(1) 
C14 2190(4) 1991(2) 2141(1) 43(1) 
C15 1045(4) 8(2) 4072(1) 44(1) 
O16 4187(3) -112(1) 4335(1) 44(1) 
O17 2776(2) 1531(1) 4813(1) 32(1) 
O18 2878(3) 2192(1) 5700(1) 43(1) 
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Table 3.   Bond angles [°]. 
____________________________________________________________________ 
C(10)-C(1)-C(2) 123.20(18) 
C(10)-C(1)-C(5) 129.46(19) 
C(2)-C(1)-C(5) 107.29(16) 
C(1)-C(2)-C(3) 105.21(17) 
C(1)-C(2)-H(2A) 110.7 
C(3)-C(2)-H(2A) 110.7 
C(1)-C(2)-H(2B) 110.7 
C(3)-C(2)-H(2B) 110.7 
H(2A)-C(2)-H(2B) 108.8 
C(2)-C(3)-C(4) 104.22(18) 
C(2)-C(3)-H(3A) 110.9 
C(4)-C(3)-H(3A) 110.9 
C(2)-C(3)-H(3B) 110.9 
C(4)-C(3)-H(3B) 110.9 
H(3A)-C(3)-H(3B) 108.9 
O(16)-C(4)-C(15) 111.19(18) 
O(16)-C(4)-C(3) 109.60(18) 
C(15)-C(4)-C(3) 111.4(2) 
O(16)-C(4)-C(5) 108.83(18) 
C(15)-C(4)-C(5) 113.33(19) 
C(3)-C(4)-C(5) 102.15(17) 
C(6)-C(5)-C(1) 113.37(16) 
C(6)-C(5)-C(4) 115.49(17) 
C(1)-C(5)-C(4) 104.84(16) 
C(6)-C(5)-H(5A) 107.6 
C(1)-C(5)-H(5A) 107.6 
C(4)-C(5)-H(5A) 107.6 
O(17)-C(6)-C(5) 109.87(16) 
O(17)-C(6)-C(7) 104.50(15) 
C(5)-C(6)-C(7) 115.23(17) 
O(17)-C(6)-H(6A) 109.0 
C(5)-C(6)-H(6A) 109.0 
C(7)-C(6)-H(6A) 109.0 
C(11)-C(7)-C(8) 117.62(18) 
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C(11)-C(7)-C(6) 101.23(16) 
C(8)-C(7)-C(6) 112.87(18) 
C(11)-C(7)-H(7A) 108.2 
C(8)-C(7)-H(7A) 108.2 
C(6)-C(7)-H(7A) 108.2 
C(7)-C(8)-C(9) 112.4(2) 
C(7)-C(8)-H(8A) 109.1 
C(9)-C(8)-H(8A) 109.1 
C(7)-C(8)-H(8B) 109.1 
C(9)-C(8)-H(8B) 109.1 
H(8A)-C(8)-H(8B) 107.9 
C(10)-C(9)-C(8) 120.2(2) 
C(10)-C(9)-H(9A) 107.3 
C(8)-C(9)-H(9A) 107.3 
C(10)-C(9)-H(9B) 107.3 
C(8)-C(9)-H(9B) 107.3 
H(9A)-C(9)-H(9B) 106.9 
C(1)-C(10)-C(9) 127.72(19) 
C(1)-C(10)-C(14) 119.5(2) 
C(9)-C(10)-C(14) 112.7(2) 
C(13)-C(11)-C(12) 122.4(2) 
C(13)-C(11)-C(7) 131.3(2) 
C(12)-C(11)-C(7) 106.20(16) 
O(18)-C(12)-O(17) 121.6(2) 
O(18)-C(12)-C(11) 129.23(19) 
O(17)-C(12)-C(11) 109.13(15) 
C(11)-C(13)-H(13A) 120.0 
C(11)-C(13)-H(13B) 120.0 
H(13A)-C(13)-H(13B) 120.0 
C(10)-C(14)-H(14A) 109.5 
C(10)-C(14)-H(14B) 109.5 
H(14A)-C(14)-H(14B) 109.5 
C(10)-C(14)-H(14C) 109.5 
H(14A)-C(14)-H(14C) 109.5 
H(14B)-C(14)-H(14C) 109.5 
C(4)-C(15)-H(15A) 109.5 
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C(4)-C(15)-H(15B) 109.5 
H(15A)-C(15)-H(15B) 109.5 
C(4)-C(15)-H(15C) 109.5 
H(15A)-C(15)-H(15C) 109.5 
H(15B)-C(15)-H(15C) 109.5 
C(4)-O(16)-H(16A) 109.5 
C(12)-O(17)-C(6) 109.58(15) 
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Table 4. Hydrogen coordinates (x 104) and isotropic displacement parameters (Å2 x 
103). 
 x      y  z  U(eq) 
_______________________________________________________________________  
H2A 3322 371 2448 49 
H2B 1372 270 2746 49 
H3A 4718 -286 3238 49 
H3B 2844 -799 3251 49 
H5A 4657 1250 3805 32 
H6A 1111 1767 4113 32 
H7A 4397 2704 4075 33 
H8A 2423 3835 3701 43 
H8B 894 3114 3656 43 
H9A 2367 3333 2728 51 
H9B 4212 3053 3024 51 
H13A 2149 3870 5404 51 
H13B 2364 4280 4727 51 
H14A 1645 1431 2047 65 
H14B 3288 2062 1906 65 
H14C 1351 2455 2042 65 
H15A 795 286 4458 65 
H15B 867 -617 4109 65 
H15C 234 238 3766 65 
H16A 3735 -532 4519 65 
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Table 5.   Anisotropic displacement parameters (Å2x 103).  The anisotropic 
displacement factor exponent takes the form:  -22[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
_____________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
_____________________________________________________________________ 
C1 28(1)  38(1) 22(1)  0(1) -1(1)  6(1) 
C2 50(2)  46(1) 26(1)  -7(1) -6(1)  10(1) 
C3 58(2)  34(1) 30(1)  -7(1) -1(1)  7(1) 
C4 47(1)  27(1) 26(1)  -1(1) -3(1)  3(1) 
C5 31(1)  28(1) 22(1)  1(1) -1(1)  5(1) 
C6 30(1)  28(1) 22(1)  3(1) -3(1)  2(1) 
C7 26(1)  26(1) 30(1)  1(1) 0(1)  2(1) 
C8 44(1)  28(1) 36(1)  6(1) -3(1)  4(1) 
C9 55(1)  39(1) 34(1)  12(1) 1(1)  3(1) 
C10 31(1)  45(1) 25(1)  5(1) 2(1)  6(1) 
C11 28(1)  30(1) 33(1)  -3(1) -1(1)  0(1) 
C12 31(1)  33(1) 31(1)  -4(1) -1(1)  4(1) 
C13 47(1)  36(1) 44(1)  -7(1) -2(1)  2(1) 
C14 42(1)  61(2) 26(1)  11(1) -1(1)  6(1) 
C15 54(2)  35(1) 42(1)  -1(1) 4(1)  -9(1) 
O16 68(1)  28(1) 35(1)  6(1) -12(1)  6(1) 
O17 45(1)  28(1) 23(1)  0(1) -1(1)  3(1) 
O18 58(1)  47(1) 24(1)  -3(1) -1(1)  -1(1) 
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Table 6.  Torsion angles [°] for 11143a. 
________________________________________________________________________  
C10-C1-C2-C3 166.6(2) 
C5-C1-C2-C3 -11.2(2) 
C1-C2-C3-C4 32.5(3) 
C2-C3-C4-O16 -156.0(2) 
C2-C3-C4-C15 80.6(2) 
C2-C3-C4-C5 -40.7(3) 
C10-C1-C5-C6 41.7(3) 
C2-C1-C5-C6 -140.7(2) 
C10-C1-C5-C4 168.5(2) 
C2-C1-C5-C4 -13.9(2) 
O16-C4-C5-C6 -85.2(2) 
C15-C4-C5-C6 39.0(3) 
C3-C4-C5-C6 158.93(18) 
O16-C4-C5-C1 149.26(17) 
C15-C4-C5-C1 -86.5(2) 
C3-C4-C5-C1 33.4(2) 
C1-C5-C6-O17 171.77(17) 
C4-C5-C6-O17 50.8(2) 
C1-C5-C6-C7 -70.5(2) 
C4-C5-C6-C7 168.45(18) 
O17-C6-C7-C11 -30.0(2) 
C5-C6-C7-C11 -150.70(17) 
O17-C6-C7-C8 -156.67(18) 
C5-C6-C7-C8 82.7(2) 
C11-C7-C8-C9 169.2(2) 
C6-C7-C8-C9 -73.5(3) 
C7-C8-C9-C10 62.9(3) 
C2-C1-C10-C9 -175.6(2) 
C5-C1-C10-C9 1.7(4) 
C2-C1-C10-C14 0.4(3) 
C5-C1-C10-C14 177.6(2) 
C8-C9-C10-C1 -43.2(4) 
C8-C9-C10-C14 140.6(2) 
C8-C7-C11-C13 -27.5(4) 
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C6-C7-C11-C13 -150.9(3) 
C8-C7-C11-C12 149.1(2) 
C6-C7-C11-C12 25.7(2) 
C13-C11-C12-O18 -14.8(4) 
C7-C11-C12-O18 168.3(2) 
C13-C11-C12-O17 165.0(2) 
C7-C11-C12-O17 -12.0(2) 
O18-C12-O17-C6 171.6(2) 
C11-C12-O17-C6 -8.2(2) 
C5-C6-O17-C12 148.90(19) 
C7-C6-O17-C12 24.7(2) 
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Table 7.   Bond lengths [Å]. 
_____________________________________________________________________________________ 
C(1)-C(10) 1.336(3) 
C(1)-C(2) 1.522(3) 
C(1)-C(5) 1.531(3) 
C(2)-C(3) 1.524(3) 
C(2)-H(2A) 0.9900 
C(2)-H(2B) 0.9900 
C(3)-C(4) 1.527(3) 
C(3)-H(3A) 0.9900 
C(3)-H(3B) 0.9900 
C(4)-O(16) 1.427(3) 
C(4)-C(15) 1.516(4) 
C(4)-C(5) 1.550(3) 
C(5)-C(6) 1.507(3) 
C(5)-H(5A) 1.0000 
C(6)-O(17) 1.472(2) 
C(6)-C(7) 1.521(3) 
C(6)-H(6A) 1.0000 
C(7)-C(11) 1.502(3) 
C(7)-C(8) 1.515(3) 
C(7)-H(7A) 1.0000 
C(8)-C(9) 1.530(3) 
C(8)-H(8A) 0.9900 
C(8)-H(8B) 0.9900 
C(9)-C(10) 1.513(3) 
C(9)-H(9A) 0.9900 
C(9)-H(9B) 0.9900 
C(10)-C(14) 1.518(3) 
C(11)-C(13) 1.319(3) 
C(11)-C(12) 1.483(3) 
C(12)-O(18) 1.204(2) 
C(12)-O(17) 1.349(2) 
C(13)-H(13A) 0.9500 
C(13)-H(13B) 0.9500 
C(14)-H(14A) 0.9800 
C(14)-H(14B) 0.9800 
C(14)-H(14C) 0.9800 
C(15)-H(15A) 0.9800 
C(15)-H(15B) 0.9800 
C(15)-H(15C) 0.9800 
 
 
